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The objective of this project was to investigate effects of isometamidium (ISMM. Samorin®) on
immune responses to Trypanosoma congolense infection in order to understand mechanisms of
prophylaxis. (1) the efficacy of ISMM on T. congolense in vitro and in vivo was examined. (2) effects
on sheep peripheral blood mononuclear cell (PBMC) phenotypes, proliferation, and IFN-y production
were investigated. (3) effects on IL-12 and IFN-y production by mice splenic cells were studied. (4)
effects on sheep PBMC phenotypes following BCG vaccination in sheep were also investigated in
order to establish whether effects of ISMM were specific for trvpanosome antigens.
Three groups consisting of four sheep were used in the trypanosome study. One group was
prophylactically treated with ISMM and one was used as a normal control group. Four and half
months later, all sheep were infected with T. congolense plus a third group that was later treated
with ISMM 14 days post infection. Two groups of three sheep were used in BCG experiments: one
was first treated with ISMM and 14 days after treatment both groups were inoculated with BCG
vaccine. The efficacy of ISMM on T. congolense was studied on cultures in vitro and in sheep and
mice in vivo. IL-12 and IFN-y production by mice splenic cells was investigated at different points
after ISMM treatment
Pre-infection results showed a significant increase in IFN-y production by sheep PBMC 14 to 21 days
after ISMM administration when cultured with live tyrpanosomes. while cultures from the control
group were negative. No significant amounts of IFN-y were detected in all groups during the
infection period. ISMM prophylaxis suppressed polyclonal lymphocyte proliferation in vivo.
Increases in B-cells in the control and treated groups 14 to 21 days after infection were significantly
higher than in the prophy lactic group. A significant decrease in CD4" T-cells was recorded in the
control and treated groups 14 to 21 days post infection, while in the prophylactic group no changes
were observed. CD8~ T-cells increased only after treatment. The ratio of CD4LCD8" T-cells
significantly dropped 21 days after infection in the control and treated groups, while it increased in
the prophylactic group. There were no significant differences in CD5* and yS* T-cell responses.
Trypanosome specific IgG antibodies in serum of the prophy lactic group were significantly higher
than those in the control, while they were absent in the treated group. Following BCG vaccination,
ly mphocy te proliferation in vivo was suppressed in the ISMM treated group. The ratio of CD4LCD8
T-cells was higher in the ISMM group than in the control. Also ISMM. prevented a decrease in the
percentage of CD4~ T cells and suppressed polyclonal CD5" T cells and B cell expansion. Little or no
differences were observed on yd'. CD8" T cells, and PPD skin test. ISMM was trypanostatic in vitro
and T cell suppression decreased the prepatent period in prophylactically treated mice.
■nseIn conclusion. ISMM prophylaxis modified cellular and antibody responses to T. congole
infection probably via the IFN-y and 1L-12 feedback mechanisms. This immunomodulation enhanced
prophylaxis and is not specific for trypanosome antigens since similar changes were observed
following BCG vaccination, although the end result of an infection may depend on the type of host
animal and nature of antigen.





Animal trypanosomiasis is one of the most important diseases affecting livestock
productivity in Africa. Approximately 30% of Africa's estimated cattle population of
160 million and a comparable percentage of small ruminants are at risk of
trypanosomiasis (ILRAD 1993/4). In Zambia, more than 60% of an estimated 2
million cattle population are at risk of the disease (Mumba and Chizyuka 1987).
Morbidity and mortality caused by trypanosomiasis seriously affects or in some
regions precludes, the rearing of livestock especially cattle. Infections also occurs in
many wildlife species such as warthog, and bush pig but are usually subclinical thereby
providing an extensive reservoir of infection from which domesticated livestock can
become infected. Partly as a result of this disastrous situation Africa produces about
70 times less animal protein per unit area than Europe (Allsopp. Hall and Jone 1985).
Losses in milk production, milk yield and tractive power and costs of running
programmes to try to control the disease are estimated at US$500 million per year.
Adding to this figure estimates of the lost potential in crop production which depends
on draught power, increases the cost to US$5 billion each year (ILRAD 1993/4).
fhe aetiological agents of the disease are protozoan parasites belonging to the genus
Trypanosoma. There are many different species of pathogenic trypanosomes most of
which are transmitted to animals by arthropod vectors through either cyclical or
noncvclical (mechanical) means in different ways. T. equiperdum which causes a
venereal disease affecting mainly horses and related animals is the exception, where
the parasite is transmitted in coiton
Non cyclical transmission is effected by a simple mechanical transfer of the
trypanosomes from one mammalian host to another by the interrupted feeding of
biting insects like the Stomoxys and tabanids. In domestic animals T. brucei evansi is
the most important and is widely distributed in Africa. Asia. Central and South
America In cyclical transmission the arthropod is a necessary intermediate host in
which the trypanosomes undergo a period of development involving a series of
morphological transformations before forms infective for the mammalian host, called
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metacyclic trypanosomes, are produced. Cyclical transmission can further be divided
into Salivarian and Stercorarian groups on the basis of their life cycle. The
Salivarian group is restricted to Africa south of the Sahara, and includes all
trypanosomes transmitted by tsetse flies (Glossina) such as I congoleiise, T. vivcix, T.
brucei and T. simiae. Multiplication of the tsetse-transmitted trypanosomes takes
place in the intestinal tract and the proboscis of the fly so that the infection of the
mammalian host takes place while the fly is feeding. In the Stercorarian group,
multiplication and transmission occurs in the gut of the vector, and the infective forms
migrate to the rectum so that the metacyclic trypanosomes are passed with the faeces
on to abrasions in the skin of a mammalian host. In domestic animals this group is
relatively non-pathogenic and is transmitted by tabanid flies and sheep keds. The
Stercorarian group contains T. cruzi, which is the cause in human of the serious
Chagas Disease in South America, transmitted in faeces of triatomine bugs. In
domestic animals the Stercorarian group is important only because of interferences
with serological tests.
In Africa, the tsetse-transmitted trypanosomes (7. congolense, T. iwax, T. b. brucei
and T. simiae) are the most important span of pathogenic trypanosomiasis. An area of
approximately 10 million square kilometres of .Africa between latitudes 14°N and 29"S
(Urquhart and Holmes 1987) is infested by tsetse flies carrying these parasites (Figure
2.2). Although the infection rate in Glossina is low, ranging from 1 to 20% of the
flies, each fly is infected for life. Two groups of tsetse-transmitted trypanosomes can
be distinguished: the haematic and humoral group. The haematic group, which
includes T. congolense and I vivax, comprises parasites which are confined to blood
and the lymphatic system. This group is characterised by the major pathology being
anaemia The humoral group, is characterised by tissue damage and includes T. b.
brucei, T. b. evansi and the human pathogens 7". brucei rhodesiense and 7. brucei
gambiense) are found in body cavities and intercellular tissue, and parasitaemia is
observed mainly in terminal stages (Losos and Ikede 1972). The severity of the
disease depends on a number of factors including the trypanosome species, strain
variant, and species of host. The infection can vary from acute, as in T. simiae in pigs
and T. b. evansi in camels to mild or almost inapparent, as in T. b. brucei in cattle In
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West Africa T. vivax produces the most important form of trypanosomiasis. T.
congolense causes serious disease and death in cattle, horses, sheep and dogs, and is
most prevalent in East, Central, and Southern Africa. At the site of tsetse fly bite
metacyclic trypanosomes multiply in the skin producing within a few days a raised
cutaneous oedematous swelling called a chancre (Mwangi 1991). Thereafter,
trypanosomes enter the blood stream, multiply and a detectable parasitaemia becomes
apparent in the peripheral blood within 7 to 14 days post infection. The parasitaemia
may persist for many months, though its level may fluctuate due to the immune
response of the host. The major clinical signs in ruminants are anaemia, generalised
enlargement of the superficial lymph nodes, fever, lethargy and progressive loss of
bodly condition. I congolense infection is typically chronic, lasting for several
months, and usually leads to death in susceptible untreated animals (Boyt 1985).
There is considerable evidence indicating that antibodies are important in the
development of immunity against trypanosomes. Antibodies capable of in vitro
neutralisation, agglutination, lysis and in vivo protection against variant specific
surface antigens (VSSA) have been detected in the IgG and IgM fractions of cattle
serum (Luckins 1976; Musoke el a/ 1981). IgG antibodies against common antigens
have also been demonstrated (De Raadt 1974). However, there is no evidence that
antibodies against common antigens play an important role in protection but may be
involved in pathogenesis through the formation of immune complexes. The crucial
role of antibodies in providing protection has been further supported by passive
immunisation studies in mice There are many reports that mice can be protected
against T. b. brucei by immune serum or by transfer of B cell enriched fractions of
spleen cells, but not with T cell enriched fraction (Seed 1977; Takayanagi and
Enriques 1973. Takayanagi and Nakatake 1975; Campbell and Phillips 1976). No
passive immunisation experiments in ruminants have been reported
T cell deficient congenitallv athvmic nude (nu/nu) mice infected with T. b. brucei had
lower parasitaemia and survived longer than intact control mice (Campbell. Esser and
Phillips 1978). In contrast, congenitally nude (nu/nu) mice infected with T.
congolense had higher parasitaemia and their survival time was shorter than intact
->
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control mice (Morrison et al 1978). Results obtained from T. brncei infections imply
that T cell mediated responses against trypanosomes contribute to pathology, while
those from I congolense infection imply that they are important for an effective
control of trypanosomiasis. In addition, specific delayed type hypersensitivity
reactions against trypanosome antigens have been detected in rabbits infected with T.
b. brucei (Tizard and Soltys 1971), mice injected with formalin fixed T. b.
rhodesiense (Finerty, Krehl and McKelvin 1978), and cattle infected with T.
congolense (Emery and Moloo 1980),
Although the immune system can be effective at clearing parasites, the effect may be
short lived because trypanosomes have a very sophisticated way of evading the host's
immune system through the process of antigenic variation. Extensive studies and
reviews have been written on the subject of antigenic variation (Cross 1990; Gray and
Luckins 1976; Doyle 1977). Briefly, antigenic variants that arise during infection are
unique biochemically and serologically. The immune response to each specific variant
may clear parasites expressing that particular variable antigen epitope but provides no
protection against trypanosomes bearing different surface coats, thereby allowing new-
variants to appear This results in a fluctuating parasitaemia. Antigenic variation is one
of the main reasons why artificial immunisation has not been successful (Duxburv el al
1972; Wellde et al 1973), The other reason is that the nature and pattern of the actual
protective immune mechanisms is poorly understood despite the fact that much of
work on antibody responses and antigenic variations has been done. This may partly
be due to the fact that until recently, cellular responses have not been investigated in
great detail.
Because immunity to trypanosome infection has a very strong antibody dependence,
until recently very little had been done to investigate cell-mediated immune responses
to trypanosomiases. Studies in cattle and sheep infected with T. congolense have
shown significant changes in CD4 . CD8\ CDS (Williams el al 1991; Mwangi 1991)
and yd (Flynn and Sileghem 1991) T cell responses. Effector T cells may have no
direct role in destroying trypanosomes. but significant changes in regulatory cytokine
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and T cell function might have a profound effect on the function of the immune
system during infection, hence the need to investigate them in more detail.
Control of trypanosomiasis is achieved by control of or eradication of the vector,
treatment of infected animals and breeding of trypanotolerant animals, vector, and
parasite control Usually integrated control programmes are employed.
Vector control methods that are currently in use include: aerial and/or ground spray of
residual insecticides such as deltamethrin. application of insecticides on the body of
animals (pour-ons) and the use of traps or targets which involves the spraying of an
insecticide onto a piece of cloth (target) coupled with a tsetse attractant, acetone and
l-octen-3-ol (Allsopp, Hall and Jone 1985). Due to environmental concerns, methods
aimed at tsetse eradication have been abandoned in many areas, and since the existing
vector control methods are expensive and protection is not full proof the risk of
infection always exists.
Trvpanotoierance means reduced susceptibility to trypanosomiasis and denotes an
inherited biological characteristic enabling animals to live, breed, grow and survive in
a naturally infected environment without showing signs of disease after harbouring the
trypanosomes (Murray, Morrison and Whitelaw 1982; Camus 1981).
Trvpanotolerance is found in cattle such as the N'dama (Bos taunts), sheep, goats and
some pony types (Chabeuf 1983). Field studies by Njogu el a! 1985 have
demonstrated that even among Zebu (Bos indicus) cattle which are generally
considered to be susceptible, some types of Borans can be more tolerant than others
However, breeding for trypanotolerance alone is not a sufficient control programme
and in general, most trypanotolerant Bos ramus cattle have a low productivity-
compared to susceptible Bos indicus.
Parasite control measures involve diagnosis and treatment as well as
chemoprophylaxis. Treatment of trypanosomiasis in cattle depends on mainly three
drugs; diminazine. homidium and isometamidium, Diminazine and homidium are used
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as therapeutic agents and only isometamidium is used for both therapeutic and
prophylactic purposes.
ISMM has a high activity against T. congolense, and T. vivax, but low against T.
brucei and T. evansi probably because their presence in tissues makes them less
accessible. The suggested mode of action is through interference with parasite DNA
synthesis by intercalating between base pairs: ISMM has been shown to inhibit both
DNA and RNA polymerases. However, since it affects both trypanosome and
mammalian DNA in the same manner, the selective toxicity must be elsewhere. ISMM
is usually administered by intramuscular injection at 0.5 mg/kg and 1 mg/kg for
therapy and prophylaxis respectively. It binds to tissue macromolecules and also
precipitates proteins causing inflammation and necrosis with leukocyte and later
macrophage infiltration at the injection site. Accumulated concentrations are highest
at the injection site followed by the liver, kidney and spleen (Kinabo and Began
1988a). These sites provide depots for long term release. After intramuscular
administration of 0 5 mg/kg Kinabo and Bogan (1988a) measured an average
maximum serum concentration of 20 ng/ml in cattle 30 to 45 minutes after
administration. Braide and Eghianruwa (1980) reported higher mean plasma levels of
2.17 fig/ml after 24 hours in goats In camel 24 hours following intravenous injection
of 0.5 mg/kg ISMM the mean maximum plasma level was 0.7 ug/ml (Ali, Hassan and
Malik 1984) However, protection is longer with intramuscular than with intravenous
injection. ISMM is widely used for prophylaxis and has been shown to protect animals
against trypanosome infection for periods up to 6 months (Fairclough 1963; Pinder
1984; Eisler el a! 1994).
Prophylactic failure is the major problem associated with the use of ISMM. The
manufacturers recommends a 3 month dosing interval. At this frequency of use the
drug is generally considered to be cost effective. However, it is very common for a
considerable number of animals to become infected by the end of one month even
after careful administration (Fairclough 1963. Pinder 1984. Eisler el al 1994). A
dosing interval of less than 3 months generally ceases to be cost effective and
increases treatment costs or animal losses. In order to correct the problem of
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prophylactic drug failure, a substantial understanding of protective mechanisms
involved is vital. The mechanism of protection when ISMM plasma levels are low or
undetectable is still not well known. Whitelaw et al (1986) reported that only drug
residues are important and not the immune system because they were unable to detect
trypanolytic antibodies in treated animals. However, the fact that they were unable to
detect trypanolytic antibodies in serum does not rule out the involvement of other
aspects of the immune system.
A number of observations have been made which suggest that the drug can be
effective even when plasma levels are very low or undetectable (Kinabo 1993). For
instance following intramuscular or intravenous administration to cattle, plasma levels
can fall below 6.1 ng/ml by the end of one month (Kinabo and Bogan 1988a; Eisler el
a! 1994) but still offer protection against challenge by sensitive trypanosome strains
(Eisler et a! 1994) However, in vitro sensitivity tests have shown that exposing
sensitive trypanosomes to 5 ng/ml of ISMM for less than 10 minutes (Sutherland,
Mounsey and Holmes 1991), 10 ng/ml for less than 24 hours (Kaminsky, Chuma and
Wasike 1994) and 10 ng/ml for less than 48 hours (Gray and Peregrine 1993) could
not completely eliminate the parasites or prevent infection. This implies that the direct
minimum effective concentration (MEC) for ISMM should be in the range of 5-10
ng/ml. What accounts for the observed protection when plasma levels are below that
which is considered to be the MEC (5 ng/ml) is still a mystery. Nevertheless, only free
(unbound) drug in serum can be absorbed by the parasite and therefore, affect its
growth There are a number of views that try to explain the effectiveness of ISMM at
undetectable levels. They include: special trypanosomal uptake mechanisms which
lead to lethal drug levels inside the parasite; the level of tsetse challenge; the possible
production of active metabolites (Kinabo 1993) and boosting of the immune
responses. Out of all these, special uptake mechanisms, and level of tsetse challenge
have been studied and found to have no significant effect. Information on putative
active metabolites is not yet available. No trypanolytic antibodies have been detected
in prophylacticallv treated cattle infected with T. congoietise six months later
(Whitelaw et al 1986: Peregrine et al 1988). However, there is no existing
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information on the possible enhancement of T cell immune responses in
prophylacticallv treated animals.
ISMM is trypanostatic and not trypanocidal which makes it more likely to be
dependent on the immune system for its effectiveness. Culturing of trypanosomes, in
vitro in the presence of 5 ng/ml ISMM for less than 10 minutes (Sutherland, Mounsey
and Holmes 1991), 10 ng/ml for less than 24 hours (Kaminsky, Chuma and Wasike
1994) and 10 ng/ml for less than 48 hours (Gray and Peregrine 1993 ) could not
completely eliminate the parasites or prevent infection. Yet at concentrations of
ISMM less than 6 ng/ml, the establishment of a T. congolense infection was prevented
(Eisler et al 1994). This makes potentiation of some aspects of the immune system a
possible mechanism of action. However, interactions of the drug with the immune
system of both normal and trypanosome infected animals is not well known.
Knowledge of this interaction could be very useful in understanding the mechanism of
prophylaxis as well as the development of drug resistance. This would in turn lead to
a better utilisation of the drug to obtain the maximum benefit and could also probably
pave the way for the development of other much needed prophylactic drugs
In a trypanosmiasis endemic area, animals are usually found in different disease states
when a chemoprophvlactic agent like isometamidium is administered. Some will be
completely free of the infection while others might be already infected The drug will
therefore act as a prophylactic agent for those animals that would not be infected and
act as a therapeutic agent for those already infected. As a result any possible drug
modulation of immune responses in an endemic population is expected to be different
depending on the state of the disease the animal might be in at the time of
administration It is therefore, necessary to study immune responses in the
prophylactic and treated groups and make comparisons with the control group in
order to draw a meaningful relationship with the situation in the field
The objective of this project was to investigate effects of isometamidium ISMM. on
immune responses to 7. congolense infection in order to understand mechanisms of
prophylaxis so that the monitoring of prophylaxis can be improved in the field. (1) the
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efficacy of ISMM on T. congolense in vitro and in vivo was examined. (2) effects on
sheep peripheral blood mononuclear cell (PBMC) phenotypes, proliferation, and IFN-
y production were investigated. (3) effects on IL-12 and IFN-y production by mice
splenic cells were studied. (4) effects on sheep PBMC phenotypes following BCG
vaccination in sheep were also investigated in order to establish whether effects of





2.1 NOMENCLATURE AND CLASSIFICATION OF TRYPANOSOMES
Trypanosomes are eukarotic organisms found in the blood or tissues of vertebrate
animals and the gut of arthropods and other organisms (Hoare 1972). Members of the
genus Trypanosoma (Figure 2.1) are elongated protozoa which are 8-39 pm long.
They have a tlagellum which runs to the anterior end of the body and is attached to
the body by an undulating membrane. The flagellum functions as a locomotion
organelle and may be free in some species. Staining with Giemsa or most other
conventional stains shows a kinetoplast at the base of the flagellum and a centrally
located dark staining nucleus (Vickerman et al 1980).
Figure 2.1 Classification of the genus Trypanosoma
Genus Trypanosoma
Section Stercoraria Salivaria
Subgenus Megatiypanum Herpetosoma Schizotiypanum Duttonella Xannomonas Ttypanozoon Pycnomonas
Species T.(M) theileri T.(H) lewisi T.(S) cruzi T. (D) uniforme T.(N) congolense T.(T) brucei T.(P) suis
T. (H) musculli T.(D) vivax T.(N) simiae T.iT) b. brucei
T. (Hi rangeli T.iT) b. gambiense
T. (T) b. rhodesiense
T. (T) equiperdum
T.iTi b. evansi
The Sa/ivarian group includes all trypanosomes transmitted by tsetse flies (Glossina)
in addition to T.CI) equiperdum, which is transmitted during coitus in horses and
related species, and T.(T) b. evansi which is transmitted mechanically by tabanid flies.
Multiplication of Sa/ivarian trypanosomes takes place in the intestinal tract and the
proboscis of the fly so that the infection of the mammalian host takes place while the
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fly is feeding. Mechanical transmission occurs by a simple transfer of the
trypanosomes from one mammalian host to another by the interrupted feeding of
biting insects like the Stomoxys and tabanids. In this group T. brucei evansi is the
most important and is widely distributed in Africa, Asia, Central and South America.
Trypanosomes of the Stercorarian group multiply in the gut of the tsetse fly, and the
infective forms migrate to the rectum so that the metacyclic trypanosomes are passed
with the faeces on to abrasions in the skin of a mammalian host. Stercorarian
trypanosomes are relatively non-pathogenic in domestic animals and are important
only because of interference with serological tests especially T. (M) thei/eri which is
transmitted by tabanid flies and sheep keds. The group is important in human because
it contains T. cruzi, which is the cause Chagas Disease in South America, transmitted
in faeces of triatomine bugs. However, in addition to the typical Salivarian or
Stercorarian pathways of infection any trypanosome can also be transmitted
mechanically.
T. congo/ense is the major cause of animal trypanosomiasis in Central. East and
Southern Africa (Fiennes 1950; Mulligan 1970), while by T. vivax is the major cause
in West African trypanosomiasis (Losos and Ikede 1972). The disease affects
domestic ruminants, horses and pigs, while wildlife such as warthogs are reservoir
hosts. Since T. congo/ense is tsetse transmitted, the distribution of the disease is
limited to tsetse infested areas of .Africa (Figure 2.2).
Three major groups of tsetse flies (Glossina species) are recognised: morsitans,
pa!pa/is and fusca. G. morsitans is the major vector of animal trypanosomes because
their habitat (Savannah woodland) is shared by livestock. G. palpa/is is the second
most important because it inhabits the riverline but is not as widely distributed as G.
morsitans. G. fusca inhabits the forest, and although they are very efficient at
transmitting trypanosomes they are the least important because livestock rarely graze
in the forest (Jordan 1986).
Figure 2.2 Map of Africa showing the distribution of tsetse flies, the vector for
trypanosomiasis
Tsetse distribution
2.2 LIFE CYCLE OF T. CONGOLENSE
The life cycle and survival of T. congolense requires the tsetse fly (Glossina) and a
mammalian host and has been studied extensively by many researchers (Hoare 1972,
Evans, Ellis and Stomford 1979) (Figure 2.3).
Figure 2.3 Life cycle of T. congolense
Tsetse fly (Glossing) Tlammal
Metacycllc forms
• do not divide
• acquire VSG coat
Epimastlgote forms
multiply in the proboscis
(mouthparts)
Procyclic forms
multiply in the gut
Metacyclic forms transform
into dividing mammalian forms,
in the skin of the host, multiply




> multiply by binary lission
• undergo antigenic vanalion
• are infective lor olher mammals
Bloodstream (orms
are taken up by the tsetse
fly as it leeds on an
inlectad animal
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Procyclics, epimastigotes, and metacylics (infective forms) are found in the tsetse fly.
Trypanosomes ingested by the fly begin their development in the endopeirtrophic
space of the midgut. Blood stream forms lose their surface coat and morphologically
become elongated procyclics which have the kinetoplast positioned posterior to the
nucleus. Procyclics escape through the posterior end of the peritrophic membrane and
migrate to the proventriculus where they enter the endoperitrophic space They
migrate through the oesophagus to the proboscis where they attach to the walls of the
labrum and transform into epimastigotes. Epimastigotes have no surface coat and
their kinetoplast is positioned anterior to the nucleus. Epimastigotes then transform
into infective metacyclics which migrate to the hypopharynx. Metacyclics are
morphologically similar to blood stream forms and have a surface coat but are non-
dividing. Completion of all stages in the tsetse fly can take 19 to 53 days (Hoare
1972) or 7 to 40 days (Nantulya, Doyle and Jenni 1978) depending on the type of
isolate and host used in the study. When tsetse flies feed on mammalian hosts they
inoculate a mixture of procyclics. epimastigotes and infective metacyclics. Metacyclics
transform into dividing mammalian forms (Dwinger et al 1987) and migrate to the
lymphatics and blood stream where they multiply continuously as trypomastigotes by
binary fission (Dwinger et a! 1987; Akol and Murray 1982). The cycle is completed
when tsetse flies ingest trypomastigotes when they feed on the host, and
trypomastigotes develop into procyclics in the tsetse fly.
2.3 IN VITRO PROPAGATION OF 7. CONGOLENSE
Almost all life cycle stages of T. congolense and other trypanosome species can be
propagated in vitro. Gray et al (1981) reported the initial success in the production of
culture-derived metacyclic forms of T. congolense Continuous cultures of procyclic,
epimastigote and metacyclic forms have been maintained in Eagles minimum essential
medium supplemented with 20% foetal calf serum and 2% of 200mM L-glutamate in
plastic culture flasks at 28"C (Gray and Luckins 1979; Ross et al 1985) without a
feeder layer such as dermal collagen (Hirumi and Moloo 1982). Culture-derived
metacyclics retain the antigenic characteristics of their parent isolate and can be
infective to rabbits (Luckins. Rae and Gray 1981) and cattle (Akol and Murray 1985).
Continuous cultures of blood stream (trypomastigotes) forms of T. congolense is also
possible in a 1:1 supplemented mixture of RPMI 1640 and IMDM (Ross and Taylor
1990).
2.4 PATHOGENESIS OF TRYPANOSOMIASIS IN DOMESTIC ANIMALS
Acute, subacute and chronic forms of the disease have been reported, with severity
varying according to the susceptibility of the host (Losos et al 1973; Griffin and
Allonby 1979). However, the chronic form, which persists for longer than three
months, is the most common (Morrison, Murray and Mclntyre 1981). The pre-patent
period varies from 7 to 25 days in sheep and cattle (Griffin and Allonby 1979).
Clinical signs include; enlarged superficial lymph nodes, fluctuating fever, pale
mucous membranes, loss of body condition, infertility and abortions (Wellde et al
1974; Griffin and Allonby 1979, Mutayoba, EcKersall and Cestnik 1995). The major
pathological signs include; anaemia, enlarged lymph nodes, spleen and liver as well as
inflammatory changes in the heart, kidneys, lungs and testicles (Valli and Forsberg
1979; Kaava and Oduor-Okelo 1980). However, anaemia is the most significant and
probably the primary cause of death in most domestic ruminants (Mamo and Holmes
1975; Morrison, Murray and Akol 1985)
2.5 IMMUNE RESPONSES TO TRYPANOSOMES
Infected animals show a great variation in the immune responses against
trypanosomes. When cattle are infected with a single serodeme they may sometimes
be able to eliminate the parasites and recover from the infection (Morrison, Murray
and Akol 1985). Certain breeds of cattle e g the N'dama of West and Central .Africa
are resistant to trypanosomiasis because they have a greater capacity to control the
infection (Murray, Morrison and Whitelaw 1982). A major feature of immune
responses in both laboratory and domestic animals is the change in cellularity and
architecture of various lymphoid organs (Mansfield 1982). These changes are
expected to interfere with the normal immune functions because of the important role
played by lymphocytes and their interaction with other cells of the immune system.
14
2.5.1. HUMORAL IMMUNE RESPONSES TO TRYPANOSOMES
After infection with trypanosomes, there is an elevated level of IgM antibodies in
most mammals such as cattle, sheep, rodents, humans, monkeys and bush buck
(Houba, Brown and Allison 1969; Luckins 1972; Mackenzie, Boyt and Nesham 1979;
Hudson et al 1976). Most of these IgM antibodies produced are not specific for the
particular serodeme (Hudson et al 1976; Terry, Hudson and Faghihi-Shirazi 1980,
Corsini et al 1977; Musoke et al 1981). The ability of the host to control the infection
is however, dependent on the ability to produce IgM antibodies (MacAskill et al
1983), although IgG antibodies are now considered to play a significant role in
parasite clearance. Antibody mediated lysis (trypanolysis) occurs rapidly in vitro in the
presence of complement (Barry and Vickerman 1977). Most studies have
demonstrated that complement is required for immune lysis of trypanosomes to take
place in vitro, however, the role of complement in immunolysis in vivo is
controversial since trypanosome infected animals are hypocomplementaeinic probably
as a result of complex formation and direct activation by trypanosomes (Mansfield
1981). It is more likely that clearance of antibody coated trypanosomes occurs
primarily by phagocytosis and there is a considerable evidence in support of this view.
In vitro studies have shown that T. brucei and T. gambiense are ingested by
macrophages in the presence of immune serum (Lumsden and Herbert 1967). In vivo
evaluation of the role of opsonisation and macrophage uptake of radiolabeled
trypanosomes showed that whereas labelled parasites remained in circulation of
normal mice, they rapidly disappeared from blood of immune animals. In the
immunised mice the liver was found to be the principal site of uptake, removing over
50% of trypanosomes within 15 minutes of an intravenous injection of labelled
parasites (Holmes et at 1979; MacAskill et a! 1980) The possibility that immune lysis
was a pre-requisite to phagocytosis of trypanosomes was investigated in vivo by
measuring trypanosome clearance ability of passively immunised C5-deficient and C3-
depleted mice. Results of this experiment showed that C5-deficiency which is
necessary in complement mediated lysis did not affect immune clearance, while
reduction in C3 which is essential for full opsonic activity prevented immune clearance
in passively immunised mice (MacAskill et al 1980).
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The specific antibody response to trypanosomes is highly related to the variable
surface glycoprotein (VSG). Very few antibodies to non-variable antigens are
detected The primary antibody response to trypanosome VSGs in laboratory and
domestic animals usually reaches a peak 7-14 days after infection, then decreases
slowly for more than 100 days ( Herbert et al 1980; Roelents and Pinder 1984). The
actual duration of protection for the particular serodeme in cattle varies from 35 days
(Wiesenhutter 1970) to 14 months (Wellde et al 1973). There are conflicting reports
about the dominant secondary antibody isotype involved. Some reports show that
IgM still dominates (Oka et al 1981) while others show an increase in IgG isotype
(Roelants and Pinder 1984; Musoke et al 1981). The antibody isotype present at any
particular time is important since different isotypes have different binding affinities.
2.5.2: CELL-MEDIATED IMMUNE RESPONSES TO TRYPANOSOMIASIS
Very little work on cell-mediated immune responses to trypanosomes was performed
before the 1980s because of strong evidence that immunity was antibody mediated.
However, the little evidence that was available then suggested that cell-mediated
immune responses were either absent or played no protective role (Campbell, Esser
and Phillips 1978; Clayton. Ogilvie and Askonas 1979; Askonas et a! 1979; Takanagi
and Nakatake 1975) However, effector T cells may have no direct role in destroying
trypanosomes, but significant changes in regulatory T cell function might have a
profound effect on the function of the immune system during infection. Evidence in
support of cellular immune responses include results from studies that have shown in
vitro proliferation of mononuclear cells occurring 5-10 days after priming and
decreasing after 15 days (Gasbarre. Hugh and Louis 1981. Flynn et a! 1991; Lutje et
al 1995) when antibody levels would be high enough to control the infection. The
decrease in proliferative responses observed 15 days onwards may be a result of a
negative feedback to reduce adverse effects that would result from a hyperstimulated
immune system. Further evidence for cellular response playing a significant role in the
control of trypanosomiasis came from studies in rodents infected with trypanosomiasis
which showed a delayed type hypersensitivity reaction to trypanosome antigens
16
(Tizard and Soltys 1971). It is expected that if cellular responses were not involved in
the control of the disease, no delayed type hypersensitivity reactions could be
observed.
A skin reaction called chancre which develops at the site of inoculation of the
metacyclic trypanosomes is also a cellular immunological reaction which usually starts
within 3-5 days due to multiplying trypanosomes that produce an inflamed
oedematous lesion several centimetres in diameter and persists for 10 - 15 days (Gray
and Luckins 1980; Akol and Murray 1982; Mwangi, Hopkins and Luckins 1990). Cell
types involved in the reaction are initially inflammatory then immunological, with a
progressive increase of lymphoblasts and plasma cells (Mwangi 1991). A chancre is a
feature of naive animals and those treated with drugs before it develops and
subsequently challenged Chancre is not observed during secondary infections or in
animals treated with antitrypanosomal drugs after it had developed (Wilson et al
1971; Luckins 1986). Consequently, it is not common to come across animals with
chancres in trypanosome infected areas unless they had just been introduced from a
trypanosomiasis free area.
T cell phenotype responses have been demonstrated in sheep (Mwangi 1991) and
cattle (Williams el al 1991; Lutje et al 1995). In these studies, animals resistant to
trypanosomes showed significant increases in the ratio of CD4 :CD8 T cells
indicating an increase in helper T cell activity which up-regulates immune responses.
On the other hand trypanosome infections can influence cytokine production such as;
suppression of IL-2 production in mice infected with T. congolense (Mitchell, Pearson
and Gauldie 1986), and T. brucei (Sileghem et al 1987) and suppression of IL-2 and
IL-2R expression in cattle (Sileghem et al 1989b; Lutje et a! 1995) Induction of IFN-
y production by T. brucei infection in mice which leads to suppression ofmononuclear
cell proliferation (Darji et al 1991; Sileghem, Darji and De Baetselier 1991; Olsson et
al 1991; Bakhiet el al 1996) and T. congolett.se infection in cattle where highest levels
were detected 11 days post infection onwards (Lutje et al 1995; Taylor, Lutje and
Mertens 1996). Tavlor et al (1996) also demonstrated an up-regulation of IL-10 in
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cattle infected with T. consoleuse. Suppression of IL-2 production and IL-2R
expression and an increase in IFNy production in mice seem to contribute to the
pathogenesis since IFNy appears to promote parasite growth and suppress
mononuclear cell proliferation (Olsson el al 1991; Bakhiet el al 1996). It is well
documented that cytokines are very important in regulating immune responses
(Trinchieri 1997) and detailed effects of these cytokine changes is discussed below in
section 2.6.2 under the heading of'suppression of specific cell mediated responses1.
2.5.3 Antigenic variation
Immunity to trypanosomes is rapid and strong and is mediated by antibody response
against the variant surface glycoproteins (VSG) (Murray and Urquhart 1977), but
because of antigenic variation protection does not last long (Vickerman and Barry
1982; Morrison, Murray and Akol 1985). Antigenic variation by trypanosomes is a
way of evading the defence system of the host and is manifested by the sequential
expression of VSGs which form the surface coat covering the trypanosome body and
flagellum (Vickerman 1969; Cross 1990). fhe VSG is a unique feature of
trypomastigote (blood stream) forms and metacyclic (infective) forms of
trypanosomes which come in contact with host defences (Vickerman 1969). After an
infection the animal elicits an immune response against the invading variant antigen
types (VAFs) but the trypanosome has the genetic ability to recognise danger and
generate a different VSG that is not recognised by the mounted immune response
(Cross 1978) fhe new VAFs are seen by the animal as if they were a fresh infection
and it takes time before an effective immune response against the new variant would
develop and by then the parasites would be launching another distinct variant,
resulting in a persistent fluctuating parasitaemia (Vickerman 1978). Fluctuating waves
of parasitaemia results from immunological destruction by the host of trypanosomes
expressing VAFs against which an immune response has already been mounted
(Esser, Schroenbechler and Gingrich 1982).
fhe switch from one VSG type to another is a consequence of sequential activation of
as many as 1000 different VSG genes present in trypanosomes (Gibson. Marshall and
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Godfrey 1980) and is independent of antibody pressure since it has been demonstrated
that antigenic variation occurs in vitro in the absence of antibodies (Doyle et aI 1980;
Luckins et at 1990). At present the factor responsible for triggering antigenic
variation is not known, but considering that all in vitro culture systems contain animal
serum (Ross and Taylor 1990) it is very likely that the triggering factor should be a
constituent of animal serum. This is an area that needs to be investigated further as
well as the effect of ISMM and other antitrypanosomal drugs on antigenic variation
both in vitro and in vivo. It is possible that any agent that inhibits antigenic variation
would be useful for prophylaxis even without having trypanocidal effects since
immunity to any particular serodene is strong enough to eliminate non-variant
trypanosomes.
During the life cycle of trypanosomes, antigenic variation stops after trypomastigotes
have been ingested by the tsetse fly and in vitro when transformation to procyclics
takes place (Ehlers, Czichos and Overath 1987). It starts again in the tsetse salivary
glands when non-dividing metacvclics have been produced (Tetley et al 1987).
However, the population of metacvclics is heterogeneous, with a small predictable
number of VAT (Le Ray, Barry and Vickerman 1978). For instance, one strain of T.
consoleuse contains only 12 metacyclic VATs and the number is also limited in T.
rhodesien.se (Turner et ill 1988). Metacyclic VATs of T. congolense continue to be
expressed in the mammalian host while new VATs are being produced in the chancre
(Luckins et a1 1990). In contrast those of T. hrncei cease to be expressed after
inoculation into the animal leaving only trypomastigote VATs (Barry, Crowe and
Vickerman 1983). This means metacyclics of T. congolense are more susceptible to
early immunological responses than those of I hrucei. In addition re-expression of
metacyclic VATs by trypomatigote forms of trypanosomes is possible (Nantulva et al




2.6.1 Anaemia and tissue damage
A significant loss of red cells and a decrease in the packed cell volume usually
corresponds to the duration of parasitaemia. Anaemia is less severe in animals that are
resistant to trypanosomiasis such as the N'dama cattle (Dargie et al 1979). The
aetiology of anaemia is multifactorial with the formation of trypanosonre-antibody-red
cell immune complexes playing a major role. Initially haemolysis occurs probably
mediated by bioactive substances released by dying parasites (Haun 1975; Tizard et al
1978). These bioactive substances include enzymes, lipids, haemolysins, inflammatory
substances and mitogenic factors (Tizard el al 1978; Olsson et al 1991; Bakhiet et a!
1996) which have the potential to cause red cell damage and that of other tissues.
This mechanism may be effective in rodents which develop acute infections with high
parasitaemias but may not be that effective in chronic infections in ruminants which
are characterised by low parasitaemia. Destruction of trypanosomes produces both
soluble, and fragments of antigen which complex with several cells and tissues in the
host. Later, antitrypanosomal antibodies attach to produce cell-antigen-antibody
complexes which are susceptible to phagocytosis. In the case of erythrocytes,
phagocytosis of complexes with trypanosome antigens takes place in the spleen, liver,
and lymph nodes and is probably the major cause of anaemia in ruminant infections
(Mackenzie and Cruickshank 1973). However, during the chronic stages of infection
anaemia is due to failure of haemopoiesis in the degenerated bone marrow (Dargie et
a! 1979).
Immune complexes in tissues may initiate acute and later chronic inflammatory
responses which may be responsible for tissue damage and muscle wasting observed
in chronic infections. The other possible cause of tissue damage is the activation by
immune complexes for the release of pharmacologically active substances such as
histamine and 5-hydroxyltryptamine (5-HT) which increase the vascular permeability
causing tissue oedema (Richards 1965). However, tissue damage is a feature common
in T. brueei. while anaemia is common in T. cotigoletise infections.
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2.6.2 Immunosuppression in trypanosomiasis
Trypanosomes suppress both the specific humoral antibody and cell mediated immune
responses resulting in the establishment of the infection and predisposing the host to
secondary infections (Parkin and Hornby 1930; Fiennes 1954). However,
immunosuppression in cattle may not be as severe as in rodents (Morrison and Murray
1979; Masake and Morrison 1981).
Suppression of specific antibody responses
Antibodies specific for an existing trypanosome VAT continue to be produced
throughout the infection although the degree of response becomes progressively
depressed (Hudson and Terry 1979). In chronically infected mice there is progressive
suppression of trypanosome specific IgM and IgG antibodies such that by the third
wave of parasitaemia there are only very low levels of IgM and no detectable IgG
(Sacks and Askonas 1980). In cattle antigen specific antibody responses were
depressed in T. brucei infected (Nantulya ft a/ 1982) and in T. congolense infected
cattle (Morrison. Murray and Akol 1985). However, the decrease in variant specific
antibodies may be due to the gradual elimination of the particular variant by the
immune system leaving new variants which may not react with the antigen used in the
assay which is based on the variant that was inoculated but would have changed
Hence, although a decrease in specific trypanosome antibodies is generally considered
to be suppression, the consequences of antigenic variation indicates that it is probably
due to the removal by the immune system of the invading VAT which is associated
with the antibody assay.
Clonal B cell exhaustion as a result of polyclonal B lymphocyte activation by a non¬
specific trypanosome derived mitogen (Askonas el a/ 1979; Clayton, Ogilvie and
Askonas 1979. Oka el a/ 1984) has been proposed as a mechanism leading to specific
suppression of antibody responses. Evidence for this came from in vitro studies of
antibody producing B cells. Normally high levels of IgM and IgG are observed when
cells proliferate in vitro. They are seen to rise when they are first put in culture and
decrease as the infection progresses, suggesting exhaustion of B lymphocytes (Corsini
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et al 1977). Nevertheless, due to antigenic variation occurring in vitro, these findings
may again not be relevant if the antibody assay relies on the invading VAT.
Other possible mechanisms leading to suppression of antibody activity that have been
observed in cattle infected with T. congolense include; increased immunoglobulin
catabolism and hypocomplementaemia (Nielsen et al 1978). Progressive
hypocomplementaemia is the reason trypanolysis in vivo may not be an important
effector mechanism since it requires the presence of complement.
Suppression of non-specific antibody responses
Depression of antibody responses to non-trypanosome antigens during the period of
trypanosome infection is very important because it renders animals susceptible
secondary infection. There is evidence that mice infected with T. brucei had reduced
antibody responses specific to sheep red blood cells (Goodwin et al 1972; Wellhausen
and Mansfield 1979; Jayawardena, Waksman and Eardley 1978). Also T. congolense
infection lead to depressed secondary antibody response to polyvalent clostridial
vaccine in cattle. This may lead to reduced success of vaccination programmes in
trypanosomiasis endemic areas (Holmes et al 1974; Scott 1977). Rurangirwa et al
(1983) also found a profound suppression of IgGj, IgG2 and IgM responses to
Brucella abortus (S-19) vaccine in cattle chronically infected with T. congolense.
However, studies that measured antibody responses in the first few weeks of infection
with T. congolense or T. iwax showed little or no suppression of non-specific
antibody responses (Ilemobade et a! 1982; Whitelaw et al 1979; Rurangirwa et al
1980). These results demonstrate that non-specific suppression of antibody responses
occurs during the chronic stage of infection probably as a result of polyclonal B cell
activation and exhaustion of cells of the immune system.
Suppression of specific cell-mediated responses
At present investigations on proliferative responses of peripheral blood mononuclear
cells (PBMCs) is commonly performed in vitro PBMCs from infected and treated
cattle proliferate in vitro in response to stimulation with homologous ultrasonicated
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trypanosomal antigens. This response was suppressed in animals with active infection
(Emery et al 1980). In addition peripheral blood lymphocytes (PBLs) from T.
congolense infected cattle proliferated in vitro in response to ultrasonicated
trypanosomal antigens when PBLs were collected 3-7 days post infection but
thereafter, the proliferation was suppressed but appeared after treatment (Morrison,
Murray and Akol 1985). These results demonstrate that mononuclear cells from
animals in a stage of active trypanosome infection are refractive to any further antigen
specific proliferative stimulus. However, during the period of active infection, there is
usually increased lymphocytosis in vivo (Mwangi 1991; Williams et al 1991) which
implies that results from in vitro proliferative responses are inversely related to what
goes on in vivo. Therefore, although a decrease in specific in vitro proliferation during
the period of active trypanosome infection is generally considered to be suppression,
it is not truly immunosuppression in vivo.
In cattle and sheep infected with T. congolense there are changes in lymphocyte
subsets such as depletion of CD4 ,CD8 and yS T cells in susceptible Boran cattle
which required treatment while only CDS T cells were depleted in trvpanotolerant
N'dama cattle which self cured (Williams et al 1991). In trypanotolerant N'dama
cattle a decrease in the proportion of CD8 T cells with a constant proportion of
CD4 T cells implies an increase in helper T cell activity resulting in an up-regulation
of immune responses. On the other hand, a decrease in both CD4 and CDS T cells
indicates that there was suppression of helper T cell activity in the susceptible Boran
cattle.
Earlier studies had proposed that immunosuppression in rodents was a result of the
loss of antigen presenting cells. Mice infected with T. rhotlesieti.se exhibited a
progressive loss of antigen presenting macrophages from spleen cells, lymph nodes
and peritoneal cavity (Bagasra, Schell and Le Frock 1981) and reduced expression of
mannose. Fc-, and complement receptors (Grosskinskv et al 1983) which may lead to
a reduction in antigen handling capabilities of antigen presenting cells. However, the
present understanding of immunosuppression in rodents is based on the regulation of
M0 function and other effector cells such as CD8 T cells, than on the physical loss of
cells. Spleen cells from T. congolense or T. brticei infected mice failed to respond to
mitogenic stimulation in vitro and suppressed the ability of normal cells to respond to
the same mitogens (Jayawardena and Waksman 1977; Mansfield et al 1981; Borowav
et al 1990). It is possible that cells from infected animals were producing cytokines
that inhibit cell proliferation but these studies did not investigate cytokine production.
Later studies on cytokine production by mononuclear cells showed that IL-2
production by T cells was usually depressed in mice infected with T. congolense
(Mitchell, Pearson and Gauldie 1986) and in T. brucei infection (Sileghem, Holmes
and De Baetselier 1986). In addition, interferon gamma (IFN-y) production increased
in T. brucei and T.cruzi infected mice which appeared to be responsible for the
dysfunction of T cells (Darji et al 1991). IFN-y activated macrophages (M0) are now
at the centre of the proposed mechanism of immunosuppression in rodents. The
theory is that trvpanosomes release factors which activates CDS' T cells to release
IFN-y which activates M0 leading to the suppression of proliferative responses
(Pinder 1984; Eardlev and Jayawardena 1977). M0 inhibit proliferation via two
proposed mechanisms; prostaglandin (PG) dependent and PG- independent
mechanisms. In the PG-dependent mechanism. M0 interact with a trypanosomal
fragment (70kD Mw) and secrete PG which actively inhibits IL-2 secretion by CD4 T
cells. In the PG-independent mechanism. IFN-y activated M0 release nitric oxide
which then inhibit IL-2 receptor (IL-2R) expression on CD4 and CD8 T cells
(Sileghem et al 1989c; Darji 1991). IL-2 promotes mononuclear cell proliferation,
therefore any stimulus that inhibits its production or receptor expression will inhibit
cell proliferation
The role of IFN-y in suppressing cell proliferation in rodents has been tested by
culturing cells in the presence or absence of anti-IFN-y antibodies. Results indicated
that cells cultured in the presence of antibodies proliferated while those without
antibodies to IFN-y did not proliferate (Olsson et al 1991). In addition it has been
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demonstrated that IFN-y promotes T. brucei multiplication in vitro, and in vivo mice
that were treated with anti-IFN-y antibodies had lower parasitaemia and survived
longer (Olsson et at 1991; Bakhiet et al 1996). The prostaglandin mechanism of
suppression was tested by culturing mononuclear cells from mice infected with 7.
brucei in the presence or absence of indomethacin. a prostaglandin inhibitor. Cells
with the inhibitor proliferated while those without it did not (Schleifer and Manfield
1993). The role of nitric oxide was also demonstrated by culturing mononuclear cells
from 7 brucei infected mice in the presence or absence of a nitric oxide synthetase
inhibitor N-monomethy-L-arginine acetate (NMMA). Results showed that cells that
were grown in the presence of the inhibitor proliferated while those grown without
the inhibitor did not (Schleifer and Mansfield 1993; Sternberg and MacGuigan 1992).
It was therefore, concluded that IFN-y induced prostaglandin and nitric oxide were
involved in the suppression of proliferative responses by mononuclear cells from T.
brucei infected mice.
Although activated MO and CD8 T cells from 7. congo/ense infected cattle have
been shown to suppress mononuclear cell proliferation in vitro (Taylor, Lutje and
Mertens 1996; Flynn and Sileghem 1991) the mechanism seems to be different from
that observed in rodents. The addition of indomethacin to inhibit prostaglandin
synthesis had no effect on the ability of lymph node cells from cattle infected with 7.
congolense to suppress proliferative responses of responder cells from uninfected
cattle (Flynn and Sileghem 1991; Taylor. Lutje and Mertens 1996). The addition of
nitric oxide inhibitors to the cells had no effects on proliferative responses. In addition
measurement of levels of nitric oxide and IL-10 in culture supernatants showed a
decrease in concentration of nitric oxide while that of IL-10 increased as the infection
progressed (Taylor. Lutje and Mertens 1996). These results demonstrate that
prostaglandins and nitric oxide are not involved in the mechanism of suppressing
proliferation of mononuclear cells from 7. congolense infected cattle. Moreover, nitric
oxide is down-regulated during the course of infection. Therefore, the mechanism in
cattle may involve IL-10 a cytokine that is known to mediate suppression ofMO and
effector cell function by inhibiting the expression of IFN-y.
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Suppression of non-specific cell-mediated responses
Non-specific suppression of cell-mediated immune responses has been observed in
trypanosome infected rodents and ruminants. Spleen cells from T. brucei or T.
congolense infected mice failed to respond in vitro to stimulation with either T cell
mitogens such as concanavalin A (ConA) and phytohaemagglutinin (PHA) or to
lipopolysaccharide (LPS) a B cell mitogen (Mansfield el al 1981; Pearson el al 1978
and 1979). Suppression of delayed type hypersensitivity reaction to purified protein
derivative of tuberculin was observed in rabbits infected with T. congolense for 6
weeks (Mansfield and Wallace 1974). However, Freeman et al (1973) observed
normal cell-mediated responses to T. brucei infection with suppression being observed
only during the terminal stages of the infection probably due to differences in the
virulence of trypanosomes used in the experiments. Investigations in cattle
demonstrated that T. vivax infection in goats may be associated with more than 50%
suppression of mitogen-induced lymphocyte function in vitro. Suppression was
observed after 20 days of infection. Other studies showed no suppression of cellular
responses e.g. there was no significant suppression of in vitro responses to mitogens
for leukocytes from cattle infected with T. congolense or T. vivax (Masake and
Morrison 1981; Sollod and Frank 1979; Morrison, Murray and Akol 1985). Strain
differences in the ability to induce polyclonal proliferation may explain the differences
in response. It seems most strains of trypanosomes induce polyclonal lymphocyte
proliferation of un-stimulated cells in vivo leaving little or no naive cells to be
stimulated by mitogens. Therefore, in vivo infection or antigens that induce non¬
specific cell mediated responses such as purified tuberculin protein derivative will be
suppressed (Mansfield and Wallace 1974).
2.7 CONTROL OF ANIMAL TRYPANOSOMIASIS
Control of trypanosomiasis is achieved by chemotherapy and chemoprophylaxis,
vector control or eradication and breeding of trvpanotolerant animals. However,
integrated control programmes are usually employed.
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2.7.1 Chemoprophylaxis
The use of suitable antitrypanosomal drugs aimed at protecting animals from
infection, forms a very important part of most integrated trypanosomiasis control
programmes (Leach and Roberts 1981 review). Thus in the absence of a suitable
vaccine, chemotherapy and chemoprophylaxis seem to be the most effective method
available, (for reviews refer to Williamson 1970; Finelle 1976; Soulsby 1982; Kinabo
1993). Chemotherapy of trypanosomiasis caused by T. congolense in cattle depends
on mainly three drugs; ISMM, homidium and diminazine. Diminazine and homidium
are used as therapeutic agents and only ISMM is used for both therapeutic and
prophylactic purposes (Whitelaw et al 1986, Kinabo 1993). ISMM is the sole agent
used for prophylaxis against animal trypanosomiasis. It has greatly contributed to
improving the productivity of livestock especially cattle reared in trypanosomiasis
endemic areas and although it has been used since 1958 very little is known about its
immunological effects, metabolic profile, teratogenic, mutagenic and carcinogenic
effects. The hypothesis that it may improve immune responses to T. congolense is an
attractive one because if verified it would prove a 'tried and tested' model of an
immunomodulator that would be used in search of new prophylactic agents
ISMM is a chloride salt chemically called 8- [(m- amidinophenylazo) amino] -3-
amino -5- ethyl -6- phenylphenanthridium chloride hydrochloride. It is marketed under
the trade names of (SamorinU RMB Animal Health Ltd , Dagenham. U.K.) in
.Anglophone or (Trypamidium*", Rhone-Merieux, Lyon. France) in Francophone
countries It was first svnthesised by coupling homidium with p-
aminophenyldiazonium chloride (Wragg et al 1958) and subsequently the yield and
purity was improved and the chemical structure elucidated (Berg 1960 and 1963).
ISMM is a dark-brown powder which is cationic because it contains a quaternary
nitrogen atom (Figure 2.3) and has a solubility of 6% in water at 20"C. It is less
soluble in pure organic solvents and is labile at high temperature, and low and high
pH conditions.
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Figure 2.3 Chemical structure of ISMM
Hawking (1963) tested ISMM for activity against T. congolense and T. b.
rhodesiense in vitro and found that it was ineffective up to concentrations of 100 000
ng/ml. However, Hill (1965) demonstrated that activity against T. congolense in vitro
was less than that observed in vivo. These differences could be attributed to the
possibility of potentiation by the immune system or metabolism to active metabolites
in vivo. Activity against T. congolense was 10-20 times greater than that against T.
rhodesiense. The difference is probably because T. rhodesiense usually resides in
tissues where very little drug concentrations are found while T. congolense is usually
found in the blood and lymphatics where high drug concentrations can be achieved.
Further investigations on activity of ISMM have reviewed that the minimum effective
concentration which killed T. evansi and T. equiperdum (MECioo) in 24 hours of drug
exposure was 1 000 - 4 000 ng/ml (Zhang, Giroud and Baltz 1991) and 1 - 300 ng/ml
after 96 hours of exposure (Brun and Lun 1992). Culturing of trypanosomes, in vitro
in the presence of 5 ng/ml ISMM for less than 10 minutes (Sutherland et al 1991b),
10 ng/ml for less than 24 hours (Kaminsky, Chuma and Wasike 1994) and 10 ng/ml
for less than 48 hours (Gray and Peregrine 1993 ) could not completely eliminate the
parasites or prevent infection. These results demonstrate that ISMM is trypanocidal at
high but not at low concentrations. Nevertheless, ISMM serum or plasma
concentrations during the protective period is usually less than 5 ng/ml, which
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according to these results may have little trypanocidal effects. These observations lead
to the hypothesis under present investigation that; ISMM provides protection against
trypanosome infections by improving the responsiveness of the immune system.
However, the difficulty has always been to provide evidence in support of this
hypothesis.
Initial and successful therapeutic trials of ISMM on T. congolense in mice were
performed by Wragg et al (1958), a few years before any in vitro assays were
attempted. Subsequently a number of laboratory and field studies showed that the
drug was active against T. vivax, T. britcei, and I. evansi infections in domestic
animals (Kirkby 1963, Toure 1970; Arowolo and Ikede 1980; Ali 1985; Peregrine,
Moloo and Whitelaw 1987). ISMM has also been shown to protect pigs from
outbreaks of T. simine infections for up to 5 months at doses of 12 - 35 mg/kg
(Finelle 1973; Otaru and Nsengwa 1987). However, these doses are too toxic to be
recommended for routine use (Kinabo, MacKellar and EcKersall 1991). The
therapeutic dose of ISMM in animals other than pigs varies from 0.5 mg/kg in
ruminants to 10 mg/kg in mice.
Chemoprophylactic activity of ISMM against trvpanosomes has been well
documented, but the duration of protection after an intramuscular injection varies
widely from as little as 2 weeks (Dolan el al 1992, Munstermann et al 1992) to 7
months (Weisenhutter et al 1970) However, sustained release devices containing
ISMM have extended the mean period of protection up to 20 months at serum
concentrations less than 1 ng/ml (Geerts et al 1997). The sustained release device was
a cylindrical rod of 3 mm in diameter and 3 cm long consisting of a mixture of
poly(D,L-Lactide) and 25% ISMM. The device was implanted subcutaneously in the
shoulder region. The mean period of protection in the sustained release device group
was 20 months compared to 5.7 months resulting from an intramuscular injection of a
2% ISMM solution at a dose of 0.5 mg/kg body weight. In the same study, no
trypanolytic antibodies were detected during the protective period and based on that
observation they concluded that only drug residues were responsible for the
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protection. Nevertheless, many studies have shown that trypanolysis requires the
presence of complement (Mansfield 1981). However, it has been demonstrated by
other researchers that phagocytosis of trypanosomes in the liver alone is responsible
for the clearance of more than half of the circulating trypanosomes in immunised but
not naive mice (Holmes et al 1979; MacAskill et al 1980). This implies that in vivo
opsonising antibodies are more relevant than trypanolytic antibodies, a view
supported by the depletion of complement in trypanosome infected animals which
means cellular immune responses may still be involved in animals protected by ISMM.
The primary mode of action that is currently considered to account for the molecular
mechanism of anti-trypanosomal activity of ISMM is the blockade of nucleic acid
synthesis through intercalation between DNA base pairs (Wagner 1971), inhibition of
RNA polymerase (Richardson 1973), DNA polymerase (Marcus et al 1982) and
incorporation of nucleic acid precursors into RNA and DNA (Lantz and Van Dyke
1972). Other proposed mechanisms include, inhibition of glycoprotein biosynthesis
(Casero, Porter and Bernacki 1982), lipid metabolism (Dixon et al 1971), ATP
metabolism (Frank-Henderson et a! 1977), membrane transport (Girgis-Takla and
James 1974) and selective cleavage of kinetoplast DNA (Shapiro and Englund 1990).
However, effects on nucleic acid synthesis does not explain the selective toxicity of
ISMM for trypanosomes in vivo since it also affects mammalian nucleic acids.
However, effects on kinetoplast DNA. trypanothione which maintains intracellular
redox balance (Fairlamb 1990) and glycosome organelles (Opperdoes 1985) might be
more selective for trypanosomes but the precise role of each one is not known
Therefore, the true mechanism of action of ISMM on trypanosomes in vivo is yet
unknown.
Experimental and field observations have demonstrated the existence of strains of
trypanosomes resistant to ISMM ( Schonefeld, Rottcher and Moloo 1987. Peregrine,
and Whitelaw 1991. Codjia et al 1993). The actual mechanism of resistance is not
known, but reports of reduced uptake of ISMM into trypanosomes have been
postulated (Sutherland et a! 1991a) However, the most interesting aspect of drug
30
resistance is the close association with the status of the host immune system.
Repeated sub-curative drug treatment with cymerlarsan, berenil and ISMM was found
to lead to the development of drug resistant trypanosomes only in immunosuppressed
animals (Osman, Jennings and Holmes 1992). These results, once more underscore
the importance of the immune system in trypanosomiasis chemoprophylaxis.
ISMM is normally administered via an intramuscular injection at 0.25 - 0.5 mg/kg for
therapeutic and 0.5-1 mg/kg for prophylactic purposes. Although slow intravenous
administration is effective for therapeutic purposes (Dowler, Schillinger and Connor
1989) it is associated with a reduced duration of protection (Sutherland et al 1991b).
ISMM is poorly absorbed from subcutaneous sites and is not orally administered
because of breakdown in acidic stomach and poor absorption (Philips et al 1967).
The kinetics of ISMM after an intramuscular administration vary widely. It is
absorbed slowly and maximum plasma concentrations are achieved within 1 hour
(Kinabo and MacKeller 1990) Twenty four hours after administration plasma level
were 2170 ng/ml in goats (Braide and Eghianruwa 1980), below 10 ng/ml (Kinabo,
McKeller and WcKersall 1991, Geerts et al 1997) and 40 - 50 ng/ml (Eisler et al
1994) in cattle The concentration then falls rapidly to below 1 - 6 ng/ml by the end of
one month after administration. However, despite plasma concentrations being below
1 ng/ml, most animals remained protected for up to 20 months (Geerts et a! 1997).
ISMM accumulates at concentrations higher than those found in plasma at the
intramuscular injection site, liver, kidney, spleen, skeletal and cardiac muscles in that
order (Kinabo and Bogan 1988). Little is known about metabolism but cumulative
excretory data of [14C] ISMM in faeces and urine of cattle given the drug
intramuscularly (Kinabo and McKeller 1989; Kratzer et a! 1989) suggested that the
major route of excretion of unchanged ISMM and/or its putative metabolites is via the
bile while excretion via urine is very low. Breakdown of ISMM to homidium has been
demonstrated only in rats after an oral administration (Phillips et a! 1967).
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The therapeutic index of ISMM is very low and the maximum tolerated dose after
intravenous administration were 2, 1.5, 1, and 0.05 mg/kg in dogs, cattle, camel and
goats respectively in order of susceptibility (Schillinger, Moloo and Rottcher 1985). A
dose of 1 mg/kg intravenously is lethal to 100% of goats, while 4 mg/kg is lethal to
50% of cattle (Robson 1962) and dogs (Phillips et al 1967). Signs of acute toxicity
include; convulsions, flaccid paralysis of extremities and respiratory dysfunction
probably due to blockade of neuromuscular transmission, direct stimulation of
cholinoceptors and potentiation of histamine release (Phillips et a/ 1967; Arowolo and
Eyre 1984). Acute toxicity is not common following an intramuscular injection
because of slow absorption. However, the site is usually damaged by inflammation
and fibrosis followed by coagulative necrosis. Leakage of drug to subcutaneous
tissues may result in sloughing of the skin (Robson 1962; Kinabo and Bogan 1988b).
Due to the persistence of the drug in tissues of treated animals and its ability to
intercalate with base pairs of nucleic acids, concerns have been raised on the safety of
ISMM in meat destined for human consumption (Braide and Eghianruwa 1980;
Kinabo and Bogan 1988d) and its mutagenicity potential (Lecointe et al 1981).
Mutagenicity experiments demonstrated hepatic metabolism of ethidium (homidium)
to reactive nitrogen species and although this has not been demonstrated for ISMM,
the possibility of metabolic conversion to homidium (Phillips et aI 1967) is what
raises concerns. However, existing data on the stability of ISMM seem to indicates
that the risk from the unchanged drug may be very low since it breaks down at low or
high pH and at high temperatures, therefore can not withstand the process of cooking.
Nevertheless, a maximum residual level for ISMM has not yet been recommended
because of insufficient data particularly from carcinogenicity, teratogenicity and
metabolic studies as well as short term oral administration studies (WHO 1989 and
1990)
2.7.2 Vector control
In isolated small areas with low or moderate tsetse density the control method of
choice is eradication of the vector (Rommel 1983). through ground or aerial sprays of
insecticides with residual effects such as synthetic pyrethroids (MacLennan 1981;
WHO 1986a). Insecticide impregnated traps or targets which requires the insecticide
to be sprayed onto a trap or piece of cloth (target) coupled with a tsetse attractant,
acetone and l-octen-3-ol (Allsopp, Hall and Jone 1985) are also employed.
Insecticides have also been sprayed on the body of animals (pour-ons) where the
animal acts as a moving lethal target. There are experimental findings that ISMM is
capable of eliminating the insect form of T. vivcix, which may be of potential
significance in the control of the disease in the field, particularly in relation to the
operation of the sterile insect technique (Agu 1985). However, uninterrupted cycles in
wildlife would still make this method less effective.
2.7.3 Breeding of Trypanotolerant animals
Trypanotolerance means reduced susceptibility to trypanosomiasis and denotes an
inherited biological characteristic enabling animals to live, breed, grow and survive in
a naturally infected environment without showing signs of disease after harbouring the
trypanosomes (Murray, Morrison and Whitelaw 1982; Camus 1981).
Trypanotolerance is found in local .African breeds of cattle such as the NTdama (Bos
taunts), sheep, goats and some pony types (Chabeuf 1983). Field studies by Njogu et
a! (1985) have demonstrated that even among Zebu (Bos indicus) cattle which are
generally considered to be susceptible, some types of Borans (Bos indicus) can be
more tolerant than others. However, breeding for trypanotolerance alone is not a
sufficient control programme and in general, most trypanotolerant Bos taunts cattle
have a low productivity compared to susceptible Bos indicus.
2.1A Induction of immunity by vaccination
The changing of the surface coat by blood stream forms (trypomastigotes) of
trypanosomes has frustrated efforts in search of a vaccine (Crowe et al 1983;
Vickerman and Barry 1982; Barry 1986). There are numerous examples of
unsuccessful attempts to immunise animals with different strains of trypanosomes
(Schilling 1935; Duxbury et al 1972. Wellde et a! 1973) Immunisation with T.
rhodesien.se produced a strong resistance to challenge in cattle which lasted at least 8
months, but was waning by 14 months. The number of trypanosomes used was very
large and success was only achieved with 6 weekly intravenous inoculations of about
101() trypanosomes (Wellde et al 1973). Morrison et al (1982) using either single
inoculum of 107 irradiated T. brucei or 200pg of variant specific surface antigens of
T. brucei found that protection was conferred against challenge with lCfi
trypanosomes 14 days later. Also a group of mice which received 12-15 infective
tsetse bites on two occasions 21 days apart, were resistant to infection when subjected
to subsequent fly challenge with the same clone, while a second group of mice
immunised and challenged by a clone from a different stock of T. congo/ense became
infected (Nantulya, Doyle and Jenni 1980b). These results demonstrate that it is
essentially easy to immunise animals against trypanosomiasis provided the challenge
infection contains only the same variant antigen types as were used to immunise.
However, antigenic variation has made it impossible for a field challenge to contain
only one variant type to which animals would have already been exposed to. It is now
established that a tsetse fiv even when infected with a cloned population, after cyclical
development inoculates a mixture of metacyclics into the mammalian host.
Trypanosomes remain uncoated for several weeks while developmental stages mature,
during which period the fly ingests a blood meal every few days. If this blood
contained antibodies against 'common" antigens of the uncoated trypanosomes,
infection of the fly may be inhibited (Barry 1986). Nevertheless, this approach has
been tried by immunising goats with freeze dried procyclic trypanosomes and then
infecting them with T. congo/ense. T. vivax. and T. brucei (Murray, Morrison and
Whitelaw 1982). When parasitaemia developed, tsetse flies were allowed to feed on
the goats and it was subsequently found that T. congo/ense infection rates for these
flies was significantly reduced as compared to tsetse flies fed on unimmunised goats.
No difference was observed with T. vivax or T. brucei. However, were this approach
successful, it would still have the practical reservation that unimpeded cyclical
development would still occur in flies feeding on wild animals. However, traces of
hope exist in the development of a vaccine based on the surface coat expressed by
metacyclic forms in the tsetse fly since the overall composition of the metacyclic
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surface coat is relatively constant although it may change with time (Nantulya,
Musoke and Moloo 1986).
Murray and Morrison (1979) were able to induce an increased non-specific host
defence activity (e.g. macrophage function) against T. congolense by using Bacillus
Calmette-Guerin (BCG) and Corytiebacterium parvum. These agents were able to
enhance the immune response to T. congolense infections in susceptible A/J mice and
more resistant C57BL/6J mice, both showing reduced parasitaemias and increased
survival times. The development of effective immunostimulants may provide attractive
complementary tools for future control of trypanosomiasis, but so far nothing much
has been done in this area.
2.7.5 Immune responses and chemotherapy in trypanosomiasis
The combined effects of chemotherapeutic agents and the immune system against
trypanosome infections remain in its infancy. Experimental evidence has shown that
the immune system plays a significant role in the effectiveness of
difluorometlylornithine (DFMO) chemotherapy in African trypanosomiasis in mice
(DeGee, MacCann and Mansfield 1983). Also repeated sub-curative drug treatment
with cymerlarsan, berenil or ISMM was found to lead to the development of drug
resistant trypanosomes only in immunosuppressed animals (Osman, Jennings and
Holmes 1992). These results suggest that the state of the host immune system may
play an important role in the development of drug resistance. However, the role
played by the immune system on the efficacy of isometamidium, the sole prophylactic
drug against livestock trypanosomiasis is not well understood. The relationship
between immunocompetence and prophylaxis is of great clinical importance since it is
known that trypanosome infections and other stress factors are associated with
immunosuppression.
Cattle infected with T. congolense and treated with Berenil developed characteristic
delayed type hypersensitivity skin reactions when inoculated intradermaly with
ultrasonicated 7 congolense antigen. PBLs from these animals proliferated in vitro
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when collected before chancre development or after drug treatment but not during the
period of active infection (Emery and Moloo 1980). Immunisation of goats with tsetse
transmitted T. congolense and drug treatment after chancre development on day 13
post infection resulted in protection against homologous challenge. On the other hand
immunisation by intravenous inoculation ofmetacyclics or treatment of tsetse infected
goats before chancre development failed to produce protection (Taiwo et al 1990).
Morrison, Murray and Akol (1985) showed that cattle experimentally infected with
trypanosomes could be made immune to homologous challenge by a brief period of
infection followed by trypanocidal drug treatment. Cunningham (1968) and Wilson
(1971) obtained similar results but Wellde et al (1981) failed to induce protection in
cattle infected with T. congolense and treated with Berenil at various intervals after
infection, then challenged with the parent stock 28 - 128 weeks after treatment.
Protective immunity induced against trvpanosome infection and drug treatment is said
to be specific for the surface coats that develop during the course of infection
(Nantulya et a! 1980b. Akol and Murray 1985). Rabbits immunised by cyclical
infection and treatment with homidium chloride 7 days after development of chancre
showed immunity lasting about 10 months (Luckins and Gray 1983). Nevertheless,
animals that recover from the infection on their own, also develop protective
immunity to subsequent homologous challenge. Cattle that self cured from a primary
T. congolense infection after 30-61 weeks became fully immune to the same stock
25 - 54 weeks after the parasitaemia had disappeared (Wellde et al 1981).
Serum IgM levels increase many times during infection and persist for quite sometime
even after drug treatment (Luckins and Gray 1979; Boid et ct! 1980). No trypanolytic
antibodies have been detected in prophylactically treated cattle infected with T.
congolense six months later (Whitelaw et al 1986, Peregrine et al 1988 ). However,
there is no existing information on the effect of drugs on T cell immune responses in
prophylactically treated animals. In addition, these studies could not rule out the





Working solutions and a list of several reagents used in all experiments and their
suppliers is provided in appendix I.
3.1 TRYPANOSOMES
Three isolates of T. congolense (TREU 1476 and TREU 1881) that had been adapted
for in vitro axenic culture conditions were all stored in liquid nitrogen at the Centre
for Tropical Veterinary Medicine. TREU 1476 was a blood stream form while both
insect and blood stream forms of TREU 1881 were used.
3.2 EXPERIMENTAL ANIMALS
Scottish black face male sheep approximately two and a half years and average body
weight of 41kg were obtained from Moredun Pentlands Buildings and maintained on a
normal diet and management at the Centre for Tropical Veterinary Medicine animal
quarters. Twelve week old female T O. outbred mice were supplied by A.Tuck and
Son Ltd, Beeches Road, Battlebridge, Essex, SI 1 8TJ, U.K., while C57 BL/6 and
BALB/c inbred strains of mice were from B&K Universal, Grimston. Aldborough,
Hull, HU1 1 4QE, U.K.
3.3 EXPERIMENTAL DESIGN
Three groups of sheep were used for trypanosome infection experiments (Table 3 .1).
The prophylactic group was injected with 1 mg/kg ISMM intramuscularly. Plasma
was collected daily for four days, rhen 7, 14 and 21 days after treatment and stored at
-20"C till required for drug concentration determination. Blood in EDTA was
collected weekly for the determination of total RBC, total WBC, differential WBC,
PBMC phenotypes. proliferation and IFN-y production in vitro. Four and half months
after ISMM treatment of the prophylactic group all three groups were inoculated with
1(4 metacvctics of T. congoien.se isolate TREU 1881 and rectal temperature was
recorded daily till termination of experiment 35 days post infection. Plasma collected
35 days post infection was stored at -20"C and later used to determine trypanosome
specific IgG antibodies.
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Control 4 IFNy, phenotypes, in vitro
proliferation.
Clinical, parasitaemia. IFN-y,
phenotypes. in vitro proliferation. IgG
antibodies
Prophylactic 4 ISMM plasma conc. IFN-y,
phenotypes. in vitro proliferation.
Clinical, parasitaemia, IFN-y,
phenotypes. in vitro proliferation. IgG
antibodies
Treated 4 IFN-y, phenotypes. in vitro
proliferation.
Clinical, parasitaeinia. IFN-y,
phenotypes. in vitro proliferation. IgG
antibodies
N = number of sheep per group
The BCG-ISMM group (Table 3.2), was first injected with 1 mg/'kg ISMM and 14
days later both groups were inoculated with 5 human doses of BCG vaccine. Blood in
EDTA was collected weekly from 14 days before BCG inoculation to 35 days after
inoculation for the determination of PBMC phenotypes and estimation of proliferation
in viva. When the experiment was terminated 35 days after inoculation at which point,
two 0 1 ml of PPD was injected intradermaly to determined delayed type
hypersensitivity reaction.





BCG-Control J Phenotypes. in vivo proliferation. Phenotypes. in vivo proliferation. PPD
skin test
BCG-ISMM 3 Phenotypes. in vivo proliferation Phenotypes. in vivo proliferation. PPD
skin test
N = number of sheep per group
Four groups consisting of 20 mice were used for determining the efficacy of ISMM in
mice (Table 3.3). Group one was used as control, group two was given 0.02 mg
hydrocortisone daily for four consecutive days, group three received a single
prophylactic dose of 1 mg/'kg ISMM Group four was given a single prophylactic dose
of 1 mg/'kg ISMM and 0.02 mg hydrocortisone daily for four consecutive days.
Eleven days post ISMM treatment all groups were inoculated with 10" trvpanosomes
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intraperitoneally. Thereafter tfiey were examined for parasitaemia, pre-patent period
and survival time.




Control 5 Parasitaemia. pre-patent period and survival time
Hvdroco. 5 Parasitaemia. pre-patent period and survival time
ISMM 5 Parasitaemia. pre-patent period and survival time
ISMM
+Hvdroco.
5 Parasitaemia. pre-patent period and survival time
N = number ofmice per group
Hvdroco. = Hydrocortisone
Table 3.4 shows the chronology of injecting ISMM to mice for determining its effects
on IL-12 and IFN-y production. Three mice were injected with ISMM 21, 14, and 7
days before in vitro culture of splenic cells. All mice including 3 for the untreated
control group were killed on the same day and spleens aseptically removed for the
separation of splenic cells.




Control 3 IL-12 and IFN-y production in vitro
Day 7 3 IL-12 and IFN-y production in vitro
Dav 14 3 IL-12 and IFN-y production in vitro
Dav 21 3 IL-12 and IFN-y production in vitro
N = number of mice per group
3.4 Determination of ISMM plasma profile
Plasma was collected from the four prophylactically treated sheep at certain intervals
post treatment for measuring ISMM levels. The method used is a competitive ELISA
as described by Eisler el ul (1994). The principal of the assay is that free drug in
plasma competes with ISMM-horseradish peroxidase conjugate for binding to anti-
ISMM antibodies bound to the plate. The intensity of colour produced is inversely
proportional to the amount of free drug present in the sample. Therefore, a high
optical density means drug concentration is low and vice versa Rabbit anti-ISMM
antibodies were diluted 1 8000 in carbonate/bicarbonate coating buffer. 100 ul were
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dispensed into 96 weii plates and incubated overnight at 4°C. Plates were stored at -
20°C in situ for not more than 3 months. Prior to use plates were thawed and brought
to room temperature. The following 1:3 serial dilutions of ISMM standards were
prepared: 500, 166.7, 55.55, 18.51, 6.17, 2.05, 0.686, 0.229, 0.076 and 0.0225 ng/ml.
ISMM-horseradish peroxidase conjugate was diluted 1: 128 000 in PBST. Each
sample/standard was diluted 1:10 in the diluted ISMM-horseradish peroxidase
conjugate. Thawed plates were then washed five times and 100 pi of sample/standard
plus ISMM-horseradish peroxidase were added to anti-ISMM coated wells in
duplicate. 100 pi of PBST were added to a blanking well Plates were then incubated
at 4°C overnight. A 1:1 dilution of substrate/'TMB chromogen was prepared and
warmed-up to 37°C. Plates were again washed five times, after which 100 pi of
substrate/'chromogen were added and incubated at 37"C for 10 minutes. Then 100 pi
of 2M ortho-phosphoric acid were added to stop the reaction. The plate was vortex
mixed for 2 minutes before reading absorbency at 450 nm on a Multiscan ELISA
plate reader. A plot of absorbency (Y-axis) against standard concentration (X-axis in
log units) was made. Sample concentrations were obtained by extrapolation from the
standard graph.
3.5 In vitro efficacy of ISMM on T. congolense
T. congolense isolate TREU1467 and TREU1881 were cultured axenicaliv according
to the method of Ross and Taylor (1990) at an initial concentration of 5 x 10"
trypanosomes/'ml in 96 well culture plates in a humidified 5% carbon dioxide
incubator at 33.5°C. ISMM was incorporated in cultures at an increasing
concentration of 0, 1. 10, 100, and 1000 ng/'ml. Promega Cell Titer96* Proliferation
assay was used to determine the proportion of viable cells present in cultures. After a
48 hour incubation period. 15 pi of Promega dye solution were added directly into
culture wells. Incubation was continued for 4 hours after which 100 pi of
solubilisation/'stop solution were added to all wells. Plates were left in a humid
chamber overnight to allow blue formazan crystals to solubilise, thereafter absorbency
was read on a Multiscan ELISA plate reader at 570 nm. The assay is non-radioactive
and is based on a viable cellular enzymatic conversion of a tetrazolium salt into a
formazan product that is easily detected using an EL1SA plate reader at 570 nm.
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Colour intensity is proportional to the number of viable cells present. Inhibition of
trypanosome growth was calculated as a percentage of the control cultures subtracted
from 100 since assay readings corresponded to the number of viable not dead cells
present.
3.6 Clinical, haematological and parasitological examinations
All animals inoculated with trypanosomes were observed frequently for any clinical
signs. Parasite detection and packed cell volume (PCV), were performed using the
heamatocrit method where capillary tubes containing EDTA blood were centrifuged
at 10 000 g (Biofiige). After recording the PCV, the buffy coat was examined for
parasites under the microscope. Total red and white cell counts were performed using
a Coulter counter. Differential white cell counts were performed by fixing thin blood
smears with methanol for 1 minute followed by staining in 10% Giemsa stain for 10
minutes. Slides were examined under a microscope and neutrophils, eosinophils,
monocytes and lymphocytes were scored out of a total of 200 cells counted. Rectal
temperatures were taken every morning after infection using a digital thermometer.
3.7 Preparation of peripheral blood mononuclear cells (PBMC)
Approximately 14 ml of venous blood was collected from each sheep using EDTA as
an anticoagulant. Samples were centrifuged at 1000 g for 20 minutes at 4°C. The
huffy coat was then suspended in 9 ml of PBS containing 20 U/'ml heparin (wash
buffer). This was slowly layered on top of Ficoll-Paque (Pharmacia, Uppsala,
Sweden) and cenlrifuged at 1000 g for 35 minutes. PBMC were removed from the
interface and washed twice in wash buffer at 350 g for five minutes. Cells were re-
suspended in 5 ml of culture media (RPMI 1640 supplemented with, 7% foetal calf
serum and 100 U/ml penicillin plus 100 mg/'mi streptomycin) They were counted on a
6 .
heamocytometer and cultured at a density of 5 x 10 /ml in 96 well culture plates in a
volume of 200 pi media at 37°C for the required period of time.
3.8 Cell phenotype analysis
For each sample, 200 pi of cell suspension prepared above were put in FACS tubes
labelled, blank, CD4, CD5, CDS, y5 and B ceil. Cells were washed once with ice cold
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wash buffer by centrifuging at 350 g for 5 minutes. Then 25 pi of wash buffer were
added to blank tubes and 25 p.1 of each antibodies (undiluted) to appropriate test tubes
and incubated at 4"C for 30 minutes. Cells were then washed twice and 25 pi of
1:1000 FITC-conjugated antimouse-isotype were added to appropriate tubes
including blanks and incubated for 30 minutes at 4"C in the dark. After that cells were
washed once and re-suspended in 200 pi of wash buffer and 200 pi of 1%
paraformaldehyde and kept at 4°C till analysis on the flow cytometer. The FACSAN
cell analyser was used for analysis. 10 000 cells analysed and data calculated in
histogram mode. Different cell populations were detected using Forward (FSC) and
Side (SSC) Scatter parameters (in linear amplification mode). Fluorescent light
emission were detected in logarithm amplification mode. Cell phenotype proportions
obtained from the FASCAN for trypanosome experiments were converted to absolute
number of cells per millilitre of blood by first calculating absolute lymphocyte
numbers by multiplying total white cell counts by the percentage of lymphocytes in
blood. Then, multiplying the percentage of each phenotype by the absolute
lymphocyte count yields the absolute phenotype count.
3.9 Determination of PBMC proliferation in vitro
Peripheral blood mononuclear cells were prepared from blood in EDTA as described
in section 3.6. Each sample was divided into three for culture with: 2.5x107ml live T.
congolen.se, 6.25 pg/ml ConA, and normal media. Cultures were kept at 37°C in a
humidified 5% CCF atmosphere for 72 hours. Proliferation of cells was estimated
using the Promega Cell Titer96* Proliferation assay and verified by flow cytometry.
3.9.1 Cell proliferation using Promega Cell Titer96" Proliferation assay
The Promega assay is non-radioactive and is based on the cellular conversion of a
tetrazoiium salt into a fonnazan product that is easily detected using an ELISA plate
reader at 570 nm. It has an advantage over other assays, of being able to detect an
increase in cell numbers as well as activation-induced programmed cell death.
However, the assay is not as sensitive as the radio-labelled thymidine uptake assay,
but has the advantage of being able to detect activation-induced programmed cell
death, which the radio-labelled thymidine uptake assay cannot detect.
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PBMCs were cultured in 96 well plates in 200 pi of media (RPMI 1460 containing
7% foetal calf serum) at a density of 5 x 105 cells per well with or without 2.5 x
lOVml trypanosomes or 6.25 pg/'mi ConA. After the 72 hour incubation period, 30 pi
of dye solution were added to each well and incubation continued for a further 4
hours at 37°C in a humidified 5% CO2 atmosphere. Thereafter, 100 pi of
solubization/stop solution were added to all wells. Plates were left to stand overnight
(18 - 24 hrs) in a sealed humidified container at room temperature to completely
solubilize the blue formazan crystals. Absorbance was read at 570 nm wavelength
using a Multiscan ELISA reader. Colour intensity is proportional to the number of
viable cells present. The stimulation index was obtained by dividing the test
absorbance reading by that of media only. An index of 1 indicates that the number of
viable cells in the test well is the same as that in the media only (blank) well. A value
above 1 indicates that there is an increase in cell numbers (proliferation) while that
below 1 means that there is accelerated cell death in test cultures.
3.9.2 Cell proliferation using Flow Cytometry
The use of flow cytometry is a novel approach which is non-radioactive and is more
sensitive than the Promega Cell Titer96" Proliferation assay. The method also has a
further advantage of being able to detect proliferation in vivo by analysing freshly
prepared WBCs or PBMCs But like the radio-labelled thymidine uptake assay, it is
not capable of detecting activation induced programmed cell death Determination of
cell proliferation using Flow Cytometry is based on the principle that cells increase in
size (blast) when they are activated before they divide. The difference in size between
normal un-stimulated cells and blast cells can be delected by the How cvtometer. The
percentage of blast cells is directly proportional to the stimulation of ceils to
proliferate. PBMCs from cultures or prepared straight from the animal were
suspended in 400 pi of PBS in How cytometry tubes. 10 000 mononuclear cells were
acquired through a dot plot display without the need for antibody staining and stored
on computer for further analysis. Stored events were analysed on a dot plot display by
selling two gates, one for all mononuclear cells and the other for blast cells only. For
in vitro assays, the stimulation index was obtained by dividing the percentage of
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iymphoblasts in test sample by that of the media only. An index of 1 indicates that the
number of viable cells in the test well is the same as that in the media only (blank)
well. In vivo, the percentage of iymphoblasts increases above pre-infeetion levels. The
reference normal level of lympnobiasts depends on the gating of the two cell
populations but does not affect the stimulation index obtained since it is a ratio.
3.10 IFN-y determination assays
3.10.1 Sheep IFN-y assay
PBMC preparation and culture plate set-ups were carried out as described in section
7.2.1 above. After a 48 hour incubation period culture supernatants were collected
and stored in vials at -70°C. Sheep IFN-y levels in supernatants were determined using
the Bovine y interferon Test. The test recognises bovine, ovine and caprine IFN-y. It
is a solid phase sandwich enzyme immunoassay designed to detect biologically active
IFN-y in plasma. The use of the test in ovine and caprine IFN-y detection has been
reported to be effective in demonstrating cell mediated immunity to various
experimental antigens, T cell epitopes and adjuvant formulations in these species. The
test will detect less than 50 pg/ml of recombinant IFN-y or less than I unit of
"natural" IFN-y.
Test samples were assayed in duplicate in adjacent wells while positive and negative
controls were assayed m triplicate serial wells. 50 pi of diluent were added to the
required number of wells followed by 50 pi of test and control samples. Control
samples were added last to each plate, mixed well, and incubated at room
temperature for 60 minutes. Plates were washed five times and 100 pi of freshly
prepared conjugate reagent added to all wells, then left to incubate at room
temperature for 60 minutes. Thereafter, plates were once again washed 5 times and
100 pi of freshly prepared enzyme substrate solution added. Plates were incubated for
30 minutes at room temperature, after which 50 pi of stop solution were added to all
wells. After mixing by gentle agitation, absorbance was read at 450 nm within 20
minutes of terminating the reaction blanking on air Control results were examined
before sample results could be interpreted Firstly, the mean absorbance ol the
negative and positive controls were calculated Results were acceptable if the ratio
of positive to negative mean controls was greater than 7.5. The cut-off point was
taken to be the mean of the negative control plus two times its standard deviation.
3.10.2 Mouse IFN-y assay
All mice shown in Table 3.4 were killed and spleens were aseptically removed, and
mashed on sterile stainless steel mesh to separate mononuclear cells from connective
tissue. Splenocytes were then suspended in 1 ml of culture media, counted and their
concentration adjusted to 5x10 /ml. 100 pi of each sample were added to 96 well
plates followed by 100 pi of media or iOOpl of two times the desired final
concentration of LPS (i.e. 2 pg/mf) or trypanosomes (i.e. 5x 107ml) in culture media.
Plates were then incubated for 24 hours at 37"C in a 5% C02 humidified incubator,
after which supernatants were collected and used to assay IFN-y and 1L-12
immediately.
The assay used was the InterTest-y™ Mouse IFN-y ELISA which is a solid-phase
ELISA employing the multiple antibody sandwich principle. The assay can detect upto
5 pg/'mi mIFN-y. Samples were assayed in duplicate and negative and positive (540
pg/ml) controls in quadruplicates. First, 100 pi of control and test samples were added
to 96-well microtitre plate (pre-coated with anti-mlFN-y antibody) and incubated for
1 hour at 37"C. Plates were washed 4 times and 100 pi of biotinylated anti-mouse-
IFN-y added to each well and incubated for 1 hour at 37"C Plates were again washed
4 times and 100 pi of horseradish peroxidase - conjugated streptavidin were added to
ail wells and incubated for 30 minutes at 37°C. After washing 4 times 100 pi of TMB
substrate reagent were added and incubated for 15 minutes at room temperature.
Colour development was stopped by adding 100 pi of stop solution to every well. The
ELISA reader was blanked on air and absorbance read at 450nm. Results were
acceptable if the ratio of positive to negative mean controls was greater than 7.5.
The cut-off point was taken to be the mean of the negative control plus two times its
standard deviation
45
3.11 Mouse IL-12 determination assay
Total IL-12 and IL-12p70 in supernatants from cultures were assayed as described
below.
3.11.1 Total Mouse IL-12 assay
InterTest™-I2X Total Mouse IL-12 ELISA Kit is a solid-phase ELISA employing
the multiple antibody sandwich principle. A 96-well microtitre (pre-coated with anti-
mouse IL-12p40) was used to capture mouse IL-12 from control and test samples.
Three secreted forms of IL-12 have been identified and this assay will detect all the
three forms: p70 heterodimer, p402 homodimer and p40 monomer. All samples were
run in duplicate while negative and positive (540 pg/'ml) controls were run in
quadruplicates. 50 pi of assay diluent and 50 pi of samples were added to wells, while
100 pi of controls were added without further dilutions followed by incubation at
room temperature for 30 minutes. Plates were washed 4 times and 100 pi of anti-
mouse IL-12 biotinylated antibody added to all wells, then incubated at room
temperature for 30 minutes. .After another similar wash 100 pi of horseradish
peroxidase-conjugated streptoavidin were added and incubated at room temperature
for 15 minutes. At the end of this incubation plates were washed again 4 times and
100 pi of substrate added and incubated for 10 minutes at room temperature.
Reaction was stopped by the addition of 100 pi of stop solution. After mixing well,
absorbance was read at 450 nm. Results were acceptable if the ratio of positive to
negative mean controls was greater than 7.5. The cut-off point was taken to be the
mean of the negative control plus two times its standard deviation.
3.11.2 Mouse IL-12p70 assay
InterTestrM- 12X Mouse IL-12p70 ELIS.A Kit is also a solid-phase ELIS.A employing
the multiple antibody sandwich principle. A 96-well microtitre (pre-coated with anti-
mouse IL-12p35) was used to capture mouse IL-12p70 from control and test
samples. All samples were run in duplicate while negative and positive (540 pg/'ml)
controls were run in quadruplicates. 50 pi of assay diluent and 50 pi of samples were
added to wells, while 100 pi of controls were added without further dilutions
followed by incubation at room temperature for 2 hours while shaking at 150g. Plates
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were washed 4 times and 100 pi of anti-mouse IL-12 biotinylated antibody added to
all wells, then incubated at room temperature for 1 hour while shaking at 150g. After
another similar wash 100 pi of horseradish peroxidase-conjugated streptoavidin were
added and incubated at room temperature for 15 minutes with shaking at 150g. At the
end of this incubation plates were washed again 4 times and 100 pi of substrate added
and incubated for 20 minutes at room temperature without shaking. Reaction was
stopped by the addition of 100 pi of stop solution. After mixing well, absorbance was
read at 450 nm. Results were acceptable if the ratio of positive to negative mean
controls was greater than 7.5. The cut-off point was taken to be the mean of the
negative control plus two times its standard deviation.
3.12 Trypanosome specific plasma IgG antibody titration
Antigens from T. cottgolense isolate number TREU 1881 were prepared in PBS by
three cycles of freeze thaw at -20°C. The lysate was centrifiiged at 3000 rpm. The
supernatant was collected and the protein concentration estimated using a modified
method of Lowrv et al (1951). Antigen was diluted in carbonate/bicarbonate coating
buffer pH 9.6 at a final protein concentration of 1 pg/'ml. 100 pi of diluted antigen
were added to all wells of a 96 well Immulon* 4 plate. Plates were incubated
overnight at 4"C. A serial dilution of negative and test sera was performed in a 96 well
culture plate in duplicate columns. Final serum dilutions were:, 1:2, 1:4, 1:8, 1:16,
1:32. i:64. 1:128, 1:256. 1:512, 1:1024, 1:2048. 1:4096, 1:8192, 1:16384, 1:32768,
and 1:65536 Antigen coated plate were washed 4 times with 0.05% tween 20 in PBS
(wash buffer). Then 100 pi of serial diluted sera was added to coated plates and
incubated at 37"C for 30 minutes. After incubation plates were washed four times.
Then. 100 pi of 1:30000 anti-bovine-IgG-'norseradish peroxidase conjugate was
added to all wells and incubated for 30 minutes at 37°C. Again plates were washed
four times and 100 pi of substrate/'chromogen (H2O2/TMB) were added and plates
incubated for 15 minutes at 37"C After that iOO pi of 1M ort'no-phoshoric acid
(ITPO4) were added and optical density read at 450 nm. The antibody litre was the
highest dilution that gave a positive result after subtracting readings for the negative
serum.
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3.13 Statistical analysis of results
Statistical analysis of results was done in two ways. The first was within group
analysis where pre-infection results were compared with post infection results. For
some results, the second analysis was carried out between groups, where comparisons
were made between the control and the prophylactic or treated groups during the
period during the post infection or post treatment periods. Some of the results were,
normally distributed while others were not, therefore all results were analysed non-
parametrically using the Mann-Whitney test (GraphPAD Instat, GraphPAD Software,
version 1.13, 1990)
The magnitude of fever (estimated from rectal temperature) was compared by
performing statistical analysis on the area under the temperature time curve using the
trapezoidal equation rule (Hail 1958) for all animals. Approximation of the area
under the graph was done in four steps: (1) data of temperature and time was plotted
on a 5 mm square grid such that each unit of time was 5 mm and each decimal unit of
temperature was also 5 mm. (2) the plot was then divided into 5mm wide panels on a
baseline at 40"C. (3) the number of grid points between 40°C and each observed
temperature were counted (4) the approximate area under the temperature curve was
calculated from the trapezoidal rule equation as follows:- Area =
(h)(n')/{y\,+yt/2/+y,+y2+ where h is panel height, w is panel width, and y„,
>'/ ,j'2 y„ are panel numbers. Tables of representative statistical analyses are




PARASITOLOGICAL, CLINICAL AND HAEMATOLOGICAL
RESPONSES
4.1 INTRODUCTION
Haematological changes in white and red cells have been well documented as major
pathophysiological feature of trypanosomiasis in domestic livestock (Valli and Mills
1980: Ellis et al 1987). Infection with T. congolense resulted in lymphocytopaenia
followed by lymphocytosis and anaemia after the onset of parasitaemia (Valli.
Forsberg and Mills 1979; Ellis et al 1987; Williams et al 1991). Fever usually
fluctuates with waves of parasitaemia when the disease enters the chronic stage
(Williams et al 1991; Onah 1990). Similar haematological changes were observed in
sheep infected with T. congolense (Mwangi 1991) and 7. evansi (Onah 1990).
Parasitological examination, rectal temperature and haematological analysis constitute
reliable methods of monitoring the pathology of the infection. Anaemia is the main
pathological lesion and is clinically determined by the packed cell volume. Severe loss
of red blood cells results in a decrease in the packed cell volume. In addition to
disease monitoring, haematological parameters mark the starting point for studying
white blood cell subsets in the peripheral blood Therefore, these parameters are
discussed in this chapter
4.2 MATERIALS AND METHODS
Parasitaemia. rectal temperature, total and differential cell counts were determined as
described in Chapter 3. section 3.6. Parasitaemia and eel! counts were determined
once a week while PCV was performed twice a week and rectal temperature was




Parasitaemia was estimated by counting parasites from the buffy coat on a
heamocytometer. Results presented in Figure 4.1 indicate that there were no parasites
detected in the prophylactic group using the haematocrit method throughout the
infection period. Animals in the control and treated groups were all parasitaemic 7 day
post infection. The control group remained parasitaemic throughout the study period.
Sheep 1863 and 2381 from the control group were jaundiced by day 28 post
infection. Parasites were subsequently cleared from the treated group, except sheep
2BF which relapsed by 35 days post infection.
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4.3.2 Determination of fever
The rectal temperature was taken every morning and used to monitor the progression
of fever. Rectal temperature of 40.5"C was taken as the critical value Recordings
above the critical value were indicative of a febrile state. In order to make a
quantitative comparison of fever, the area under the temperature time curve was
approximated in four steps: (1) data of temperature and time w as plotted on a 5 mm
square grid such that each unit of time was 5 mm and each decimal unit of
temperature was also 5 mm. (2) the plot was then divided into 5 mm wide panels on a
baseline at 40°C. (3) the number of grid points between 40"C and each observed
temperature were counted (4) the approximate area under the temperature curve was
calculated from the trapezoid rule equation described in Chapter 3, section 3.13. The
area obtained was proportional to the magnitude of fever.
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Results indicate that the control group showed waves of fluctuating fever throughout
the study period (Figure 4.2; Table A 1(a)-Appendix II). The onset of fever ranged
from 4 to 9 days post infection and the magnitude was highest in sheep 2381 and
lowest in sheep 1736. The area under the curve being; 5575 mm2 for sheep 2381,
5150 mm2 for sheep 2383, 4500 mm2 for sheep 1863, 3050 mm2 for sheep 1736 and
the median value was 4825 mm2.
Figure 4.2 Rectal Temperature for the Control group following primary
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None of the sheep in the prophylactic group developed fever and their rectal
temperature values were all below the critical value of 40.5°C (Figure 4.3; Table
A 1(b)-Appendix II). The areas under the temperature time curve were; 300 mm2 for
sheep 1618, 225 mm2 for sheep 1746, 75 mm2 for sheep 1895 and 50 mm2 for sheep
1826. The median value of 150 mm2 was significantly different (P<0.05) from that of
the control (4825 mm2).
Figure 4.3 Rectal Temperature for the Prophylactic group following primary
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The treated group also showed waves of fluctuating fever which subsided following
treatment with ISMM (Figure 4.4; Table A1(c)-Appendix II). However, sheep 2BF
became febrile again 31 days post infection. The magnitude was highest in sheep 1499
and lowest in sheep 3WS. The area under the curve being; 3025 mm2 for sheep 1499,
2875 mm2 for sheep 2BF, 2675 mm2 for sheep 2386 and 2425 mm2 for sheep 3WS.
Median area under the curve from zero to 17 days post infection was 1688 mm2 and
dropped non-significantly (P>0.05) to 1350 mm2 thereafter. The median area under
the curve for the whole study period for the treated group of 2775 mm2 was
significantly (P<0.05) lower than that of the control group of 4825 mm2.
Figure 4.4 Recta! Temperature for the Treated group following primary
infection with 7. congolense
Sheep 2BF
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4.3.3 Packed cell volume (PCV, (%)) following primary infection with T.
congolense
Figure 4.5 and Table A2-Appendix II, show results for the PCV. In the control group
the PCV dropped significantly (P<0.0001) from a pre-infection median value of 32%
to that of 22% thirty five days post infection, while no significant changes in the
prophylactic group were observed. In the treated group, the PCV decreased
significantly (P<0.0001) from a median of 35% to 28% 21 days post infection, but
returned to normal about 3 weeks after treatment.
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Figure 4.5 PCV (%) following primary infection with T. congolense
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4.3.4 RBC count following primary infection with T. congolense
Results in Figure 4.6 and Table A3-Appendix II, show a significant loss of red cells in
the control group 21 to 35 days post infection compared to pre-infection levels
(P<0.0001). Despite, a decrease in the PCV in the treated group, RBC count
remained unchanged throughout the period (P>0.05). No changes in RBC counts
were recorded in the prophylactic group (P>0.05).
Figure 4.6 RBC count following primary infection with T. congolense
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4.3.5 WBC counts following primary infection with T. congolense
WBC counts increased significantly (PO.OOOl) in the control group from 14 to 35
days post infection compared to pre-infection levels (Figure 4.7; Table A4- Appendix
II). Only sheep 1746 in the prophylactic group showed a non-significant transient
increase 21 days post infection (P>0.05). No significant increase in the treated group
was observed after infection (P>0.05). However, levels were slightly higher than
normal for all sheep in the treated group, but returned to normal in sheep 1499 and
2386 after treatment.
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4.3.6 Absolute Lymphocyte counts following primary infection with T.
congolense
Absolute lymphocyte counts increased significantly (PO.OOOl) in the control groups
from 14 to 35 days post infection compared to pre-infection levels (Figure 4.8; Table
A5-Appendix II). Only sheep 1746 in the prophylactic group showed a non-significant
transient increase 21 days post infection. A significant increase was also observed in
the treated group after infection (P<0.01).
Figure 4.8 Absolute Lymphocyte counts following primary infection with T.
congolense
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4.3.7 Absolute Monocyte counts following primary infection with T. congolense
Figure 4.9 and Table A6-Appendix II, shows that the median monocyte count in the
control group 14 to 35 days post infection was significantly different from that before
infection (P<0.05). The highest increase was observed 14 days post infection. In the
prophylactic group, the change was not significant (P>0.05), although sheep 1746 and
1826 seemed to show an increase 14 to 28 days post infection. A significant increase
was recorded in the treated group 14 to 21 days post infection (P<0.01), but returned
to normal about 2 weeks after treatment.
-Control —-—Prohy lactic —A—Treated
Figure 4.9 Absolute Monocyte counts following primary infection with 7.
congolense
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4.3.8 Absolute Neutrophil counts following primary infection with T. congolense
Absolute neutrophil counts, did not show any significant changes (P>0.05) in all
groups (Figures 4.10; Table A7-Appendix II), even in the control group where sheep
1736 and 1863 had high levels 35 days post infection.
Figure 4.10 Absolute Neutrophil counts following primary infection with T.
congolense



















l—i—i 0 1 —i—\—i—i—i—r—i—i—i
-14 -7 0 7 14 21 28 35
Days pre/post infection
■1736 1863 2381 -2383







-14 14 21 28 35
Days pre/post infection
















-7 0 7 14 21
Days pre/post infection
1618 1746 1826 1895
(d) Median absolute Neutrophil








^ i -A. /
1 •
0 , , ,
-14 -7 0 7 14 21 28
Days pre/post infection
35
-Control -Prohy lactic —*—Treated
60
4.3.9 Absolute Eosinophil count following primary infection with T. congolense
Results summarised in Figure 4.11 and Table A8-Appendix II, indicate that absolute
eosinophil counts, did not show any significant changes in all groups throughout the
study period (P>0.05).
1736 2381 —*—2383
Figure 4.11 Absolute Eosinophil count following primary infection with T.
congolense
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4.4: DISCI SSION
Parasitaemia was determined using the haemotocrit method and results show that no
sheep in the prophylactic group was parasitaemic throughout any of the study period,
while all sheep from the control and treated groups became parasitaemic 7 days post
infection. The control group remained parasitaemic. while after treatment parasites
were cleared from the treated group, (although sheep 2BF relapsed 35 days post
infection). Sheep 1863 and 2.381 from the control group showed signs ofjaundice (i.e.
yellow mucous membranes and serum) 28 days post infection This was an indication
of severe destruction of red blood cells. Rectal temperature above the critical value of
40.5"C was used to determine fever and the area under the temperature time curve
gave an estimate of the magnitude of fever Results show that the magnitude of
fluctuating fever were highest in the control group with a median area under the curve
of 4825 mm' followed by the treated group with 2775 mm2. The magnitude of fever
in the treated group of 1688 mm2, zero to 17 days post infection was not significantly
higher than 1350 mm2 that prevailed after treatment because although rectal
temperature for sheep 1466 and 2386 was below the critical value it remained
consistently above the baseline of 40°C used for calculating the area under the curve.
Sheep from the prophylactic group were all not febrile and the median area under the
curve was the lowest (150 mmj. Fever usually fluctuates with waves of parasitaemia
(Williams el a! 1991. Onah 1990) and each peak of fever normally correspond to a
peak of parasitaemia. but in this study it was not possible match fever with
parasitaemia because parasitaemia was determined weekly while temperature was
taken daily Comparing NMama and Boran cattle undergoing a primary infection with
T. congolense, Williams el al (1991) found that parasitaemia was lower and usually
intermittent in the trvpanotolerant Ndama than in the susceptible Boran cattle.
Results of this study demonstrate that a prophylactic dose of 1 mg/kg ISMM was
capable of preventing the establishment of a 1. eongolense infection four half months
after treatment and that a similar dose was also capable of clearing an established
infection although relapses could occur in some cases Complete protection was also
afforded bv 1 mg/kg ISMM for four months (Peregrine el al 1988). and for one to six
months (Eisler el al 1994) in Boran cattle Sones. Ngoju and Holmes (1988) assessed
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the sensitivity of different strains of T. congolense to ISMM and found that certain
strains of /. congolense could only be temporarily cleared from some animals.
Anaemia was assessed by measuring PCV and total red cell count. Both parameters
decreased from 14 days post infection till end of experiment 35 days post infection in
the control group In the group that was treated with I mg/kg ISMM 14 days post
infection, the PCV begun to return to normal around 25 days post infection
However, a change in total red cell count was not observed in the treated group even
during the period of low PCV for yet unknown reasons This result was unexpected,
but probably the fluorescence properties of ISMM interfered with the electronic cell
counting principle of the Coulter counter, after binding to RBCs, resulting in an
overestimation of their count For instance, an increase in background fluorescence
was observed on a FASCAN when PBMCs had been incubated in more than 10 ng/ml
ISMM However, a blank for each sample on a FASCAN eliminates that effect, but it
is not possible to do that on a Coulter counter for each sample In the prophylactic
group there w as no change of the PCV as well as total red cell count Anaemia is one
of the major pathological lesions associated with animal trypanosomiasis The
principal factor in the causation of anaemia is accelerated red cell loss from the
circulation (Jennings el a! 1974. Alamo and Holmes 1975) The onset and degree of
red cell loss are closely associated with the development and level of parasitaemia.
The precise aetiology of anaemia is still obscure but four mechanisms are proposed
The currently favoured hypothesis is that antibodies specific for trvpanosomes become
complexed with antigen on the red cells leading their sequestration and destruction in
the reticuloendothelial system (Kobavashi. Tizard and Woo 1976; Dodd el ol 1978).
The second possible cause of red cell loss my be haemolysis produced by
trvpanosomes. however, the specific nature of these haemolvsins has not been
characterised (Huan 1975; Tizard el ol 1977) Other possible causes could be the
consequence of a non-specific expansion of the mononuclear phagocytic system or an
increased red cell fragility caused by fever Trypanotolerant N'dama cattle have the
ability to control the parasitaemia and hence the loss of red cells unlike most of the
susceptible Zebu cattle Dargie ei al (1979) observed that the PCV decreased to a
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steady state of 22% in Zebu and 27% in N'dama from a mean of 35%. However,
parasitaemia in N'dama cattle fell to undetectable levels 5 weeks post infection while
Zebu cattle entered a chronic phase of infection.
Total white blood cell (WBC) and absolute lymphocyte counts increased significantly
in the control group 14 days post infection till end of experiment 35 days post
infection The pattern of increase in WBC counts is similar to that of absolute
lymphocyte counts because lymphocytosis is the major contributing factor to
increased WBC count. On the other hand, in the prophylactic group only two sheep
(1746 and 1618) showed a transient rise 21 days post infection, resulting in a non¬
significant increase for the group. Levels of WBC and lymphocyte counts in sheep
2BF and 3WS from the treated group remained higher than normal throughout the
period while those for sheep 1499 and 2386 returned to normal 2 weeks after
treatment. Lymphocytosis and increased WBC counts were also demonstrated by
Mwangi (1991) in sheep infected with i. consoleuse 25 days post infection onwards.
In studies involving cattle infected with T. congolense (Williams el al 1991).
lymphocytopoenia was observed in Boran cattle upto 14 days post infection, while
N'dama cattle showed lymphocytosis from 28 days onwards. Lymphocytopaenia
followed by lymphocytosis (Valli and Forsberg 1979) or continued lymphocytopoenia
(Wellde et al 1974) have been documented in cattle infections with T. congolense
Absolute monocyte counts increased in the control and treated groups 14 to 21 days
post-infection and were almost normal thereafter in both groups There were no
significant monocyte changes in the prophylactic group Absolute neutrophil and
eosinophils counts, did not show any significant changes in all groups It is possible
that changes in neutrophil and eosinophil counts were missed because they are likely
to occur before 7 davs after infection, which happened to be the sampling interval in
this study. Results of monocyte changes are not in agreement, while neutrophil and
eosinophil counts are in agreement with those obtained by Mwangi (1991). where no
changes in monocyte, neutrophil and eosinophil counts were observed in sheep.
Williams ei a! (1991) observed a decline in neutrophil counts 7 to 14 days after
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infection in Boran but not in N'dama cattle, but were unable to find significant
changes in eosinophil counts in both breeds over time but found some increases in
monocytes without any breed differences.
In conclusion, these results demonstrate that ISMM prophylaxis inhibited the
establishment of a T. congolense infection four and a half months after treatment,
thereby preventing the development of major pathological lesions associated with the




IN VITRO AND IN VIVO EFFICACY OF ISOMETAMIDIUM
PROPHYLAXIS
5.1 INTRODUCTION
It is generally understood that therapeutic agents against trypanosomiasis either kill
the parasites (trypanocidal) or simply suppress their multiplication (trypanostatic).
Some agents can be trypanocidal at high concentrations and trypanostatic at low
concentrations. Therefore, without an effective immune response trypanostatic agents
are quite ineffective ISMM is considered to be trypanostatic at the prophylactic dose
Despite this understanding, several studies seem to state that ISMM is trypanocidal
and rule out the involvement of the immune system (Whitelavv el al 1986; Peregrine el
al 1988) simply because they were not able to detect neutralising antibodies. This is
quite misleading and needs to be seriously redressed
Parameters which influence the effectiveness of ISMM have not been well defined, as
a result a considerable uncertainty remains as to the most effective way to use the
drug in the field The study of combined effects of chemotherapeutic agents and the
immune system against infection remain in its infancy. Experimental evidence exists
which shows that the immune system plavs a significant role in the effectiveness of
difluorometlvlornithine (DFV10) chemotherapv in African trypanosomiasis in mice
(DeGee. MacCann and Mansfield 1983) Also, repeated sub-curative drug treatment
with cymerlarsan. berenil or ISMM was found to lead to the development of drug
resistant trypanosomes only in immunosuppressed animals (Osman. Jennings and
Holmes 1992). These results suggest that the state of the host immune system may
play an important role in the development of drug resistance. However, the role
played by the immune system on the efficacy of isometamidium, the sole prophylactic
drug against livestock trypanosomiasis is not well understood. The relationship
betw een immunocompetence and prophylaxis is of great clinical importance since it is
known that trypanosome infection and other stress factors are associated with
immunosuppression
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Breakdowns in isometamidium prophylaxis have been frequently observed in the field
but it is not usually clear whether these are due to inadequate dosing, poor immune
status of the host or to the development of drug resistant trypanosomes. The duration
of prophylaxis varies from as little as 2 weeks (Dolan el al 1992. Munstermann el al
1992) to 14 months (VVellde el al 1973). The relative contribution of drug resistance,
variability in pharmacokinetics and the state of the host's immune system to the
variation in the duration of prophylaxis could not be determined previously due to the
lack of a method capable of measuring low ISMM plasma or serum levels during the
prophylactic period. An enzyme-linked immunosorbant assay (ELISA) has been
developed (Whitelaw el al 1991) for the measurement of ISMM levels in sera of
treated cattle and has made assessment of contributing factors possible.
The objective of this experiment was to: (a) establish ISMM plasma levels prevalent
during the protective period, (b) determine trypanocidal effects of ISMM
concentration present during the protective period, (c) establish the role played by the
innate immunity during ISMM prophylaxis.
5.2 MATERIALS AND METHODS
Methods for determining the profile of ISMM concentration in plasma, in vitro and in
vivo efficacy of ISMM are described in Chapter 3. sections 3.4 and 3.5.
5.3 RESULTS
5.3.1 ISMM plasma profile
The concentration of ISMM was extrapolated from the standard absorbance plotted
against the logarithm of the concentration, A semi-logarithmic plot of concentration
against time yielded a biexponential graph showing that the bioavailability of ISMM
varied greatly between animals although the elimination process was very similar in all
animals The elimination of the drug was bi-phasic in all animals with a rapid
elimination rate in the first week followed by a slow phase there after. The mean
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ISMM levels were 2.7 ng/ml (range 1.1-6.9 ng/ml) after one week (Figure 5.1; Table
B1-Appendix III).
Figure 5.1 ISMM plasma profile







5.3.2 In vitro sensitivity of T. congolense to ISMM
Blood stream forms of T. congolense isolates TREU1467 and TREU1881 were
cultured in vitro at an initial concentration of 5 x 105 trypanosomes/ml for 48 hours in
increasing concentrations of ISMM. After a 48 hour incubation period, viable
trypanosomes were estimated using the Promega®' cell proliferation assay. Inhibition
of trypanosome growth was calculated as a percentage of the control cultures (media
only) subtracted from 100 since assay readings corresponded to the number of viable,
and not dead cells present. Results show that the percentage inhibition of I
congolense multiplication nearly reached a maximum of 72% for isolate TREU1467
and 85% for TREU1881 at the same concentration of approximately lOOng/ml.
Thereafter any increase in drug concentration produced very little inhibition. At
concentrations less than 10 ng/ml the inhibitory effect was less than 45% for isolate
TREU1467 and less than 69% for TREU1881 (Figure 5.2; Table B2-Appendix III).
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Figure 5.2 In vitro sensitivity of T. congolense to ISMM
48 hour in vitro T. congolense growth inhibition by ISMM
-♦— Strain 1467
-A— Strain 1881
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5.3.3 Prepatent period and survival time in mice infected with T. congolense
Four groups consisting of 20 mice were used in this experiment. Group one was a
control, group two received 0.02 mg hydrocortisone daily for four consecutive days,
group three received a single prophylactic dose of 1 mg/kg ISMM. Group four was
given a single prophylactic dose of 1 mg/kg ISMM and 0.02 mg hydrocortisone daily
for four consecutive days. Eleven days post ISMM treatment all groups were
inoculated with 106 trypanosomes intraperitoneally. Thereafter they were examined
for parasitaemia, pre-patent period and survival time. Results show that the prepatent
period (Figure 5.3; Table B3-Appendix III) and the survival time (Figure 5.4; Table
B4-Appendix III) for the control, hydrocortisone and ISMM plus hydrocortisone
groups were not significantly different (P>0.05). However, the prepatent period for
the ISMM only group was significantly longer than that of the ISMM plus
hydrocortisone group (P<0.01). The survival time in the ISMM group varied widely
but was in general longer than that observed in the other groups.
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Figure 5.3 Median prepatent period in mice infected with T. congolense
£3Control E3 Hydroco. OlSMM □Hydroco.iISMM
Figure 5.4 Median survival time for mice infected with T. congolense
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5.4 DISCI SSION
After administering 1 mg/ml of ISMM to four sheep, a semi-logarithmic plot of
concentration against time yielded a biexponential graph. The bioavailability of ISMM
varied greatly between animals and the drug concentration 24 hours after
administration ranged from 3.21 to 40.52 ng/ml, with a median value of 18.48 ng/ml
Elimination of the drug was bi-phasic in all animals with a rapid elimination rate in
the first week followed by a slow phase there after By the end of the first week the
median plasma ISMM levels were 2.7 ng/ml (range 1.1-6.9 ng/ml). Three weeks post
treatment drug levels had dropped very significantly to a median of 15 (range 1 - 3
ng/ml). Despite these low drug levels all sheep were protected when challenged with
T. congolcn.se four and half months later A similar kinetic profile was observed in
cattle following ISMM administration (Eisler el al 1994). In that experiment the
highest ISMM concentrations were observed at the time of first sampling 24 hour
after administration were 40 -50 ng/ml. Serum concentrations fell rapidly for the first
8 days and rather more gradually thereafter At the end of one month the mean
concentrations was 6.1 ng/ml (range 2.8 - 12 ng/ml). All animals were protected when
challenged with congolen.se one month later. In an experiment bv Geerts el a!
(1997). serum mean ISMM levels were less than 10 ng/ml 24 hours after
administration and they had dropped to undetectable lex els after 90 days. However,
all animals were protected from I. congolen.se infection for an average period of 5.7
months In all of these experiments ISMM lex els in plasma or serum were assaved
using the ISMM-ELISA assay (Eisler el al 1994). These results demonstrates that
even though the drug concentration can be very low or undetectable. ISMM provides
protection against T. congolen.se infection in cattle as well as in sheep.
In order to determine the trypanocidal effects of ISMM concentrations prevalent
during the protective period in vitro, two strains of 7. congolen.se (TRUE 1467 and
TRUE 1881) were cultured for 48 hours in increasing concentrations of ISMM
Results showed that the percentage inhibition of I. congolen.se multiplication
plateaued at 72° o for isolate TREU1467 and 85% for TREU188I at the same
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concentration of approximately 100 ng/ml. Thereafter, any increase in drug
concentration produced very little further inhibition. At concentrations less than
lOng/ml the inhibitory effect was less than 45% for isolate TREU1467 and less than
69% for TREU1881. In addition, at the end of the 48 hour incubation period some
viable trypanosomes were still present in all cultures including those at 1000 ng/ml.
Related experiments have shown that culturing of different strains of T. congolen.se,
in vino in the presence of 5 ng/ml ISMM for about 10 minutes (Sutherland. Mounsey
and Holmes 1991). 10 ng/ml for about 24 hours (Kaminsky. Chuma and W'asike
1994) and 10 ng/ml for about 48 hours (Gray and Peregrine 1993 ) could not
completely eliminate the parasites or prevent infection In this study strain TREE1
1881 was used to infect the control and ISMM treated sheep with plasma profiles
discussed above. These results demonstrate that the concentration of ISMM that was
protective against congolen.se strain TREU 1881 in vivo, was incapable of
eliminating the same strain in vitro after 48 hours of incubation. Since drug residues
alone seem not be sufficient to protect animals against T. congolen.se infection, then
the immune system is the most likelv factor. Protection bv ISMM is non-specitlc and
does not depend on previous knowledge of the inv ading v ariant of trypanosome This
implies that the innate immunitv is most likelv to be factor potentiating actions of
ISMM
An experiment w as set up to inv estigate w hether some aspects of the innate immunity
potentiates actions of ISMM in vivo. One group of mice was used as a control, the
second group received 0.02 mg hydrocortisone daily for four consecutive days, the
third one received a single prophylactic dose of 1 mg/kg ISMM. Group four was
given a single prophvlactic dose of 1 mg/kg ISMM and 0.02 mg hydrocortisone daily
for four consecutive days. Eleven days post ISMM treatment all groups were
inoculated with 10" trypanosomes intraperitoneallv. Results show that the prepatent
period and the survival time for the control, hydrocortisone and ISMM plus
hvdrocortisone groups were not significantlv different However, the prepatent period
for the ISMM only group was significantly longer than that of the other groups. The
survival time in the ISMM group varied widely but was in general longer than that
72
observed in the other groups. Results showed a median prepatent period of 3 days
for the control and 7 days for the ISMM group, while that for ISMM plus
hydrocortisone was 3 days. This implies that suppressing T cell responses by
hydrocortisone reduced the ability of ISMM to control the establishment of the
infection In addition even though all mice developed parasitaemia and died, those in
the ISMM only group had lower parasitaemia and survived longer than all the other
groups including the ISMM plus hydrocortisone. However, the prepatent period for
the ISMM only group was significantly longer than that of the other groups. The
survival time in the ISMM group varied widely but was in general longer than that
observed in the other groups. It is known that the dose of ISMM required to prevent
or treat I. congolen.se infection effectively in mice is about ten times that for
ruminants (Sones. Njogu and Holmes 1991). In this experiment the same dose on a
body weight basis (1 mg/kg) was used in order to make comparisons relevant
Hydrocortisone is a natural glucocorticoid hormone. Higher than normal levels can be
produced during T. congolen.se infection (Mutayoba. Eckersall and Cestnik 1995 and
Ogwu. Njogu and Ogbogu 1992) and under stress conditions leading to anti¬
inflammatory and immunosuppressive effects. The major immunosuppressive effects
include; a decrease in concentration of various complement components, reduced
proliferative responses to mitogens and antigens in vitro. decreased cytokine
production (e.g. IT-2. IL-1) and decreased sensitivity of macrophages to cytokines
resulting in decreased phagocytosis. Mice that received both ISMM and
hydrocortisone exhibited no form of resistance to infection compared to those that
were given ISMM alone which not onlv had a longer prepatent period but also had
lower parasitaemia and lived longer.
It is therefore, concluded that ISMM drug concentration present during the
prophvlaxis period is not trypanocidal in vitro and the effectiveness of ISMM





CELLULAR AND ANTIBODY RESPONSES TO PRIMARY T.
CONGOLENSE INFECTION
6.1 INTRODUCTION
In Chapter 5 it was shown that ISMM prophylaxis was not effective at preventing T.
congolense infection when the innate immune system was suppressed with
hydrocortisone Until it became possible to study detailed T cell responses in domestic
animals, immunity to trypanosome infection was largely considered to be antibody
dependent. For this reason very little had been done to investigate cell-mediated
immune responses to trypanosomiasis. However, the little evidence that was available
till the late 1970's suggested that cell-mediated immune responses were either absent
or did not play a significant protective role (Campbell, Esser and Phillips 1978;
Clayton, Ogilvie and Askonas 1979; Askonas et al 1979; Takayanagi and Nakatake
1975). This was largely based on knowledge obtained from studies in rodents,
especially mice
Studies in ruminants have provided evidence for T-cell-mediated responses to VSG
and to invariant trypanosome antigens in cattle Decreases in CD4 and CD8 T-cell
subsets have been observed in cattle due to T. congolense infection (Lutje el a! 1995)
and in sheep due to T. evansi infection (Onah 1992). Both Tl^ and Th2 responses
have now been demonstrated in mice. The type of response seems to depend on the
manner in which the antigen is presented When purified VSG are administered a
mixed response was obtained but if VSG was administered by way of live
trypanosomes, only Thi response were observed (Mansfield 1994) Although, effector
T cells may have no direct role in destroying trypanosomes, significant changes in
their regulatory function might have a profound effect on the function of the whole
immune system It is for that reason that this chapter discusses lymphocyte phenotypic
responses in the control and treated sheep as well as those prophylacticallv treated
with ISMM The final goal was to identify any responses that were characteristic of
prophylacticallv treated animals and hence associated with resistance to infection
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6.2 MATERIALS AND METHODS
PBMCs were prepared and CD4", CD5 , CD8 y5 and B cell were analysed and
trypanosome specific IgG antibody titre assayed as described in Chapter 3; sections
3.7, 3.8. and 3.12.
6.3 RESULTS
6.3.1 Flow cytometry histogram results
In the prophylactic group and control group, cellular phenotypes were analysed
weekly after drug administration even before the infection in order to investigate any
changes associated with the treatment. However, there were no observed cellular
changes during the pre-infection period. Significant changes were obtained only after
infection and representative flow cytometry histogram results for each phenotype and
group are shown in Figures CI-CI 5; Appendix IV Phenotypes obtained as
percentages of mononuclear cells were multiplied by the absolute numbers of
lymphocytes to get the absolute number for the particular phenotype.
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6.3.2 B cell responses
All animals in the control group showed a significant increase in the percentage and
absolute number of B cells 14-28 days after 71 congolense infection peaking on day
21 (Figure 6.1; Table Cl.l and 1.2 -Appendix IV). The increase in the absolute
number of B cells from a median of 2,2 x 106/ml of blood 7 days before infection to
7.3 x 107ml 21 days post infection was statistically significant (P<0.05). Sheep 1863
and 2381 showed the highest increases in cell numbers followed by sheep 1736 and
2383.
Figure 6.1 B cell responses in the control group
(a) Percentage of B cells for the
infected-control group
Days pre/post infection
(b) Absolute B cells for the
infected-control group
Days pre/post in feet ion
1736—■—1863 T" 2381 '-*-2383
• All sheep were infected with T congolense on day zero
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The percentage and absolute number of B cells in the prophylactic group did not show
any significant increase following T. congolense infection (Figure 6.2, Table CI. 1 and
1.2 -Appendix IV). However, sheep number 1746 and 1618 showed a small increase
14 - 21 days after infection, while no detectable changes were observed for sheep
1826 and 1895.
Figure 6.2 B cell responses in the prophylactic group
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(b) Absolute B cells for the
infected-prophylactic group
Days pre/post infection
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• All sheep were infected with T. congolense on day zero
• ISMM was administered 4 72 months before infection
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Absolute B cell counts in the treated group increased significantly from 14 days after
infection onwards (Figure 6.3; Table C 1.1 and 1.2 - Appendix IV). The increase was
from a median of 2.7 x 10r' /ml of blood 7 days before infection to 6.7xlOf' /ml
(P<0.05) 21 days afterwards. Treatment with ISMM 14 days after infection prevented
any further increase in sheep 1499 and 2386 while in sheep 2BF and 3WS B cell
numbers continued to increase in the same way as in the control group. However, by
day 35 B cell numbers had returned to normal levels
Figure 6.3 B cell responses in the treated group
-O— 2BF —9— 3WS —A— 1499 —K— 23X6
(a) Percentage of B cells for the
infected-treated group
-14 -7 0 7 14 21 28 35
Weeks pre/post infection
| —&— 2BF —S— 3WS —A—1499 —X—2386
-14 -7 0 7 14 21 28 35
Days pre/post infection
i
(b) Absolute B cells for the
infected-treated group
• All sheep were infected with T. congolense on day zero
• All sheep were treated with ISMM 14 days after infection (arrow)
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6.3.3 CD5+ T cell responses
In the control group the percentage of CD5' T cell started decreasing 14 days
onwards while absolute numbers increased transiently 7 days after infection. An
increase in absolute numbers of CD5' T cells was from 2 x 106/ml, 7 days pre-
infection to 5 x 10r,/ml blood 7 days post infection. However, that increase was not
statistically significant (P>0.05). The increase was highest for two sheep 1736 and
2383 and marginal for sheep 1863 and 2381, hence the nonsignificant of the results
(Figure 6.4; Table C2.1 and 2.2 - Appendix IV).
Figure 6.4 CD5+ T cell responses in the control group
Days pre/post infection
1 863 238) —X-— 2383
(a) Percentage ofCD5+T cells for
the infected-control group
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• All sheep were infected with I congolense on day zero
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All sheep in the prophylactie group showed no changes in absolute CDS' T cells after
infection, except sheep 1746 which showed an increase 21 days post infection (Figure
6.5, Table C2.1 and 2.2 - Appendix IV).
Figure 6.5 CD5+ T cell responses in the prophylactic group
(a) Percentage of C'I>5 T cells for
Days pre/post infection
—♦— 1618 1746 —♦—1826 X 1895
(b) Absolute CD5 T cells for the
infected-prophylactic group
Days pre/post infection
1618 1746 —A—1826 —$4—1895
• All sheep were infected with 7 congolense on day zero
• ISMM was administeied 4'/2 months before infection
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None of the sheep in the treated group showed any significant changes in absolute
CDS' T cells through out the experimental period although sheep 2BF exhibited a
slight transient increase 28 days after infection (Figure 6.6; Table C2.1 and 2.2 -
Appendix IV). However, the proportions decreased from 14 days onwards.
Figure 6.6 CD5+ T cell responses in the treated group
(a) Percentage of CD5+T cells for
the infected-treated group
(b) Absolute CD5+ Tcells for the
infected-treated group
• All sheep were infected with I congolense on day zero
• All sheep were treated with ISMM 14 days after infection (arrow)
, r «-
-14 -7 0 7 14 21 28 45
Days pre/post infection
2BF —B— 3WS —A—1499 —X— 2386!
-14 -7 0 7 14 21 28 35
Days pre/post infection
2BF —0— 3WS —A—1499 -X— 2386
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6.3.4 y8+ T cell responses
In the control group proportions and absolute yS' T cells increased 7 to 14 days post
infection then decrease 21 to 28 days post infection. However, the initial increase was
not significant but the decrease to 0.3 x 106/ml 21 days post infection from 0.6 x
106/ml 7 days pre-infection was statistically significant (P<0.05) (Figure 6.7; Table
C3.1 and 3.2 - Appendix IV). Nevertheless, no significant changes were observed in
sheep 23 81
Figure 6.7 yS+ T cell responses in the control group
(a) Percentage of y 8 T cells for
the infected control group
Days pre/post infection
—♦—1736 —■—1863 2381 - 2383]
(b) Absolute y T cells for the
infected-control
-14 -7 0 7 14 21 28 35
Days pre/post infection
♦—1736 1863 2381 —*—2383
• All sheep were infected with T. congolense on day zero
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In the prophylactic group the percentage of y5' T cells decreased 14 days after
treatment and the median absolute number of y5' T cells was 0.96 xlOf,/ml 7 days
before infection and decreased to 0.38 xl06/ml 14 days post infection (Figure 6.8;
Table C3.1 and 3.2 - Appendix IV). But because of great variation when compared to
pre-infection values, the decrease was not statistically significance (P>0.05).
Figure 6.8 y§+ T cell responses in the prophylactic group
I - 1618 1746 A 1826 X 1895
14 -7 n 7 14 71 78 75
Days pre/post infection
— 1618 1746 —A—1826 —X— 18951




(a) Percentage of y d T cells for
the infected-prophylactic group
• All sheep were infected with 7 congolense on day zero
• ISMM was administered 4 V2 months before infection
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In the treated group the percentage of y6' T cells decreased in all sheep 14-21 days
after infection However, only 2BF and 3WS showed a significant decrease of
absolute y8' T cells 14 to 21 after infection (Figure 6.9, Table C3.1 and 3.2 -
Appendix IV). This resulted in a non significant difference (P>0.05) between 7 days
pre-infection (0 86 xl0f7ml) and 21 days post infection (0.51 xl0r7ml). Treatment
with ISMM 14 days after infection had no effect on yS* T cells.
Figure 6.9 yS+ T cell responses in the treated group
~e— 2BF —B— 3WS —A— 1499 —X— 2386
(a) Percentage of y 8 T cells for the
infected treated group
-14 -7 0 7 14 21 28 35
Days pre/post infection
(h) Altsolute y8 + T cells for the
infected-treated group
Days pre/post infection
I —©— 2B! —a— 3WS —A— 1499 —2386 J
• All sheep were infected with I congolen.se on day zero
• All sheep were treated with ISMM 14 days after infection (arrow)
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6.3.5 CL)8+ T cell responses
In the control group the proportions of CD8' T cells decreased in all sheep 14 - 21
days after infection. However, absolute numbers showed a decrease 14-21 days after
infection only in sheep 1736 and 1863 (Figure 6.10; Table C4.1 and 4.2 - Appendix
IV). No significant changes were observed in sheep 2381 while sheep 2383 showed
an increase 21 to 28 days after infection. Results varied greatly and there was no
statistical significance between pre-infection and post infection values (P>0.05.
Figure 6.10 CD8^ T cell responses in the control group
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-14 -7 0 7 14 21 28 35
1736
Days pre/post infection
l— 1863 2381 —x- 2383
All sheep were infected with T. congolense on day zero
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Sn the prophylactic group, the percentage of CD8' T cells decreased 21 days post
infection. Absolute CD81 T cells decreased significantly 21 days onwards for sheep
1618 and 1826 while sheep 1746 showed a slight increase 14-21 days after infection
and no changes were observed in sheep 1895 (Figure 6.11; Table C4.1 and 4.2 -
Appendix IV).
Figure 6.11 CD8+ T cell responses in the prophylactic group
D
'J
—♦— 1618 1746 —£— 1826 —x— 18951
(a) Percentage CD8T cells for the
infected-prophylactic group
1 ,-0-4 T , , T i
-14 -7 0 7 14 21 28 35
Days pre/post infection
(I)) Absolute CD8+ T cells for the
infected-prophylactic group
-14 -7 0 7 14 21 28 35
Days pre/post infection
♦— 1618 1746 —A— 1 826 X 1895
* All sheep were infected with T congolen.se on day zero
• ISMM was administered 4V2 months before infection
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The treated group showed a decrease in the proportions of CD8* T cell 14 days after
infection. However, absolute CD8* T cell counts showed that levels were normal until
after treatment when a significant (P>0.05) increase was observed 21 days onwards.
The highest increase in CDS' T cell numbers was observed in sheep 2BF and 3WS,
followed by sheep 2386, while little or no changes were observed in sheep 1499
(Figure 6.12; Table C4.1 and 4.2 - Appendix IV).
Figure 6.12 CD8+ T cell responses in the treated group
-©— 2BF —a— 3WS —A— 1499 —*--2386
• All sheep were infected with I congolense on day zero
• All sheep were treated with ISMM 14 days after infection (arrow)
-©—2BF —B—3WS —A—1499 —X—2386
(a) Percentage CD8 T cells for the
infected-treated group
(1>) Absolute OD8' T cells for the
infected-treated group
-14 -7 0 7 14 21 28 35
Days pre/post infection
0.1
-14 -7 0 7 14 21 28 35
Days pre/post infection
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6,3.6 (1)4 T cell responses
The control group showed a decrease in the percentage ofCD4' T cells from 21 days
onwards in all sheep except sheep which showed only a transient decrease 21 days
after infection (Figure 6.13; Table C5.1 and 5.2 - Appendix IV). However, absolute
numbers of CD4' T cells increased non-significantly 7 to 14 days post infection and
decreased below normal 21 days post infection (P.0.05).
Figure 6,13 CD4+ T cell responses in the control group
(a) Percentage of CD4 T cells in
the infected-control group
Days pre/post infection
1736 -a 1X63 23X1 —*—23X3
(b) Absolute CD4T cells for the
infected-control group
Days pre/post infection
j—♦— 1736 -m— 1863 2381 —X— 2383
• All sheep were infected with T. congolense on day zero
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In the prophylactic group there was no change in the proportions of CD41 T cells
throughout the experimental period. Nevertheless, absolute numbers for sheep 1746
and 1618 showed a slight increase 21 days post infection (Figure 6.14; Table C5.1
and 5.2 - Appendix IV).
Figure 6.14 CD4+ T cell responses in the prophylactic group
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• All sheep were infected with T. congolense on day zero
• ISMM was administered 4'/2 months before infection
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In the treated group a significant (P < 0.01) decrease of both percentage and absolute
numbers ofCD4' T cells was observed 21 days post infection in all the sheep (Figure
6.15; Table C5.1 and 5.2 - Appendix IV). Treatment with ISMM 14 days after
infection did not change the trend of response since, like in the control, levels
returned to normal by 28 days after infection.
Figure 6.15 CD4 T cell responses in the treated group
(a) Percentage of CD4+ T cells for
the infected-treated group
Days pro/post infection
-0—2BF —B— 3WS —A— 1499 --*-2386
(b) Absolute CD4+ T cells for the
infected-treated group
Days pre/post infection
-6—2BF —S— 3WS —A— 1499 -*-23861
• All sheep were infected with T. congolense on day zero
• All sheep were treated with ISMM 14 days after infection (arrow)
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6.3.7 CD4+:CD8+ T cell Ratio
Figure 6.16 and Table C6.0 - Appendix IV, shows that the ratio ofCD4 CD8 T cells
increased non significantly 7 to 14 days, then decreased significantly on day 21 in the
control (P<0.05). In the prophylactic group the ratio increased significantly from day
21 onwards (P <0 05). The ratio in the prophylactic 21 days after infection was the
opposite of that observed in the control group.
Figure 6.16 CD4+:Cl)8+ T cell Ratio in the control and prophylactic groups
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(l>) CD4 :CD8 ratios for the
prophylactic group
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All sheep were infected with T. congolense on day zero
ISMM was administered in the prophylactic group 4'/2 months before infection
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Figure 6.17(a) and Table C6.0 - Appendix IV shows that the ratio of CD4+:CD8' T
cells in the treated group decreased significantly 21 days post infection (P<0.01. A
small non-significant increase was observed 14 days post infection. Figure 6.17(b) and
Table C6.0 - Appendix IV shows the median ratios of CD4':CD8' T cells for all the
experimental groups and indicates that the ratio increased in the prophylactic group,
while it decreased in the control and treated groups 21 days after infection.
Figure 6.17 CD4+:CD8+ T cell Ratio in the treated group and median values for
all the groups
(c) CD4 :CD8+ ratios for the
Days pre/post infection
^9— 2BF —e— 3WS —A— 1499 2386)
• All sheep were infected with T congolense on day zero
• Prophylactic group: SSMM was administered in the 4 V2 months before infection
• Treated group: All sheep were with ISMM 14 days after infection
j—#— Control ——- Prophylactic —A— Treated




6.3.8 Serum IgG antibody response
Trypanosome specific IgG antibodies were measured 35 days post infection for all
groups. The antibody titre was determined which was the highest dilution that gave a
positive result after subtracting readings for the negative serum. Since a double
dilution was carried out on all samples, the median reciprocal antibody titre was
converted to geometric median titres (GMT) by finding the antilogarithm base two of
the reciprocal titres. The reciprocal titres in the control group ranged from 3-8 with
a median value of 5 (Figure 6.18(a)). In the prophylactic group the median reciprocal
geometric titre was 10 and the ranging from 9-11 (Figure 6.18(a)).
Figure 6.18 Serum IgG antibody response in control and prophylactic groups
35 days after infection
(a) IgG reciprocal geometric titre
for the control group 35 days post
infection
(b) IgG reciprocal geometric titre
for the prophylactic group 35 days
post infection
Steep Number
| □ 1618 Q1746 01826 @1895m 1736
Steep Number
@1863 @2381 @2383 j
• All sheep were infected with T. congolense on day zero
• Prophylactic group: ISMM was administered in the 47-2 months before infection
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Figure 6.19(a) shows that trypanosome specific IgG antibody levels in all treated
sheep were undetectable (reciprocal geometric median titre of 0.25). Figure 6.19(b)
summarises IgG responses showing that the difference between the median for the
control and the treated groups was statistically significant (P>0.05), and that between
the control and the prophylactic groups was also significant (P<0.05) indicating that
the prophylactic group had higher antibody levels than the control and treated groups.
Figure 6.19 Serum IgG response in the treated group and median values for the
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6.4 DISCUSSION
Results of these experiments indicate that all animals in the control group showed a
significant increase in the percentage and absolute number of B cells 14-28 days after
T. congolense infection peaking on day 21. Absolute number of B cells in the
prophylactic group did not show any significant increase following T. congolense
infection. However, sheep number 1746 and 1618 showed a small increase 14-21
days after infection, while no detectable changes were observed for sheep 1826 and
1895. In the treated group absolute B cell counts increased significantly from 14 days
after infection onwards. Treatment with ISMM 14 days after infection prevented any
further increases in sheep 1499 and 2386 while in sheep 2BF and 3WS B cell numbers
continued to increase in the same way as in the control group. However, by day 35 B
cell numbers had returned to normal levels. Increases in B cell responses have been
demonstrated in sheep infected with T. congolense (Mwangi 1991) and T. evansi
(Onah 1990) and in cattle infected with T. congolense (Williams et al 1991; Lutje et
al 1995). This study demonstrates that prophylactic administration prevents
polyclonal B cell proliferation and that treating an infection 14 days afterwards
interferes with B cell proliferation and probably differentiation that would result in the
interference with antibody production
Absolute numbers of CD5 T cells increased transiently 7 days after infection in the
control group However, that increase was not statistically significant. Sheep in the
prophylactic group did not show changes in absolute CD5 T cells after infection,
except sheep 1746 which showed an increase 21 days post infection. None of the
sheep in the treated group showed any significant changes in absolute CD5* T cells
through out the experimental period although sheep 2BF exhibited a slight transient
increase 28 days after infection. A decrease is proportions of CD5 T cells were
observed only in susceptible animals (Onah 1990, Williams et al 1991, Lutje et al
1995) not in those that were resistant (Onah 1990; Williams et al 1991). Similar
results were obtained in this study, where the control and the treated groups showed a
decrease in proportions of CD5 T cells while the prophylactic group did not.
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However, absolute numbers of CD5" T cells in the control showed a sight increase
followed by a decrease and not in the treated and prophylactic groups.
Absolute y8" T cells in the control group increased 7-14 days after infection then
decrease 21-28 days post infection. However, the initial increase was not significant
but the decrease 21 days post infection was statistically significant. However, no
significant changes were observed in sheep 2381. In the prophylactic group, absolute
of yd"* T cell counts decreased 14 days after infection. In the treated group only 2BF
and 3WS showed a significant decrease in absolute yb T cell counts 14-21 after
infection. As a result the median value 14-21 days after infection was not
significantly different from pre-infection levels. Treatment with ISMM 14 days after
infection had no significant effect on yb T cells. Other experiments in trypanosome
infected sheep and cattle have demonstrated decreases in ybT T cell phenotypes
(Mwangi 1991; Williams et al 1991; Lutje et al 1995). The role of yb+ T cells in
trypanosome infections is not well understood but Flynn and Sileghem 1991
demonstrated that only yb T cells from T. congolense infected trypanotolerant
N'dama and not susceptible Boran cattle proliferated in vitro suggesting that they may
be involved in the control of the infection. In this study a decrease in absolute
numbers of yb" T cells in the control group occurred 21 days after infection and 14
days after infection in the prophylactic group while only two sheep in the treated
group showed a decrease 21 days after infection. However, it is not known whether
earlier changes in the prophylactic group have any significance in the control of the
infection.
Absolute numbers of CD8 T cells in the control group showed a decrease 14-21
days after infection only in sheep 1736 and 1863. No significant changes were
observed in sheep 2381 while sheep 2383 showed an increase 21 to 28 days after
infection. Responses varied greatly and there was no statistical significance between
pre-infection and post infection values. In the prophylactic group, absolute CD8 T
cells decreased significantly 21 days onwards for sheep 1618 and 1826 while sheep
1746 showed only a slight increase 14-21 days after infection and no changes were
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observed in sheep 1895. Absolute CD8' T cell counts in the treated group reviewed
that levels were normal until after treatment when a significant increase was observed
21 days onwards. CD8" T cells have been reported to decrease in both resistant (Onah
1990; Williams et al 1991) and susceptible animals (Onah 1990; Mwangi 1991;
Williams et aI 1991; Lutje et al 1995) following an infection with trypanosomes.
Similar results were obtained in this experiment with decreases in CD8 T cells being
observed in the control and prophylactic groups except in the treated group where a
significant increase was observed after treatment with ISMM.
Absolute numbers of CD4 T cells in the control group showed a non-significant
increase 7 to 14 days after infection, then decreased non-significantly below normal
21 days post infection. Changes were not significant, only because of wide variations
between individual sheep. In the prophylactic group absolute numbers ofCD4 T cells
for only sheep 1746 and 1618 showed a slight increase 21 days post infection. In the
treated group a significant decrease in absolute numbers of CD4 T cells was
observed 21 days post infection in all the sheep. Treatment with ISMM 14 days after
infection did not change the trend of response since, like in the control, levels
returned to normal by 28 days after infection. In general trypanosomes caused a
severe loss of CD4" T cells in susceptible animals (Mwangi 1991; Onah 1992; Lutje
et al 1995). That loss could have been attributed to TCR-induced apoptosis or
programmed cell death (DosReis, Fonseca and Lopes 1995; Fresno, Kopf and Rivas
1997). Activation induced CD4^ T cell death was not observed in animals under
ISMM prophylaxis probably via Thi-type cytokines. Thi type cytokines have been
shown to block whereas Th2-type cytokines can enhance TCR-induced programmed
cell death (Fresno, Kopf and Rivas 1997).
The ratio of CD4 CD8 T cells increased non significantly 7 to 14 days, then
decreased significantly on day 21 in the control group, while in the prophylactic
group the ratio increased significantly from day 21 onwards. The ratio of CD4 :CD8^
T cells in the treated group decreased significantly 21 days post infection. A small
non-significant increase was observed 14 days post infection. The median ratios of
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CD4 CD8 T cells for all the experimental groups indicate that the ratio increased in
the prophylactic group, while it decreased in the control and treated groups 21 days
after infection. These results indicate that prophylactic administration of ISMM
results in a increase in the ratio of CD4 CD8 T cells while treating an established
infection 14 days after infection does not change the decrease in the ratio that is
observed in the control group The ratio ofCD4 CD8 cells in the blood may be used
to estimate lymphocyte function in clinical situation. An elevated CD4 count implies
increased lymphocyte reactivity as helper cells predominate, where as a high CD8
level implies depressed lymphocyte reactivity as a result of excessive suppressor
activity (Tizard 1992).
The reciprocal geometric titres of trypanosome specific IgG antibodies in the control
group ranged from 3-8 with a median value of 5. In the prophylactic group the
median reciprocal geometric titre was 10 and the ranging from 9-11. However, in
the treated antibody levels were very low or undetectable (median titre of 0.25). The
difference between the control and the treated groups was statistically significant and
that between the control and the prophylactic groups was also statistically significant
and the prophylactic group had higher antibody levels than the control and treated
groups. Therefore, prophylactic administration of ISMM resulted in a significant
increase in levels of trypanosome specific IgG antibodies while treating an established
infection 14 days after infection depressed antibody production when compared to the
control group These observations correlates well with changes in the ratio of
CD4 CD8 T cells and absolute CD8 T cell counts. Although the pattern of changes
in the ratio of CD4":CD8 T cells in the control and treated groups were similar,
absolute CD8 T cell counts in the treated group increased significantly after drug
treatment, therefore resulting in the depression of antibody production On the other
hand, the increase in the ratio of CD4 CD8 T cells in the prophylactic group
favoured an increase in helper cell (CD4 ) activity resulting in high antibody levels.
Antibody responses in both natural and experimental trypanosome infections have
been studied extensively Infection of cattle with T. congolense or T. vivax (Luckins
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1976) and sheep with T. congolen.se, T. vivax or T. brucei (MacKenzie, Boyt and
Nesham 1979) resulted in increases in serum trypanosome non-specific IgM and IgG
antibodies during the course of the infection. Similar increases in trypanosome specific
IgM and IgG antibodies following T. evansi infection of sheep were reported by Onah
(1992). Very few studies have compared patterns of antibody response in susceptible
and resistant animals. Results from Onah (1992) showed that sheep that self-cured
had higher levels of IgM and IgG antibodies than those that did not self-cure.
Suppression of trypanolytic antibodies in an ISMM prophylactic (Whitelaw et al
1986; Geerts et al 1997) and treated (Whitelaw et al 1986) groups of cattle has been
demonstrated In this study trypanosome specific IgG antibodies were down-regulated
in the treated group and up-regulated in the prophylactic group. Probably the
difference in relation to prophylactic group is a result of antibody assays used since in
this study antibody ELISA was used while Whitelaw et al (1986) and Geerts et a!
(1997) used the trypanolytic assay. However, results from treated animals are similar,
implying that trypanolytic antibodies may not be of the IgG isotype, therefore they
might be of the Ig.M isotype These observation emphasise the fact that during
trypanosome infection both parasite specific and non-specific antibody response may
decrease, and that ISMM administration can lead to down-regulation or up-regulation
of certain antibody isotype responses.
These results demonstrate that there are significant differences in immunological
responses between animals under ISMM prophylaxis and control or infected and
treated animals. ISMM prophylaxis prevented polyclonal B cell or T cell proliferation
probably in favour of clonal proliferation. It also prevented significant losses of CD4
T cells while not effecting CD8 T cell reduction resulting in an increased helper T cell
activity and a high trypanosome specific IgG antibody response However, treatment
of an infection with ISMM 14 days afterwards interfered with ongoing immune
responses resulting in an inhibition of trypanosome specific IgG antibody responses.
In conclusion, ISMM prophylaxis prevented I. congolen.se infection and modified
cellular immunological responses resulting in high IgG antibodies On the other hand
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treatment of the infection suppressed IgG antibody response. These differences
indicates that the mechanism of modulation involves cytokines which could either up-
regulate or down-regulate antibody production depending on the status of the immune




MONONUCLEAR CELL PROLIFERATION AND CYTOKINE
PRODUCTION
7.1 INTRODUCTION
This chapter describes results of the effect of ISMM on IFN-y production and
proliferative responses of sheep peripheral blood mononuclear cells as well as IL-12
and IFN-y production by mouse splenic cells. Flynn et a! (1991) reported a depression
of in vitro proliferative responses of peripheral blood lymphocytes and lymph node
cells from cattle infected with T. congolense when stimulated with T cell mitogen
concanavalin A (ConA), On the other hand, no proliferative responses to purified
trypanosome antigen specific stimulation were detected in peripheral blood
lymphocytes before infection, at any point after infection or treatment in cattle.
However, proliferation was observed in draining lymph node cells (Lutje et al 1995).
IL-12 has been reported to play a strong regulatory role on IFNy production in many
infections such as Histoplasma capsulatum (Zhou el a! 1997) and Bordetella perussis
(Mahon et til 1996). IL-12 is rapidly produced after infection by phagocytic cells
(monocyte/macrophages and neutrophils (D'Andrea et a! 1992) and by antigen
presenting cells (dendritic cells and skin Langerhans' cells (Macatonia et at 1995:
Kang et al 1996). It elicits the production by T cells and natural killer cells of IFN-y
which activates phagocytic cells. The production of IL-12 is strictly regulated by
negative and positive feedback mechanisms. If IL-12 and IL-12 induced IFN-y are
present during early T cell expansion in response to antigen, Thi cell generation is
favoured and the generation of Th2 cells inhibited. Thus IL-12 is a potent
immunoregulatory cytokine which promotes Th] resistance to intracellular parasite
infection (Trinchieri 1997). Both Th, and Th2 responses have been reported in
trypanosome infections (Scheifer and Mansfield 1993), but it is not clear which one is
associated with pathology or resistance to infection.
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7.2 MATERIALS AND METHODS
In sheep experiments, PBMCs were collected weekly and cultured in the presence of
ConA, live T. congolense and media only for 48 hours before collecting the
supernatant for the IFN-y assay. Also PBMCs were cultured in vitro in media only,
ConA and live T. congolense for 72 hours and proliferation determined using the
Promega assay and Flow cytometry. Splenic cells were obtained from naive mice and
those that had been treated with 1 mg/kg ISMM for 7, 14 and 21 days. They were
cultured in vitro for 24 hours, after which, IFN-y and IL-12 were assayed. Details of
the protocols and assays are described in Chapter 3: Sections; 3.7, 3.9, 3.10 and 3.11
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7.3 RESULTS
7.3.1 In vitro peripheral blood mononuclear cell proliferation
PBMCs were cultured in the presence of trypanosomes and ConA. The proportion of
viable cells in these cultures determined using the Promega assay were compared with
cultures in media only. A significant decrease in cell viability was observed in
trypanosome cultures with PBMCs from control sheep 1736, 1863 and 2381 (P<0.05)
21 days post infection but sheep 2383 was not affected. Proliferation in cultures with
ConA dropped significantly from day 14 to 35 in the control group (Figure 7.1; Table
D1-Appendix V).
Figure 7.1 In vitro peripheral blood mononuclear cell proliferation (Stimulation
Index) for the infected Control group
(a) Infected-control group: PBVK-
Trypanosome culture
Days pre/post infection
♦—1736 —■— 1863 -«••• 2381 -X—2383
• All sheep were infected on day zero
• Stimulation index of 1 represents normal cell viability in culture (dotted line)
• Stimulation index below 1 indicates accelerated cell death
• Stimulation index above 1 indicates cell proliferation




•1736 —ii—-1863 2381 -*-2383]
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In the prophylactic group, results of the proliferation assay before infection (i.e. day -
14 to 0) were significantly higher than those observed in the control group (P <0.01)
ConA induced significant proliferation in PBMCs from all sheep. However, 21 days
after infection proliferation in trypanosome cultures fell below normal levels (P<0.01).
In the ConA cultures, proliferation also decreased below normal (P<0.05) 21 days
after infection except for sheep 1895 (Figure 7.2; Table D2-Appendix V).
Figure 7.2 In vitro peripheral blood mononuclear cell proliferation (Stimulation









-7 0 7 14 21 28 35
Days pre/post infection















-14 -7 0 7 14 21 28 35
Days pre/post infection
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All sheep were infected on day zero
Stimulation index of 1 represents normal cell viability in culture (dotted line)
Stimulation index below 1 indicates accelerated cell death
Stimulation index above I indicates cell proliferation
All sheep were prophylactically treated with ISMM 4V2 months before infection
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Proliferation of cells in trypanosome cultures from the treated group 14 to 35 days
post infection was significantly (P<0.05) higher than normal levels (Figure 7.3; Table
D3-Appendix V). Sheep 2BF did not proliferate due to ConA at any time and
accelerated cell death was observed 14 days after infection onwards. Sheep 3WS,
1499 and 2386 proliferated due to ConA but a transient non-significant decrease was
observed 14 to 21 days after infection.
Figure 7.3 In vitro peripheral blood mononuclear cell proliferation (Stimulation
Index) for the infected Treated group
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• All sheep were infected on day zero
• Stimulation index of 1 represents normal cell viability in culture (dotted line)
• Stimulation index below 1 indicates accelerated cell death
• Stimulation index above 1 indicates cell proliferation
• All sheep were treated with ISMM 14 days after infection
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7.3.2 Supernatant sheep IFN-y levels from PBMCs in culture
PBMCs from the prophylactic group were cultured with trypanosomes and
supernatant IFN-y levels were determined. Results show that cells from the non-
infected prophylactic group cultured in the presence of trypanosomes produced
significantly (P<0.01) high level of IFN-y 14 to 28 days after ISMM administration
(Figure 7.4a; Table D4-Appendix V). Sheep 1826 continued to produce IFN-y until
21 days after infection, when it dropped to normal. During the infection period no
significant amounts of IFN-y were detected for the other sheep (Figure 7.4b; Table
D4-Appendix V).
Figure 7.4 Supernatant sheep IFN-y levels (Absorbance) for Prophylactic
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All sheep in Figure 7.4(a) were injected with ISMMon day 0
All sheep in Figure 7.4(b) were infected with 71 conglense on day 0
Cut-off point was mean of negative control plus twice its standard deviation
0.163
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PBMCs from the control group were also cultured with trypanosomes and
supernatant IFN-y levels were determined. Figure 7.5 and Table D5-Appendix V
shows that no IFN-y was detected in culture supernatants either before or after
infection
Figure 7.5 Supernatant sheep IFN-y levels (Absorbance) for Control PBlVlCs in
culture with trypanosomes
• All sheep in Figure 7.5(a) were non-treated and non-infected controls
• All sheep in Figure 7.5(b) were normal and infected with I conglense on day 0
• Cut-off point was mean of negative control plus twice its standard deviation =
0.163
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PBMCs in culture with ConA produced significant levels of IFN-y in non-infected or
infected prophylactically treated sheep. ISMM prophylaxis or infection with 71
congolonse had no effect on IFN-y production in these cultures (Figure 7.6; Table
D6-Appendix V).
Figure 7.6 Supernatant sheep IFN-y levels (Absorbance) for Prophylactic
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• All sheep in Figure 7.6(a) were injected with ISMM on day 0
• All sheep in Figure 7.6(b) were infected with /'. conglense on day 0
• Cut-off point was mean of negative control plus twice its standard deviation =
0.163
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In the control group IFN-y production in cultures with ConA produced significant
levels of IFN-y in non-infected or infected sheep. Infection with T. congolorise had
no effect on IFN-y production in these cultures as well (Figure 7.7; Table D7-
Appendix V)















I- 1863 7 238F—X—23831
• All sheep in Figure 7.7(a) were non-treated and non-infected controls
• All sheep in Figure 7.7(b) were normal and infected with T. conglense on day 0
• Cut-off point was mean of negative control plus twice its standard deviation =
0.163
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7.3.3 IL-12 and IFN-y production from non-infected mice
IL-12p40 production by splenic cell cultures with trypanosomes was high in the non-
treated group 7-14 days following ISMM administration, but was significantly
(P<0.01) suppressed in mice that had received ISMM 21 days before in vitro culture
(Figure 7.8a; Table D8-Appendix V). Levels of IL-12p40 in cultures with LPS was
significantly (P<0.01) suppressed in those treated with ISMM 14 and 21 days before
culture.
Figure 7.8(a) IL-12 production from non-infected mice
• Day zero represents cells from mice that did not receive ISMM
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The same mice splenic culture supernatants in which IL-I2 was determined was used
for measuring IFN-y levels. Significant levels of IFN-y were produced only in non-
treated LPS cultures (P<0.01). There was no IFN-y in either ISMM treated or non-
treated trypanosome cultures (Figure 7.8b and Table 7.8b).
Figure 7.8 (b) IFN-y production from non-infected mice
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• Day zero represents cells from mice that did not receive ISMM
7.4 DISCUSSION
Proliferation of PBMCs in response to ConA occurred in the control group until 14
days after infection when a decrease was observed. A stimulation index of 1 indicates
normal cell viability without proliferation or excessive cell death Twenty one days
after infection, the stimulation index was below normal implying that cell viability in
the presence of ConA was at its lowest. However, cell viability returned to normal
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thereafter, although proliferative responses to ConA were not restored throughout the
study period In the prophylactic group, only a transient loss of cell viability and
proliferative response was observed 21 days post infection. In the treated group
changes in proliferative responses to ConA varied greatly, with a decrease occurring
between 14 and 21 days. Thereafter, the proliferative responses were restored. These
results are similar to those of other workers except their experiments were not related
to ISMM prophylaxis. For instance, suppression of proliferative responses to ConA
by mononuclear cells isolated from peripheral blood, spleen, lymph nodes has been
observed in Boran cattle infected with T. congolense at different stages of infection
(Flynn and Sileghem 1991). Suppression was greatest in lymph node cells than in
spleen cells or PBMCs. Also, Taylor, Lutje and Mertens (1996) using lymph node
mononuclear cells in culture with trypanosome lysates demonstrated a significant
decrease in proliferative responses to ConA 11 days post infection
Experiments involving culture of PBMCs with heterologous trypanosomes showed no
antigen non-specific proliferative responses in the control group throughout the study
period, but a decrease in viability was observed 21 days post infection. The
stimulation index for pre-infection PBMCs was significantly higher than 1 implying
that they were sensitised to proliferate when stimulated with trypanosomes. However,
viability significantly dropped below normal 21 days after infection. Treatment with
ISMM 14 days after infection prevented a decrease in cell viability and resulted in an
increased proliferative response 21 days onwards These results indicate that antigen
non-specific proliferative responses occurred 21 days after ISMM treatment and could
only decrease transiently about 21 days after infection. In addition no antigen non¬
specific proliferation was observed on the control group. Other studies have shown in
vitro antigen specific proliferative responses of lymph node mononuclear cells not
PBMCs 1 1 days after infection and reduced responses before or afterwards (Lutje et
a/ 1995; Taylor, Lutje and Mertens 1996). Gasbarre, Flug and Louis (1981) also
demonstrated antigen specific proliferation of mice lymph node cells 2 to 3 weeks
after infection with T. brucei followed by loss of responsiveness On the other hand
Flynn, Sileghem and Williams (1992) using whole trypanosome lysates obtained the
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opposite results where there was proliferation in PBMCs and not in lymph node cells.
Purified CD8 and y8 T cells from peripheral blood of trypanotolerant N'dama cattle
undergoing a primary T. congolense infection proliferated in vitro in response to
trypanosome specific invariant but not variant trypanosome antigens 14 to 42 days
post infection. No trypanosome antigen specific proliferation was observed in
trypanosusceptible Boran cattle (Flynn and Sileghem 1994). It seems proliferation of
PBMCs to trypanosome antigens is associated with animals that are relatively
resistant to trypanosomiasis. This might explain why researchers that used susceptible
Boran cattle were unable to detect PBMC proliferation. In addition it might also
explain why ISMM treated sheep in this study showed proliferative responses to
trypanosomes 21 days after ISMM treatment onwards.
The loss of antigen non-specific proliferative responses and cell viability observed in
this study 21 days after infection coincided with the height lymphocytosis resulting
from in vivo antigen stimulation. This is in agreement with observations by Taylor,
Lutje and Mertens (1996) that an increase in antigen specific proliferative responses
coincided with a decrease in proliferation of the same cells in culture with ConA. A
decrease of cell numbers below normal (cell death) is likely to be a result of activation
induced apoptosis (Kabelitz, Pohl and Pechhold 1993). Apoptosis or programmed cell
death is an active, signal-dependent process with characteristic morphological changes
in dying cells. Activation renders peripheral T cells susceptible for apoptosis. Truly
resting mature T cells are resistant to apoptosis, but gradually become sensitive to
programmed cell death after mitogenic or antigenic activation. The sensitivity of
activated T cells to apoptosis does not appear to correlate to any distinct phenotype.
Thus CD8f, CD4 and yS T cells are all sensitive and within the CD4 compartment
there is no major difference between Thi and Th2 subsets. This suggests that
activation induced cell death occurs in CD4 T cells irrespective of the type of
cytokine they produce upon activation. ISMM prophylaxis increased proliferative
responses of PBMCs to trypanosome antigens, but had no affect on transient
activation induced cell death. On the other hand treating an established infection with
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ISMM 14 days post infection prevented activation induced cell death and improved
proliferative responses to trypanosome stimulation
IL-12p40 and IL-12p70 were assessed in the same mice splenic cell culture
supernatants that were used to assess IFN-y. None of the cultures were positive for
IL-12p70 indicating that it was either not produced or levels were too low to be
detected by the assay On the other hand. IL-12p40 levels were high in trypanosome
cultures of non-treated as well as the 7. and 14 day ISMM treatment groups but
dropped significantly in the 21 day ISMM treatment group.
At present there are no reports of IL-12 production in trypanosome infections.
Nevertheless, studies with other antigens show that its production is induced by
bacteria, intracellular pathogens, fungi, viruses or their products by T cell-independent
pathway and/or by a T cell-dependent pathway mediated through CD40-CD40 ligand
interaction (Trinchieri 1995 Trinchieri 1993 IL-12p70 is rapidly produced after
infection by phagocytic cells (monocyte/macrophages and neutrophils (D" Andrea et at
1992) and by antigen presenting cells (dendritic cells and skin Langerhans" cells
(Macatonia et at 1995. Kang et at 1996). IL-12p70 is a heterodimeric cytokine
composed of 35-kDa(p35) and 40-kDa(p40) subunits. It has been demonstrated that
the expression of p35 and p40 genes is differentially regulated by activation of the
producing cells. The p40 subunit is responsible for receptor binding and if produced
as a monomer or homodimer in the absence of p.35 can act as an antagonist to the
biological effects of IL-12p70 (Mattner et at 1993). Biological effects of IL-12 (p70
heterodimer) include: induction of cytokine production (especially IFN-y) by T and
NK cells, haematopoiesis. enhancement of cell-mediated cytotoxicity and mitogenic
effects on T and NK cells
The production of IL-12 is strictly regulated by negative and positive feedback
mechanisms, with IFN-y being the most potent upregulator (Kubin. Chow and
Trinchieri 1994) and IL-10 as the most important down regulator (D Andrea et at
1993) If IL-12p70 and IFN-y are present during early T cell expansion in response to
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antigen. Th| cell generation is favoured and the generation of Th2 cells inhibited. Thus
JL-12 is a potent immunoregulatory cytokine which promotes Tin resistance to
infection (Trinchieri 1997). Both Th, and ITo responses have been reported in
trypanosome infections (Schleifer and Mansfield 1993), but it is not clear which one is
associated with pathology or resistance to infection. Thus, in this study the absence
of 1L-12p70 and presence of high levels of IL-12p40 could have resulted in a down
regulation of IFN-y production in ISMM treated mice splenic cell cultures.
In sheep experiments IFN-y production in PBMC cultures with ConA was neither
related to stage of infection nor ISMM treatment. But the most significant IFN-y
production results in sheep were those produced in the prophylactic group 14 to 21
days after ISMM administration. Sheep 1826 remained sensitised until 21 days after
infection. These results indicate that ISMM primed naive PBMCs in vivo for high
IFN-y production in vitro after challenge with heterologous trypanosome antigens. In
the literature there are not reports of IFN-y production by PBMCs form either naive
or trypanosome infected animals when cultured with trypanosome antigens. Results
by Lutje et a! (1995) showed that high levels of IFN-y were detected from in vitro
trypanosome antigen culture supernatants of lymph node cells in Boran cattle 1 1 days
after infection with T. conviolcn.se. but not from trypanosome PBMC culture
supernatants. Similar results were obtained by Tavlor. Lutje and Mertens (1996) who
were able to detect IFN-y from lymph node cells 1 1 and 3 1 days after infection.
Trvpanosomes did not induce IFN-y production in splenocytes from either ISMM
treated or un-treated mice However. LPS induced IFN-y production only in splenic
cells from mice that were not treated with ISMM These results do not agree with
those obtained from studies in /. brttcci infected mice where IFN-y production was
induced in a non-specific manner (Darji et al 1991; Sileghem. Darji and De Baetselier
1991; Olsson et ctl 1991; Bakhiet et til 1996) The difference may be due to the fact
that, in this study /. congolen.se instead of T. hrucei was used in cultures. In addition,
the pattern of IFN-y production obtained in this studv is different from that in sheep.
In sheep the response increased 14 to 21 days after treatment while in mice, the
response was high in naive and was not there in treated mice. This would be beneficial
in mice where IFN-y is associated with pathogenesis and parasite growth promotion
(Olsson et a/ 1991; Bakhiet el al 1996), however, the role of IFN-y in ruminant
trypanosomiasis is not clear, but these results seem to indicate that it is protective.
IFN-y is produced mainly by CDS , CD4 T cells and natural killer (NK) cells Its
target cells are mainly macrophages and monocytes but also B cells and T cells
particularly CD4 T cells. The main biological effect of IFN-y is to activate
macrophages and it has been shown to have a beneficial effect of clearing intracellular
parasites such as Leishmania donovani, Trypanosoma cruzi and Plasmodium species
(Silva et al 1992; Sher and Coftman 1992). In contrast, during rat and mice infection
with T. brucei it was identified as a trypanosome growth promoting factor (Ollson el
al 1991; Bakhiet et al 1996). Based on studies in rodents infected with T. brucei a
hypothesis was proposed that immunosuppression in trypanosomiasis is mediated by
IFN-y induced nitric oxide or prostaglandin from macrophages (Olsson et a! 1992).
However, Flynn et al (1991) demonstrated that prostaglandin was not involved in
Boran cattle infected with T. congo/ense although macrophages from these animals
were able to suppress naive mononuclear cell proliferation in vitro. Nitric oxide
synthesis in /. congo/ense infected Boran cattle was down regulated from day 35
onwards while during the same period IL-10 was upregulated (Taylor, Lutje and
Mertens 1996) Therefore, effects of IFN-y in ruminant trypanosome infection might
be different from those in rodents, and the mechanism of immunosuppression also
seems to be different, probably involves IL-10 in ruminants.
In conclusion, these results demonstrate that ISMM sensitised sheep PBMCs in vivo
for IFN-y production and moderated proliferative responses to trypanosome antigens.
It also induced down regulation of IL-12p40 production which inhibits IFN-y
production in mice However, the pattern of IFN-y modulation seems to be different




EFFECTS OF ISOMETAMIDIUM PROPHYLAXIS
ON BACILLE CALMETTE-GUER1N (BCG) VACCINAHON
8.1 INTRODUCTION
This experiment was conducted as a result of significant immunomodulation by
ISMM in T. congolense infected sheep. Lymphocytosis and absolute B cells were
significantly higher in the control group than in the prophylactic group On the other
hand absolute CD4 T cells were higher in the prophylactic group than in the control
group. The working hypothesis was that ISMM immunomodulation was non-specific,
therefore, it was expected to modulate cellular responses in Bacille Calmette-Ouerin
(BCG) vaccination, therefore, provide supporting evidence for the observed effects.
BCG vaccine provided a non-trvpanosome antigen that could be used to examine
whether ISMM immunodulation was specific for trypanosome infections
BCG contains a live attenuated Mycobacterium tuberculosis bovis used for
immunising against the human form of tuberculosis caused by Mycobacterium
tuberculosis M. t. bovis is an intracellular ruminant pathogen whose immunological
responses have been studied very extensively. It provides a good model for T cell
mediated delaved-type hypersensitivity (DTH) immune responses to intracellular
parasites.
M. t. bovis multiply in unsensitised macrophages and then spread to regional lymph
nodes The ability of macrophages to kill the bacteria is enhanced only after the
development of cell mediated delayed type hypersensitivity reaction. After
sensitisation (2 weeks onwards) lymphocytes release lymphokines that attract,
activate and increase number ofmononuclear cells around the infection site (Saito and
Nakano 1996) Because .)/. /. bovis in BCG vaccine is known to induce cell mediated
immune responses, it forms a good model for studying modulation of cellular immune
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responses, hence the reason for using it in this experiment. Therefore, the objective of
this experiment was to investigate effects of ISMM on PBMC responses to BCG
vaccination, in order to determine whether immunomodulation by ISMM was specific
to trypanosome antigens.
8.2 MATERIALS AND METHODS
Peripheral blood mononuclear cell phenotypes (B cells, CD4 , CD5", CD8 and T
cells) as well as in vivo lymphocyte proliferation as indicated by an increase in
lymphoblasts observed on flow cytometry were determined as described in Chapter 3.
At the end of the experiment, 35 days after inoculation, Bovine tuberculin purified
protein derivative (PPD) skin test was performed by injecting 0.2ml of PPD
intradermally in the neck region. Skin thickness was then measured using a calliper
daily for 3 days. PPD test is a standard diagnostic aid for detecting the presence of an
active tuberculosis infection in ruminants.
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8.3 RESULTS
8.3.1 In vivo PBMC proliferation (% Lymphoblasts) following BCG inoculation
The percentage of lymphoblasts in PBMC was estimated by Flow cytometry as
described in Chapter 3 section 3.9.2. Dot plot results are presented in Appendix VI,
Figures E1-E6. A significant increase (P>0.01) in lymphoblasts was recorded in the
control group 7 to 35 days post BCG inoculation (Figure 8.1; Table El-Appendix
VI). Although sheep 2266 and 2327 in the ISMM group showed a slight increase 21
days after vaccination, the change above pre-vaccination levels was not statistically
significant (P>0.05).
Figure 8.1 In vivo PBMC proliferation (% Lymphoblasts) following BCG
inoculation
(a). CONTROL GROUP
Days pre/post BCG inoculation
2212 2305 -sir-NT
-14 -7 0 7 14 21 28 35
Days pre/post BCG inoculation
[ —#—2266 —IS— 2327 -^r-2378 I
(b). ISMM GROUP
• ISMM group was treated 14 days before BCG inoculation
• All sheep in both groups were inoculated with BCG on day zero
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8.3.2 Percentage of B cells following BCG inoculation
Figure 8.2 and Table E2-Appendix VI, shows that B cells in the control group
decreased significantly below pre-inoculation levels 7 to 21 days after inoculation,
then increased above normal 28 days onwards (P<0.05). A significant decrease in the
ISMM 7 to 21 days after inoculation (P<0.01) was followed by a return to normal
thereafter. However, there was no significant difference in the percentage of B cells
between the control and ISMM groups throughout the study period (P>0.05).
(b). ISMM GROUP
Figure 8.2 Percentage of B cells following BCG inoculation
(a). CONTROL GROUP
7 14 21 28 35
Days pre/post BCG inoculation
2266 2327 -A—2378
Days pro/post BCG inoculation
-2212 2305 —A—NT
• ISMM group was treated 14 days before BCG inoculation
* All sheep in both groups weie inoculated with BCG on day ^eiu
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8.3.3 Percentage of CD5+ T-cells following BCG inoculation
A significant (P<0.01) decrease in CD51 T cells was recorded in the control group 28
to 35 days after inoculation but not in the ISMM group (Figure 8 3; Table E3-
Appendix VI,) leading to significantly (P<0.01) lower CDS' T cells in the control
than in the ISMM group 28 to 35 days after vaccination.
Figure 8.3 Percentage of CD5+ T-cells following BCG inoculation
(a). CONTROL GROUP (a). ISMM GROUP
1 1——T KT—
-14 -7 0 7 14 21 28 35
Days pre/post BCG inoculation
— 2212 —2305 —lit—NT !
-14 -7 0 7 14 21 28 35
Days pre/post BCG inoculation
— 2266 2327 —*—2378 I
• ISMM group was treated 14 days before BCG inoculation
• All sheep in both groups were inoculated with BCG on day zero
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8.3.4 Percentage of y8+ T-cells following BCG inoculation
In the ISMM group, a transient decrease in the percentage of y5' T cells was
observed 21 after inoculation While in the control group, a significant (P<0.01)
decrease was observed 21 days onwards (Figure 8.4; Table E4-Appendix VI).
Therefore, 28 days onwards the percentages of y8' T cells in the two control group
were significantly (P <0.01) lower than in the ISMM group.
Figure 8.4 Percentage of yS+ T-cells following BCG inoculation
-14 -7 O 7 14 71 7,8 35
Days pre/post BCG inoculation
♦—2212 —2305~ —A—NT
-14 .7 0 7 14 71 28 35
Days pre/post BCG inoculation
♦—2266 2127 A 2378
(a). CONTROL GROUP (b). ISIMM GROUP
• ISMM group was treated 14 days before BCG inoculation
• All sheep in both groups were inoculated with BCG on day zero
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8.3.5 Percentage of CD4+ T-cells following BCG inoculation
Variations in the percentage of CD4' T cells in the ISMM group were not
significantly different from pre-inoculation levels. On the other hand, a significant
(P<0.01) decrease was observed in the control group 28 to 35 days post inoculation.
As a result of this, CD4' T cells in the control group were significantly (P<0.01)
lower than those of the ISMM group 28 days onwards (Figure 8.5; Table E5-
Appendix VI).
Figure 8.5 Percentage of CD4+ T-cells following BCG inoculation
-14 -7 0 7 14 21 28 35
Days pre/post BCG inoculation
r 22)2 —n— 2305 —A—NT
(b). IS MM CROUP
-14 -7 0 7 14 21 28 35
Days pre/post BCG inoculation
-2266 St 2327 —*—2378
(a). CONTROL GROUP
• ISMM group was treated 14 days before BCG inoculation
• All sheep in both groups weie inoculated with DCG on day zero
123
8.3.6 Percentage of C'D8+ T-cells following BCG inoculation
A decreased in the percentage of CDS' T cells after inoculation group was significant
(P<0.01) in the control group. In the ISMM group, pre-inoculation percentages of
CD8' T cells for sheep 2266 were much lower than the other two sheep (2327 and
2378) such that, the response after inoculation also varied greatly within the group.
However, a non-significant decrease in all the sheep was observed. There was no
difference in the pattern of response between the control and the ISMM groups
(Figure 8.6; Table E6-Appendix VI).
Figure 8.6 Percentage of CD8+ T-cells following BCG inoculation
• ISMM gioup was treated 14 days before BCG inoculation
• All sheep in both groups were inoculated with BCG on day zero
124
8.3.7 CD4+:CD8+ T-cell ratios following BCG inoculation
The ratio of CD4':CD8' T cells increased significantly (P<0.01) from 7 to 21 days
after inoculation and returned to normal thereafter in the control group. In the ISMM
a significant (P<0.05) increase from 7 until 35 days after inoculation was observed.
Therefore, the ratio differed significantly (P<0.01) between the control and ISMM
groups 28 to 35 days post vaccination, it had remained high in the ISMM group, but
had returned to normal in the control (Figure 8.7; Table E7-Appendix VI).
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ISMM group was treated 14 days before BCG inoculation
All sheep in both groups were inoculated with BCG on day zero
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8.3.8 Skin thickness (mm) after PPD injection 35 days post BCG inoculation
A positive reactor was considered to be any sheep that showed an increase in the skin
thickness greater than 4mm, 72 hours after an intradermal PPD injection. Skin
thickness in the control group had exceeded the critical value of 4mm by 72 hours
after injection (Radostits et al 1994). Sheep 2378 in the ISMM group was a negative,
while sheep 2266 and 2327 were positive reactors to PPD skin test. (Figure 8.8; Table
E8-Appendix VI).
Figure 8.8 Skin thickness (mm) after PPD injection 35 days post BCG
inoculation
(a). CONTROL GROUP
0 24 48 72
Honrs alter PPD injection
D Sleep 2212 Q Sheep 2305 B Sheep NT
(b). IS MM GROUP
25.0
0 24 48 72
Hours after PPD injection
Q Sheep 2266 □ »eep 2327 B Sheep 2378
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8.4 DISCUSSION
At present, there are no reports in the literature on lymphocyte phenotype responses
to M t. bovis in ruminants, therefore these results are discussed by simply comparing
pre- and post-inoculation values and relating then to responses observed in T.
congolense infected sheep or cattle Lymphoblasts in blood of the BCG control group
started to increase 14 days after inoculation, peaked at 28 days and by 35 days post-
inoculation, they were beginning to return to normal levels. On the other hand, in the
ISMM group, no significant increase was observed following BCG inoculation. The
same effect of ISMM on lymphocytosis was observed in trypanosome infected sheep
However, the lymphocytosis the first 3 weeks after inoculation was largely due to an
increase in T cells in BCG vaccinated sheep while in trypanosome infected sheep, a
slight T cell increase for 7 days was followed by a large increase in B cells 14 days
onwards. These results imply that ISMM moderated both T and B cell polyclonal
proliferation. In turn, this could inhibit the development of clonal anergy which
normally results from polyclonal expansion of both effector and memory cells.
Excessive clonal expansion has been shown to lead to clonal exhaustion or anergy in
trypanosome infections, a situation in which immune cells become unresponsive
(Urquhart et cil 1973 review).
The percentage of B cells in the control group decreased while lymphocytosis was
developing 7 to 21 days after inoculation. Therefore, absolute B cells remained
constant during this period in the control group, but 28 days onwards, started to
increase. On the other hand in the ISMM group, 7 to 21 days after inoculation, there
was little or no lymphocytosis, and there was a decreased percentage of B cells,
resulting in a constant absolute B cell count and no observed changes thereafter B
cell responses seemed to be different in BCG vaccinated and trypanosome infected
sheep. In trypanosome infected control sheep, absolute B cells increased for 21 days
and began to decrease 28 to 35 days post-infection, while in BCG sheep there was no
change for 21 days but started to increase 28 days onwards. However. ISMM
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inhibited polyclonal B cell proliferation in BCG vaccinated and trypanosome infected
sheep.
Seven to twenty one days after inoculation there was lymphocytosis, and a constant
percentage of CD5 T cells in the control group. This means, during this period, there
was an increase in absolute CD5" T cells in the control group. But by 28 days
onwards, CD5+ T cells were returning to normal. On the other hand in the ISMM
group, 7 to 21 days after inoculation, there was little or no lymphocytosis, with a
constant percentage of CD5' T cells. This implies that during this period there was
little or no increase in absolute CD5* T cells. In trypanosome infected sheep a similar
pattern of response was observed, in the control and the prophylactic groups. In BCG
vaccinated as well as trypanosome infected sheep, ISMM inhibited changes in CD5 T
cell responses.
The percentage of CD8 T cells decreased in the presence (control group) and
absence (ISMM group) of lymphocytosis. This means the absolute CD8 T cells
decreased in both groups throughout the period. In trypanosome infected sheep, there
was also no difference in CD8" T cell responses in control and prophylactic groups.
Therefore, ISMM did not seem to affect CD8 T cell responses.
Changes in the percentage and absolute CD4 T cells followed the same pattern as
that of CD5^ T cells in both groups. That means in the control group, 7 to 21 days
after inoculation there was an increase in absolute CD4 T cells followed by a return
to normal thereafter, while in the ISMM group, there was little or no change in
absolute CD4~ T cells. In trypanosome control sheep, a non-significant increase in
absolute CD4" T cells 7 to 14 days post infection was followed by a significant drop
below normal levels 21 days later, while no significant changes were observed in the
prophylactic group. This is an indication that ISMM affected CD4" T cell responses
by inhibiting polyclonal probably in favour of monoclonal expansion and by inhibiting
activation induced cell death.
128
The ratio of CD4 :CD8 T cells in the control group increased 7 to 21 days after
inoculation but returned to normal thereafter. In the ISMM group, an increase in
CD4 CD8 T cells was observed throughout the study period. In trypanosome
control sheep an increase in the ratio was observed 7 to 14 days after infection, but
decreased significantly below normal levels 21 days later, when an increase was being
observed in the prophylactic group. The end result was that there were unusualy more
CD4 T cells than CD8 T cells in the ISMM group.
In the control group, the percentage of y8 T cells remained constant 7 to 21 days
after inoculation when there was lymphocytosis, but decreased 28 days onwards
when lymphocytosis had subsided. Therefore, absolute y8 T cells increased 7 to 21
after vaccination and returned to normal thereafter. In the ISMM group, both the
percentage and absolute y8 T cells showed a transient decrease 21 days after
inoculation. In trypanosome controls, a non-significant increase in y8 T cell was
recorded 7 to 14 days after infection and was followed by a decrease below normal
levels 21 days later, while in the ISMM group a decrease 7 to 14 days after infection
was observed. Therefore. ISMM appeared to have inhibited an increase in y8 T cells
that occurred between 7 and 14 days in control groups of both trypanosome infected
and BCG vaccinated sheep.
The skin thickness had increased by more than 4mm in all sheep except sheep 2378
from the ISMM group which did not react. The PPD skin test may fail to detect cases
of minimal sensitivity as may occur in early or late stages of Mycobacterium bovis
infection. Non-reactors may also occur due to desensitisation caused by absorption of
tuberculin and other foreign proteins (Radostis el a! 1994) Desensitisation may last
long after subcutaneous than after an intradermal injection. However, sheep 2378
seemed not to have been properly sensitised (might have been underdosed) by the
BCG vaccine because it was the only one in the group with odd responses for most
parameters tested even before the PPD skin test was performed. However, the
reaction to the PPD skin test was not significantly different between the groups,
implying that despite modulation of certain aspects of the immune system, the actual
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reaction to the PPD skin test was not significantly different between the groups,
implying that despite modulation of certain aspects of the immune system, the actual
response to challenge was not affected or that data was not sufficient to detect an
significant difference.
In conclusion, ISMM modulated cellular responses to BCG vaccination in sheep by
favouring an increase in CD4 T cells with respect to CD8 T cells, moderating
polyclonal B cell proliferation and lymphocytosis in a way similar to effects in T.
congolense infected sheep. This provides further evidence that the difference in
immunological responses between the T. congolense control and prophylactic group is
not a result of direct destruction of trypanosomes since there is no evidence that





Because of the major economic importance of animal trypanosomiasis, the majority
of control strategies aimed primarily at the protection of these animals use ISMM as
a major component of their programmes. Although there are many different ways of
combating animal trypanosomiasis, each of the control methods available has serious
limitations. The high cost involved in conducting tsetse eradication programmes is
often beyond the reach of individual farmers or countries. Furthermore, tsetse fly
clearance is not a reliable control measure if continued surveillance cannot be
guaranteed. Nevertheless, even tsetse fly eradication will not necessarily result in the
eradication of trypanosomiasis since T. vivax and T. evansi can cause infection
without cyclical transmission and can be spread mechanically by biting flies.
Furthermore, tsetse fly eradication by aerial or ground sprays of massive amounts of
chemicals may have adverse environmental effects (Ford 1971). Chemicals sprays
despite being effective kill insects and other animals indiscriminately.
Conserving biological diversity has emerged as a priority shared by conservation and
many development projects including tsetse and trypanosomiasis control projects.
Tsetse distribution in many countries is closely associated with wildlife habitats and
adjacent areas. Therefore, emphasis on tseste eradication and livestock production
indirectly threatens the survival of wildlife. It can now be urged that tsetse and
trypanosomiasis although generally considered to be a problem to man and his
livestock, has prevented people from claiming more and more land from wildlife
habitats. National parks and wildlife reserves are at the forefront of conserving
biological diversity and its probably time livestock development became integrated
with wildlife management in order to avoid conflict of interests. For instance, people
living in tsetse infested areas could be encouraged to keep and manage wildlife
ranches instead of livestock as a source of income through tourism and sales of game
meat and trophies. As a matter of fact, these days some wild animals are more
valuable than livestock but can survive in harmony with tsetse and trypanosomiasis at
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very minimal cost. Examples of existing integrated conservation projects which are
increasingly involving the local people in wildlife management include: the
Lupande/ADMADE and Luangwa Integrated Rural Development Project (Zambia);
East Usambara (Tanzania), Amboseri National Park (Kenya) and Volcanoes National
Park in Rwanda (Wells, Brandon and Hannah 1992). If such projects could include
among their aims, the phasing out of livestock rearing in the vicinity of wildlife
habitats in favour of game animals, the benefits could be phenomenal.
In the absence of a lasting solution to conserving biodiversity in relation to wildlife
and livestock development, tsetse fly control strategies using targets or traps continue
to be used. Tsetse flies can detect odours by means of receptors on their antennae.
The knowledge of insect pheromones was used to detect the chemical component of
cattle odour which would attract tsetse flies and led to the discovery of l-octen-3-ol.
It proved highly attractive to Glossina m. morsitans and G. pallidipes (Allosopp, Hall
and Jones 1985). Traps baited with acetone and l-octen-3-ol are used in many areas
of Africa. Targets, which are also baited with acetone and l-octen-3-ol consist of a
piece of black or blue cloth (colours that also attract tsetse flies) and sprayed with an
insecticide such as deltamethrin. Attracted flies land on the target and receive a lethal
dose of the insecticide. Targets and traps are less indiscriminate since they kill only
flies that are attracted to them. However, traps and targets, despite being cheaper than
aerial or ground sprays only manage to reduce the risk of infection and not eradicate
it.
In regions with low or moderate tsetse fly density, where eradication of the fly is not
possible with present methods, genetic improvement of trypanotolerant animals could
be attempted. Such programmes could involve selection of trypanotolerant animals
under natural challenge or selection of marker traits such as aspects of immune
response associated with resistance to trypanosomes. A 1'. congo/ense cysteine
kinase (congopain) elicits a high IgG response in trypanotolerant but not in
trypanosusceptible cattle during primary infection. It is suggested that the difference
might reflect a dysfunction in the isotype switch mechanism in infected susceptible
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Zebu cattle. Therefore, regardless of the mechanism involved the antibody response to
congopain in primary infection appears to be a marker of trypanotolerance (Authie
1994). Congopain is a cystein protease produced by trypanosomes and other micro¬
organisms which has been shown to degrade host proteins such as immunoglobulins
and complement factors. However, it can also be immunogenic. Studies of immune
responses in antelopes such as buffaloes and elands could also assist in identifying
resistance markers. Many wild animals co-exist with tsetse transmitted trypanosomes
and African buffalo and eland serum contain trypanocidal protein that is able to kill
blood stream forms of T. congo/ense, T. vivax, T. evansi, T. brncei, T. gambiense
and I. rhodesiense within 4 hours in vitro (Reduth et al 1994). However, this
trypanocidal material is not lipoprotein, IgG or IgM. Trypanotolerance is probably
multifactorial and appears to involve both immunological and non-immunological
mechanisms. Whether trypanotolerance is determined by innate mechanisms or by
acquired immunity to trypanosomes is not yet known. Nevertheless, in areas of high
tsetse fly challenge even trypanotolerant animals will not survive unless they are
treated prophylactically against trypanosomes.
Thus, in the absence of a suitable vaccine or any other more effective method, ISMM
prophylaxis forms the most important part of most trypanosomiasis control measures.
However, the use of ISMM in trypanosomiasis control programmes is not without
problems. The manufacturers recommend the use of ISMM at a dosing interval of 3
months. At this frequency of use, ISMM is generally considered to be cost effective.
However, it is very common for a considerable number of animals to become infected
by the end of one month even after careful drug administration (Fairclough 1963;
Pinder 1984; Eisler et al 1994). Therefore, a dosing interval of less than 3 months
generally ceases to be cost effective and increases treatment costs or animal losses.
In order to correct the problem of prophylactic drug failure, a substantial
understanding of protective mechanisms involved is vital because the conventional
concentration (or dose)-response relationship that applies' to most drugs does not
apply to ISMM. Most drugs that have a direct parasite killing capacity have a
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minimum effective concentration (MECioo) that would kill all parasites in vitro and in
vivo. The MECioo for ISMM against different strains of trypanosomes in vitro has
proved difficult to define because of varying sensitivities to the drug. In vitro studies
with ISMM demonstrated that the MECioo for T. evansi and T. eqniperdnm after 24
hours of drug exposure was 1 000 - 4 000 ng/ml (Zhang, Giroud and Baltz 1991) and
1 - 300 ng/ml after 96 hours of exposure (Brun and Lun 1992). Also culturing T.
congolense and T. vivax, in vitro in the presence of 5 ng/ml ISMM for 10 minutes
(Sutherland, Mounsey and Holmes 1991), 10 ng/ml for 24 hours (Kaminsky, Chuma
and Wasike 1994) and 10 ng/ml for 48 hours (Gray and Peregrine 1993 ) could not
completely eliminate parasites or prevent infection in mice. Results from this study has
also shown that ISMM could not kill all trypanosomes in vitro at 100 ng/ml for 48
hours. These studies demonstrate that the MECioo for the common T. congolense
isolates in greater than lOng/ml. It is known that trypanosome sensitivity assays
carried out in vitro are "closed systems" where all metabolic and breakdown products
are not eliminated and the drug concentration is not subjected to elimination processes
that exist in vivo. Therefore, survival of parasites for more than 24 hours in such
harsh in vitro environments in the presence of ISMM is an indication of an ineffective
killing capacity of ISMM drug residues.
The plasma profile of ISMM in treated sheep showed that the concentration was
below 3 ng/ml 21 days after administration, such that by the time of infection four and
a half months later, drug levels should have been undetectable. Yet the establishment
of T. congolense did not occur. These results demonstrated that ISMM is more
effective in vivo than it is in vitro, probably as a result of potentiation of the immune
system. Several other experiments have demonstrated in vivo protection due to
ISMM at very low or undetectable plasma or serum levels (Eisler et al 1994; Geerts
etal 1997).
The mechanism of protection when ISMM plasma levels are low or undetectable is
still not well known. Nevertheless, because no trypanolytic antibodies exist in
prophylactically treated animals, the protection has been attributed to drug residues
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(Whitelaw et al 1986; Geerts et al 1997). However, the fact that trypanolytic
antibodies may not be detected in serum of animals under prophylactic cover does not
rule out the involvement of certain other aspects of the immune system. There are
suggestions in the literature that the immune system may be involved in the long term
protective effects of ISMM, the only problem has been the inability to prove their
existence. Hill (1965) demonstrated that activity of ISMM against T. congolense in
vitro was less than that observed in vivo. These differences could have been attributed
to the possibility of potentiation of the immune system in vivo.
In this study trypanosome specific IgG antibodies were almost twice as high in the
prophylactically treated sheep compared to the control group. Nevertheless, they were
almost absent in the group of sheep treated 14 days after infection. These results
demonstrate that ISMM prophylaxis results in an up-regulation of IgG antibodies
which are involved in opsonisation and phagocytosis. On the other hand treatment of
an established infection with ISMM may lead to suppression of IgG antibodies. In
primary infections in mammals, initial IgM antibody synthesis is usually replaced by
the synthesis of IgG antibodies (Uhr 1964). However, in trypanosome infections, IgM
antibodies remain characteristically high through out the infection (Luckins 1976), but
they maybe augmented by IgG antibodies (Nantulya, Musoke and Moloo 1986).
Variable surface glycoprotein specific activity is found in both IgG and IgM fractions.
IgM fractions are more efficient at neutralisation, agglutination and lysis in vitro
compared to IgG antibodies.
However, it is more likely that clearance of antibody coated trypanosomes in vivo
occurs primarily by phagocytosis and there is considerable evidence in support of this
view. In vitro studies have shown that T. brucei and T. gambiense are ingested by
macrophages in the presence of immune serum (Lumsden and Herbert 1967). In vivo
evaluation of the role of opsonisation and macrophage uptake of radiolabeled
trypanosomes showed that whereas labelled parasites remained in circulation of
normal mice, they were rapidly eliminated from blood of immune animals. In the
immunised mice the liver was found to be the principal site of uptake, removing over
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50% of trypanosomes within 15 minutes of an intravenous injection of labelled
parasites (Holmes et at 1979; MacAskill et al 1980). The possibility that immune lysis
was a pre-requisite to phagocytosis of trypanosomes was investigated in vivo by
measuring trypanosome clearance ability of passively immunised C5-deficient and C3-
depleted mice (MacAskill et al 1980). Results of this experiment showed that C5-
deficiency which is necessary in complement mediated lysis did not affect immune
clearance, while reduction in C3 which is essential for full opsonic activity prevented
immune clearance in passively immunised mice.
IgG antibody production was enhanced in the prophylactic group and suppressed in
those treated with ISMM 14 days after infection. The difference is likely to be due to
the status of the host regulatory cytokines at the time of infection. Numerous
cytokines are produced by a variety of cells after infection, but IFN-y production was
investigated in this study because of its ability to down-regulate proliferation of
mononuclear cells from T. brucei infected rodents (Olsson et al 1991; Bakheit et al
1996). IFN-y is produced by many cell types including CD8 , CD4", y8~ T cells and
natural killer cells. Biological effects of IFN-y include: increased macrophage activity
and cytokine production such as TNF; induction of IL-2 and IL-2R expression by T
cells; decreased B cell proliferation and the promotion of IgG2a antibody isotype
production (Tizard 1992).
IFN-y production in sheep was investigated as a possible target for ISMM induction
leading to modulation of cellular and antibody responses. PBMC collected 14 to 21
days after ISMM administration from the prophylactic non-infected sheep produced
significant amounts of IFN-y when cultured in vitro in the presence of live
trypanosomes. ConA cultures produced IFNy in a manner that was not related to the
time after drug administration. These results indicate that ISMM activated naive
PBMCs in vivo for IFN-y production in vitro when cultured with trypanosomes. The
heightened responsiveness was maintained in one sheep until 21 days after infection
when it dropped to normal levels, despite the fact that infection was not established.
In the literature there are no reports of IFN-y production by PBMCs from either naive
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or trypanosome infected animals when cultured with trypanosome antigens. The
results of Lutje et al (1995) showed that high levels of EFN-y were detected from in
vitro trypanosome antigen culture supernatants of lymph node cells in Boran cattle 11
days after infection with T. congolense, but not from trypanosome-PBMC culture
supernatants. Similar results were obtained by Taylor, Lutje and Mertens (1996) who
were able to detect IFN-y from lymph node cells 11 and 31 days after infection. Thus,
sensitisation of lymphocytes in prophylactically treated sheep for IFN-y production
appears to be one mechanism resulting in the modulation of cellular and antibody
responses after challenge with trypanosome antigens.
Naive lymphocytes are pluripotent, therefore they can differentiate along different
pathways to become effector cells depending on the additional signal received during
activation. These additional signals are induced by pathogens in the effector cells of
the innate immune system (Romagnani 1992). Different effector cells produce
different sets of cytokines when stimulated by antigens. Type 1 cytokines which
includes IFN-y and IL-12 induce the differentiation of T cells into Thi effector cells
and IgG2 antibody production favouring cell mediated repsonses. Type 2 cytokines
(IL-4 and IL-10) induce the Th2 differentiation pathway and IgGi and IgE antibody
production in favour of humoral immune responses (Sender and Paul 1994).
However, Tft, effector cells which produce both IFN-y and IL-4 also exist.
Therefore, the innate non-clonal system controls the initiation of the clonal adaptive
immune response by regulating the expression of co-stimulatory activity on antigen
presenting cells. A signal received through an antigen receptor is not sufficient on its
own for the activation of naive lymphocytes. A second, so called, co-stimulatory
signal is required for lymphocyte stimulation to occur. Co-stimulators are members of
the immunoglobulin superfamily especially B7.1 and B7.2 molecules (June et al
1994). In the absence of the second signal no response occurs and T cells become
anergic while in the presence of a signal through the T cell receptor and the co-
stimulator molecule, the T cell is activated to subsequently express other interactive
surface molecules such as TNF, Fas ligand and IL-2R, as well as the secretion of
cytokines (June et al 1994). T cells and cell lines derived from T. brucei infected mice
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appeared exclusively to represent Thi cells specific for the variant surface
glycoprotein determinants. In contrast T cells and cell lines from immunised mice
represented a more diverse T cell responses in which Tho, Thi and Th2 subsets were
generated (Mansfield 1994). Therefore, differences in cytokine profile present at the
time of infection might explain why IgG antibody responses in the prophylactic and
treated groups were different although the exact mechanism is unknown.
When live T. congolense were cultured with splenic cells from either ISMM treated or
un-treated mice for 24 hours, there was no induction of IFN-y production. However,
LPS induced IFN-y production only in splenic cells from un-treated mice, implying
that ISMM suppressed LPS induction of IFN-y production. The role of IFN-y in
down-regulating mononuclear cell proliferation in rodents was demonstrated by
culturing cells in the presence or absence of anti-IFN-y antibodies. Results indicated
that cells cultured in the presence of antibodies proliferated while those without
antibodies to IFN-y did not proliferate (Olsson el al 1991). Down-regulation was
effected by a feedback mechanism resulting from IFN-y activated macrophages
mediated by prostaglandins (Schleifer and Manfield 1993) and nitric oxide (Schleifer
and Manfield 1993; Sternberg and MacGuigan 1992). However, the pattern of IFN-y
production obtained in mice was different from that obtained in sheep. In sheep the
response increased 14 to 21 days after treatment while in mice, the response was high
in naive and was not there in prophylactically treated mice. Nevertheless, the role of
IFN-y in ruminant trypanosomiasis is not clear, but the association of IFN-y
production with ISMM protection in this study may be suggestive of a protective role
since so far a direct link with the proposed mechanism leading to immunosuppresion
in rodents seems to be well regulated in ruminants (Daiji et al 1991; Taylor^Lutje and
Mertens 1996).
Parasites usually interact directly with antigen presenting cells to induce the
production of IL-12 which is a potent inducer of IFN-y production on T cells.
Therefore, IL-12 production was investigated because of its important role in
regulating IFN-y production and the subsequent development of the acquired immune
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responses. Assessment of IL-12p70 in the same mice splenic cell cultures that were
assayed for IFN-y showed that none of the trypanosome or LPS cultures were
positive for IL-12p70 indicting that it was either not produced or levels were too low
to be detected by the assay. On the other hand IL-12p40 levels were high in both LPS
and trypanosome cultures of non-treated as well as those obtained 7, and 14 day after
ISMM administration but dropped significantly in cells collected 21 days after ISMM
administration. The absence or low levels of LL-12p70 and presence of high levels of
IL-12p40 could have resulted in a down-regulation of IFNy production in ISMM
treated mice splenic cell cultures. More studies on IFN-y and IL-12 production are
required since these were only a preliminary experiment aimed at elucidating the
mechanism of immunomodulation resulting from ISMM administration.
Regulation of IL-12 production is by negative and positive feedback mechanisms
involving IFN-y as the most potent up-regulator (Rubin, Chow and Trinchieri 1994)
and IL-10 as the most important down regulator (D'Andrea et al 1993). Because of
the toxic and in some cases lethal effects of IL-12 overproduction, it is necessary that
effective mechanisms should exist in vivo to limit the production or the ability of T
cells and natural killer cells to respond to it. Currently, IL-10 produced mainly by
activated macrophages, is the most effective down-regulator of the biological effects
of IL-12 (D'Andrea et a/ 1993). Biological effects of IL-12 include: induction of
several cytokine production especially IFN-y by T and natural killer cell; promotion of
haematopoiesis; enhancement of cell-mediated cytotoxicity (Mansfield 1995). It has
been demonstrated that if IL-12p70 and IFN-y are present during early T cell
expansion in response to antigen, Th] cell generation is favoured and the generation of
Th2 cells inhibited Mansfield et al (1993), reviewed the existence of both Th, and
Th2 responses in trypanosome infections. However, it is not yet clear which one of
these responses may be associated with pathology or resistance to different species of
trypanosome infections. Results of this study suggest that ISMM prophylaxis favours
an early presence of Thj cytokines resulting in the enhancement of immune
responses.
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An experiment set up to determine the effect of suppressing cell-mediated immune
responses on the efficacy of ISMM in mice showed that the prepatent period and
survival time in mice that had received hydrocortisone (a cell-mediated immune
response suppressor) and ISMM was the same as that observed in the control group.
On the other hand, even though all mice developed parasitaemia and died, those that
received ISMM only, had a long prepatent period and survived longer. The major
immunosuppressive effects of hydrocortisone include: a decrease in concentration of
various complement components; reduced proliferative responses to mitogens and
antigens in vitro; decreased cytokine production (e.g. IL-2, IL-1) and decreased
sensitivity of macrophages to cytokines, resulting in decreased phagocytosis. This
implies that suppressing cellular responses using hydrocortisone reduced the ability of
ISMM to control the establishment of the infection. It is known that the dose of
ISMM required to prevent or treat T. congolense infection effectively in mice is about
ten times that for ruminants (Sones et al 1988). However, in this study the same dose
of lmg/kg body weight was used in sheep and mice in order to make comparisons
relevant.
Three groups of sheep were used to investigate further the effects of ISMM on
cellular immune responses. A control group, ISMM prophylactic group, and another
that had to be treated with ISMM 14 days after infection, were infected with T.
congolense. Results showed that none of the sheep in the prophylactic group became
parasitaemic throughout the study period, while all sheep from the control and treated
groups became parasitaemic 7 days after infection. The control group remained
parasitaemic, while after treatment parasites were cleared from the ISMM-treated
group. The magnitude of fluctuating fever was highest in the control group while in
the treated group it subsided after treatment. None of the sheep in the prophylactic
group became febrile. Comparing N'dama and Boran cattle undergoing a primary
infection with T. congolense, Williams et al (1991) found that parasitaemia was lower
and usually intermittent in the trypanotolerant N'dama than in the susceptible Boran
cattle. The results of this study demonstrate that ISMM prophylaxis was capable of
preventing the establishment of a T. congolense infection four and a half months after
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treatment and that a similar dose was also capable of clearing an established infection.
Complete protection was also afforded by ISMM for four months (Peregrine et al
1988), for one to six months (Eisler et al 1994) in Boran cattle and for 20 months
using a sustained release device (Geerts et al 1997). Thus, ISMM does indeed protect
animals from T. congolense infection even at very low or undetectable plasma
concentrations although the duration of protection varies widely.
Anaemia, assessed by measuring the PCV, showed a significant decrease from 14 days
after infection till end of experiment 35 days later in the control group. The PCV in
the treated group returned to normal about one week after treatment and no change
was observed in the prophylactic group. This showed that ISMM prevented the
development of pathological lesions and enabled animals to recover quickly when
treated. Anaemia is one of the major pathological lesions associated with animal
trypanosomiasis. The onset and degree of anaemia are closely associated with the
development and level of parasitaemia. Trypanotolerant N'dama cattle, unlike
susceptible Zebu, have the ability to control the parasitaemia and hence the loss of red
cells. Dargie et al (1979) observed that the PCV decreased to a steady state of 22%
in Zebu and 27% in N'dama from a mean of 35%. However, parasitaemia in N'dama
cattle fell to undetectable levels 5 weeks after infection while Zebu cattle entered a
chronic phase of infection. Therefore, the management of the disease in
prophylactically treated animals is similar but more effective than that observed in
trypanotolerant N'dama cattle. Increases in absolute monocyte count were observed
in the control and treated groups 14 to 21 days after infection. There were no
significant monocyte changes in the prophylactic group. Absolute neutrophil and
eosinophil counts did not show any significant changes in all groups. Therefore ISMM
prophylaxis prevented both the establishment of the infection and development of
pathological lesions but allowed the initiation and development of immunological
responses.
Total white blood cell (WBC) counts increased significantly in the trypanosome
control group 14 days post infection till end of experiment 35 days post infection. The
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pattern of increase in WBC counts was similar to that of absolute lymphocyte counts
because lymphocytosis was the major contributing factor to increased WBC count.
Lymphocytosis was observed during the first 21 days after BCG vaccination in the
control group which was largely due to an increase in CD5+ T cells followed by an
increase in B cells 28 days onwards, while in trypanosome infected sheep a slight
CD5" T cell increase for 7 days was followed by a large increase in B cells 14 days
onwards. On the other hand, no significant lymphocytosis was observed following
BCG inoculation in the ISMM group. Similarly, there was no lymphocytosis in the
trypanosome prophylactic group. Therefore, ISMM prevented the severe
lymphocytosis in trypanosome infected and BCG vaccinated sheep that results from
CD5+ T cell and polyclonal B cell proliferation. The beneficial effects of this type of
modulation is the inhibition of the development of clonal anergy which normally
results from polyclonal expansion of both effector and memory cells. Excessive clonal
expansion has been shown to lead to clonal exhaustion or anergy in trypanosome
infections, a situation in which immune cells become unresponsive (Urquhart et al
1973 review). These results indicate that the effect of ISMM on lymphocytosis is not
necessarily due to direct destruction of trypanosomes, since it is unlikely that ISMM
has bactericidal effects against M. tuberculosis bovis. Total leucocyte and lymphocyte
numbers returned to normal in the trypanosome experiment 2 weeks after treatment.
Lymphocytosis and leucocytosis were also demonstrated, by Mwangi (1991), in sheep
infected with T. congolense 25 days after infection onwards and in cattle infected with
T. congolense (Williams et al 1991; Valli and Forsberg 1979).
In general, absolute numbers and the percentage of CD8^ T cells decreased after
trypanosome infection or BCG vaccination in control or prophylactic groups. An
increase in CD8 T cells was observed only in trypanosome infected and treated sheep
soon after treatment. Therefore, ISMM prophylaxis had no effect on CD8 T cell
responses, while treatment of an established trypanosome infection resulted in an
increased CD8 T cell phenotype. These differences may be a result of the type of
cytokines elicited at the time of either trypanosomes infection or ISMM
administration. Bakheit et a! (1990) and Olsson et al (1991) demonstrated that T.
142
brucei release a soluble factor that trigger CD8T T cells to produce IFN-y.
Sensitisation of CD8~ T cells for the production of high levels of IFN-y during
experimental infections with T. brncei were also reported by Daiji et al (1991).
In trypanosome control sheep, a non-significant increase in absolute CD4 T cells 7 to
14 days post infection was followed by a significant drop below normal levels 21 days
later, while no significant changes were observed in the prophylactic group. In the
trypanosome treated group a very small insignificant decrease in absolute CD4 T
cells was observed 21 days after infection. In the BCG control group, 7 to 21 days
after inoculation there was an increase in absolute CD4^ T cells followed by a return
to normal levels thereafter, but in the ISMM-BCG group there was little or no change
in absolute CD4 T cells. These results indicate that ISMM prophylaxis prevented
CD4+ T cell losses by inhibiting non-specific polyclonal expansion (and accelerated
cell death) probably in favour of antigen-specific expansion since trypanosome
specific IgG antibody production was enhanced.
In general the ratio of CD4 :CD8 T cells in the blood may be used to estimate
lymphocyte function in clinical situation. An elevated CD4* T cell count implies
increased lymphocyte reactivity as helper cells predominate, whereas a high CD8^ T
cell level implies depressed lymphocyte reactivity as a result of excessive suppressor
activity (Tizard 1992). However, consequences of any changes in the ratio largely
depends on the balance of cytokines produced by each cell types. In this study the
ratio of CD4 :CD8 T cells in the BCG control group increased 7 to 21 days after
inoculation but returned to normal thereafter. In the ISMM-BCG group, an increase
in CD4:CD8 T cells was observed throughout the study period. While in
trypanosome control sheep an increase in the ratio was observed 7 to 14 days after
infection, but decreased significantly below normal levels 21 days after infection,
when an increase was being observed in the prophylactic group. These findings show
increased levels of CD4 T cells in the prophylactic group, as compared to CD8 T
cells which down regulate immune responses. This provides an explanation for high
trypanosome specific IgG antibodies in the prophylactic compared to the control
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group. The ratio of CD4T:CD8f T cells in the treated group decreased largely because
of an increase in CD8" T cells while in the control group it was a result of decreased
CD4T T cells hence the probable reason for suppression of antibody levels in the
treated group.
Contact between T cells and antigen presenting cells (APC) occurs through the T cell
receptor (TCR) and MHC-peptide complex and involves a number of other accessory
molecules (Tizard 1992). CD8 molecules associated with the TCR and the CD28
molecule on T cells bind to MHC-class I and B7 molecules on APCs respectively.
CD4 molecules interact with MHC-class II molecules on APCs while interactions
involving accessory molecules is similar to that occurring in CD8" T cells. These
interactions result in the activation of T cells through signal transduction via the CD28
and the TCR. Activation of CD4r T cells leads to the induction of a high affinity IL-2
receptor (CD25), IL-2 and IFN-y. The latter increases the expression ofMHC class II
on APCs, allowing more T cells to interact. IL-2 acts as a growth factor causing T
cell proliferation and clonal expansion. IL-2 is not produced by CD8 T cells but is
important for their expansion. The net effect of these events is to increase the number
of antigen specific T cells, thereby increasing the chance of an earlier contact with the
antigen in the body. Some of these activated cells may act locally at the site of antigen
entry to help in antibody or cellular destruction of parasites, others will circulate and
home at sites of antigen presence, and others will become memory cells. Both CD4
and CD8 T cells may participate in the elimination of trypanosomes by producing
cytokines. For instance, IFN-y converts monocytes into activated macrophages which
are capable of eliminating trypanosomes by phagocytosis. Tumor necrotic factor
(TNF) is another cytokine produced by activated T cells which has trypanocidal
activity (Lucas et al 1993). The protective role of TNF was demonstrated by treating
mice with soluble trypanosome components before infection with T. brucei to induce
TNF production. One group of mice received anti-TNF antibodies at the same time
soluble trypanosome components were administered. Results showed that parasite
development occurred only in mice that received anti-TNF antibodies, implying that
trypanosome induced TNF has a negative effect on trypanosome growth.
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Absolute y§T T cell numbers increased 7 to 21 after vaccination and returned to
normal thereafter in the BCG control group. In the trypanosome control, a non¬
significant increase in absolute y5^ T cells was recorded 7 to 14 days after infection
and was followed by a decrease below normal levels 21 days later. Treatment of
trypanosome infection had little effect on absolute y8 T cell responses. On the other
hand, in the ISMM-BCG group, the absolute numbers of T cells showed a
transient decrease 21 days after inoculation while in the trypanosome prophylaxis
group a decrease 7 to 14 days after infection was observed. Therefore, ISMM
appeared to have inhibited an increase in y§^ T cells that occurred between 7 and 14
days in control groups of both trypanosome infected and BCG vaccinated sheep.
Other experiments in trypanosome infected sheep and cattle have demonstrated
similar decreases in y8 T cell phenotypes (Mwangi 1991; Williams et al 1991; Lutje
et a/ 1995). However, the role of y8 T cells in trypanosome infections is not clear.
Flynn and Sileghem 1991 demonstrated that only y5~ T cells from T. congolense
infected trypanotolerant N'dama and not susceptible Boran cattle proliferated in vitro
suggesting that they may be involved in the control of the infection. Nevertheless,
effects of ISMM prophylaxis on y8" T cells seemed to be a result of the general
inhibition of non-specific polyclonal lymhocyte proliferation rather than a specifically
affecting these cells.
The PPD skin test is a diagnostic tool for estimating cell-mediated immune responses
after exposure to M tuberculosis bovis antigens. The reaction to the PPD skin test
was not significantly different between the BCG control and ISMM-BCG groups,
implying that despite modulation of certain aspects of the immune system, the actual
response to challenge was not affected or that data was not sufficient to detect any
significant difference. However, in trypanosome experiments, ISMM prophylaxis
immunomodulated enhanced trypanosome specific IgG antibodies.
These results have relevant field implications related to the monitoring of ISMM
prophylaxis. Currently prophylactic failure is generally considered to be a result of
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either poor pharmacokinetics or trypanosome resistance through unknown
mechanisms. However, these results demonstrate a mutual relationship between
ISMM drug residues and the immune system in providing protection against
trypanosome infections. Prophylaxis resulted in high trypanosome specific IgG
antibodies in sheep while suppressing cellular responses in mice reduced the
effectiveness of ISMM against T. congolense infection. These results also explain why
certain animals may not be adequately protected even after careful administration of
ISMM since the magnitude of immunomodulation depends on the status of the
immune system at the time of drug administration. For instance, poor IL-12 and IFN-
y response might result in little or no protection while a heightened response may
result in longer protection against trypanosomes. Thus, healthy animals would be
expected to be protected for a longer period than those found with a poor state of the
immune system at the time of administering ISMM. Based on these findings, it is
important to minimise factors that suppress immune responses in order to obtain the
maximum protection due to ISMM prophylaxis. That means stress factors need to be
corrected and debilitating conditions such as worm infestation be addressed before
ISMM is administered. Immunosuppressive agents such as corticosteroids should be
contraindicated, while combination therapy with immunostimulants such as vitamin E
and levamisole (an antihelminthic) may be advantageous (Tizard 1992). Levamisole
stimulates phagocytic activity of macrophages and neutrophils. Its effects are greatest
in animals with depressed T cell function, and it has little or no effect on the immune
system of normal animals. Therefore, continuation of this work in the near future will
involve the investigation of the combined use of ISMM and levamisole in addition to
investigating further cytokine responses in ISMM treated animals.
In conclusion, this study has provided evidence that immunomodulation by ISMM
enhances prophylaxis against T. congolense infection. Modulation of responses to
BCG vaccination that were observed indicate that the mechanism of modulation is not
antigen specific. ISMM activation of naive peripheral blood mononuclear cells in vivo
for in vitro IFN-y production after challenge with trypanosome antigens occurred
suggesting that the mechanism of immunomodulation involves Th] cytokines with
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IFN-y and IL-12 feedback mechanism playing a major role. Unfortunately, these
changes were not persistent to be used for monitoring protection. Further research is
required to establish the best immunological marker that could be used for monitoring
protection. Nevertheless, it is clear that ISMM provides a model for future
prophylactic drug development if immunological parameters could be identified as
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LIST OF MANUFACTURERS WITH MATERIALS SUPPLIED
AND BUFFER SOLUTIONS
1. MANUFACTURERS AND MATERIALS SUPPLIED
Alpha laboratories Ltd, Hampshire, England: Microcentrifuge tubes and pipettes
tips.
Becton Dickinson FACS Systems, Mountain View', CA, USA: Flow cytometer
Becton Dickinson, Meylan Cedex, France. 25cm2 culture flasks, vacutainers, 96 well
culture plates, needles and syringes.
BDHLtd, Poole, England: Giemsa stain, hydrochloric acid, sodium chloride, sodium
hydrogen phosphate, potassium dihydrogen phosphate, sodium hydroxide
Bibby Sterilin Ltd, Staffordshire, England: Bijous and universals.
Commonwealth Serum Laboratories, 45 Popular Road, Parkville 3052, Victoria,
Australia. Bovine y interferon Test
Costar, Cambridge, USA: Pipetting reservoirs.
Department of Veterinary Pathology, University ofEdinburgh: Monoclonal
antibodies against CD4 (SBU-T4), CD5 (SBU-T1), CD8 (SBU-T8), y5 T
cells (86D) and B cells (VPM30).
Department of Veterinary Physiology, University ofGlasgow: ISMM-horse radish
peroxidase conjugate and anti-ISMM rabbit serum.
Distillers Scotland: 5% carbon dioxide.
Dynatech: Immulon 4 96 well micro titre plates.
Exogen Ltd, Glasgow, Scotland: Glass wool
Genzyme, One Kendall Square, Cambridge, MA 02139-1562, USA : InterTest™-12X
Total Mouse IL-12 ELISA Kit and InterTest™-12X Mouse IL-12p70 ELISA
Kit and InterTest-y™ Mouse IFN-y ELISA Kit.
Labsystems, Finland: Multichannel pipetters and Multiscan ELISA plate reader.
Life Technologies, Paisley, Scotland: IMDM (ISCOVES) RPMI 1640, MEM Eagle's
with Earles salts, penicillin/streptomycin
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May & Baker, Ltd, Dagenham, England: Isometamidium (Samorin®).
Millipore, Ireland: 0.22(.t filters.
Neubauer, Germany: Haemocytometer.
Oxoid, Hampshire, England: PBS tablets.
Pharmacia, Uppsala, Sweden: Ficoll-Paque
Promega, Madison, USA: CellTitre 96™ Non-radioactive Cell Proliferation Assay Kit.
Sigma Chemical Co. Ltd, St. Louis, USA: Donor goat serum, L-glutamine,
bathocuprionedsulphonic acid, mono-a-thioglycerol, adenosine, sodium
pyruvate, foetal calf serum, and D-glucose, heparin, concanavalin A, sodium
azide, bovine serum albumin, paraformaldehyde, EDTA, tween 20,
The Binding Site, Birmingham, England: FITC- mouse- anti-IgGi, IgG2a and IgM
conjugates.
Watman, Maidstone, England: Diethyl cellulose-52 (DE52).
Wild Leitz GMBH, Germany: Light microscope
2. BUFFER SOLUTIONS
Phosphate buffered saline (PBSpH 7.4): Prepared by either dissolving 1 PBS tablet
per 100ml of distilled deionised water or making up the following; 4g sodium
chloride (NaCl) (0.8% w/v), 0.74g sodium hydrogen phosphate (Na2HP04)
(0.148% w/v) and 0.215g potassium dihydrogen phosphate (KH2PO4)
(0.043% w/v) and made up to 500ml with distilled deionised water.
1% paraformaldehyde fixative for PBMCs: 50ml PBS were heated to 60°C and lg
paraformaldehyde added followed by the addition drop by drop of 1M NaOH
until paraformaldehyde dissolved. The solution was made up to 100ml with
PBS and cooled under tap water and pH adjusted to 7.0 before storing at 4°C
for up to a week.
Working strength of 0.1% paraformaldehyde was prepared by taking 10ml of
1% paraformaldehyde and making it up to 100ml with PBS.
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PBMCphenotyping wash buffer: 0.1% sodium azide, 1% bovine serum albumin and
20U/ml heparin in PBS.
ELISA diluent/wash buffer: 0.05% tween 20 in PBS (PBST pH 7.4): e.g. 0.25ml
tween 20 in 500ml PBS.
ELISA coating buffer: Carbonate/bicarbonate (pH9.6). consisting of 0.159% (w/v)




RECTAL TEMPERATURES AND HAEMOTOLOGICAL
RESULT TABLES
Table Al(a): Rectal temperatures (°C) for the Control group following
primary infection with T. congolense
Days post (a). CONTROL GROUP
infection 2BF 3WS 1499 2386
0 40.0 39.8 39.7 40.0
1 39.8 40.0 39.5 39.8
2 40.2 39.9 39.9 39.9
3 40.1 39.8 39.8 40.1
4 41.0 42.1 40.8 40.9
5 40.4 40.2 40.8 40.3
6 40.2 40.2 40.4 40.4
7 40.1 40.6 40.5 40.3
8 40.1 40.2 39.8 40.0
9 40.0 40.3 40.2 40.3
10 41.0 40.8 40.2 40.0
11 40.9 40.5 40.3 39.8
12 40.9 40.6 40.3 40.0
13 40.7 40.5 40.4 40.2
14 40.2 41.0 40.9 41.0
15 40.4 40.4 40.8 40.9
16 40.2 39.9 40.6 40.5
17 40.4 39.8 40.1 40.1
18 40.5 40.2 40.4 40.3
19 40.4 40.1 40.5 40.2
20 40. A 40.0 40.5 40.2
21 40.1 40.2 40.3 40.2
22 40. a 40.0 40.3 40.0
23 40.1 39.8 40.4 39.9
24 40.2 40.0 40.6 40.2
25 40.2 40.1 40.7 40.6
26 40.0 40.3 40.5 40.4
27 39.9 40.1 40.5 40.1
28 40.0 39.9 39.8 40.3
29 40.0 39.9 39.9 40.1
30 40.0 39.9 40.2 40.1
31 40.8 39.9 39.6 40.4
32 40.1 39.7 39.4 40.2
33 40.2 40.4 39.6 40.2
34 40.1 40.4 39.8 40.4
35 40.2 40.2 40.3 40.5
36 40.2 40.3 40.1 40.7
37 40.0 40.0 39.7 40.3
38 40.1 39.9 39.5 40.3
~ All animals infected on day zero
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Table Al(b): Rectal temperatures (°C) for the Prophylactic group following




1618 1746 1826 1895
0 39.7 40.0 39.8 40.0
i 39.8 39.8 40.0 39.8
2 39.7 39.6 39.9 39.9
3 39.9 40.1 39.8 40.1
4 40.1 39.8 39.6 39.5
5 40.2 40.1 39.6 39.6
6 39.8 40.2 39.9 39.6
7 39.9 40.1 .39.8 39.8
8 39.7 40.1 39.8 40.0
9 40.2 40.0 39.6 39.8
10 40.0 39.7 40.0 39.7
11 39.9 39.8 39.8 39.8
12 40.0 39.9 39.7 39.7
13 40.1 39.7 39.9 40.1
14 40.2 39.8 40.0 39.5
15 39.5 40.1 39.7 39.7
16 39.8 40.0 39.9 39.9
17 39.9 39.5 39.8 39.8
18 39.1 39.6 40.0 39.8
19 40.2 39.6 40.1 39.8
20 39.6 39.7 40.0 39.7
21 39.8 40.1 39.8 39.5
22 39.3 39.8 40.0 40.0
23 39.8 39.8 39.8 39.9
24 39.5 40.0 39.9 39.8
25 40.1 39.9 40.1 39.7
26 39.6 39.7 39.6 39.6
27 39.8 39.9 39.5 39.9
28 40.1 40.0 39.9 39.9
29 40.0 39.8 39.6 40.1
30 39.8 39.8 39.9 40.0
31 39.7 39.6 39.9 39.6
32 39.0 39.9 39.7 39.8
33 39.3 39.8 39.7 39.6
34 39.9 40.1 39.6 39.7
35 39.8 39.7 39.8 39.8
36 39.9 39.6 39.7 39.8
37 39.4 40.0 40.0 39.9
38 39.7 39.8 39.9 39.6
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
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Table Al(c): Rectal temperature (°C) for the Treated group following




1736 1863 2381 2383
0 39.7 39.9 39.7 39.6
1 39.8 39.6 39.6 39.5
2 39.7 39.7 39.9 39.7
-»
J 39.9 39.9 39.9 39.8
4 40.1 41.1 40.8 40.8
5 40.2 39.8 40.6 40.4
6 40.3 40.4 40.1 40.3
7 39.9 40.0 40.6 40.9
8 40.7 40.3 40.5 40.4
9 40.4 40.1 40.4 40.8
10 40.0 40.6 40.4 40.7
11 39.9 41.0 40.4 41.0
12 40.0 41.0 40.3 40.9
13 40.2 41.0 40.3 40.7
14 40.2 40.3 40.2 40.8
15 40.8 40.3 40.6 40.6
16 40.7 40.4 41.0 41.2
17 40.5 40.6 40.0 40.6
18 40 1 40.1 40.3 40.2
19 40.2 40.1 40.0 40.5
20 40.5 40.3 40.4 40.8
21 40.6 40.3 40.7 40.5
22 40.7 40.5 40.4 40.7
23 40.2 40.1 40.6 40.7
24 40.4 40.5 40.0 41.6
25 40.1 40.3 40.4 41.0
26 40.0 40.6 40.4 40.6
27 39.8 40.6 40.6 40.2
28 40.1 40.7 40.8 39.7
29 40.4 40.8 41.6 39.5
30 40.6 40.4 40.7 39.5
31 41.0 40.6 40.9 40.8
32 40.8 40.6 41.1 40.6
33 40.5 40.8 41.7 40 6
34 40.0 41.0 41.8 40.7
35 40.2 41.3 41.8 40.4
36 40.4 41.2 41.5 40.3
37 40.8 40.6 40.7 40.1
38 41.0 40.1 40.4 40.0
- All animals infected on day zero
~ Treatment done 14 days post infection
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Table A.2: Packed cell volume (%) following primary infection with
T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 32 32 38 32 32
-7 32 33 38 32 33
0 32 32 37 32 32
7 29 31 37 31 31
14 30 30 35 31 31
17 26 26 30 28 27
21 30 28 30 29 30
24 24 25 29 27 26
28 28 28 30 28 28
31 25 24 25 28 25
35 22 23 24 29 24
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 41 38 38 36 38
-7 41 36 38 36 37
0 40 38 39 37 39
7 41 37 37 38 38
14 40 38 38 36 38
17 41 36 39 38 39
21 42 38 38 37 38
24 41 37 37 37 37
28 41 39 38 36 39
31 40 38 38 38 38
35 42 37 39 36 38
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 34 35 37 33 35
-7 34 36 37 34 35
0 35 36 38 34 36
7 ■"> ->J.") 34 36 32 34
14 31 31 33 31 31
17 31 28 31 27 30
21 -> ->j j 27 30 j 5 32
24 -> ->J J 31 35 32 33
28 34 31 34 J J 34
31 32 31 34 34 33
35 34 34 36 30 34
~ All animals infected on day zero
~ Prophylaxis done Jour and halfmonths before infection
~ Treatment done 14 days post infection
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Table A3: Red Blood Cell count (xl09/ml blood) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 11.3 111 12.7 12.1 11.7
-7 11.4 10.6 12.2 11.6 11.5
0 10.9 10.8 12.5 11.9 11.4
7 10.2 10.7 12.3 11.7 11.2
14 12.6 11.1 14.0 11.9 12.2
21 9.9 8.9 10.1 10.6 10.0
28 9.1 8.7 9.2 10.4 9.2
35 9.9 7.7 9.1 11.0 9.5
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 13.4 12.3 12.5 11.9 12.4
-7 13.6 11.6 12.0 12.7 12.4
0 14.0 11.9 12.7 12.3 12.5
7 15.7 12.5 13.2 12.8 13.0
14 14.3 11.0 12.0 11.4 11.7
21 14.8 11.9 11.8 12.1 12.0
28 14.7 12.2 12.0 12.2 12.2
35 15.3 11.9 11.8 11.9 119
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 12.1 13.5 12.8 12.4 12.6
-7 11.9 13.9 13.5 11.9 12.7
0 1 1.5 13.4 13.6 12.4 12.9
7 11.3 14.0 12.8 12.5 12.6
14 12.0 13.1 13.8 11.5 12.5
21 12.6 10.6 13.9 11.5 12.0
28 13.1 10.9 12.2 12.6 12.4
35 15.9 13.8 12.8 10.7 13.3
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table A4: White blood cell count (xl06/ml) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 7.2 7.0 7.3 6.8 7.1
-7 7.4 7.3 7.1 6.9 7.2
0 7.4 7.4 7.0 7.0 7.2
7 8.0 10.1 10.1 9.7 9.9
14 9.6 11.2 12.9 12.2 11.7
21 9.7 11.6 13.7 10.1 10.9
28 11.0 11.4 13.3 9.5 11.2
35 6.6 11.2 14.2 10.8 11.0
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 6.1 13.0 8.7 6.8 7.8
-7 5.9 12.9 8.5 7.1 7.8
0 6.3 12.4 8.6 6.9 7.8
7 7.1 11.2 9.1 6.8 8.1
14 8.2 12.4 9.7 6.8 9.0
21 8.8 17.0 8.8 5.5 8.8
28 6.9 13.0 9.3 6.2 8.1
35 6.5 12.7 8.9 7.0 8.0
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 11.9 12.0 8.0 6.4 10.0
-7 12.4 11.7 8.4 6.7 10.1
0 12.2 11.8 8.3 6.5 10.1
7 11.5 11.8 8.2 7.6 9.9
14 12.1 15.0 10.4 10.4 11.3
21 17.2 16.6 10.9 10.5 13.8
28 15.6 13.9 8.1 8.8 11.4
35 17.4 15.1 8.5 8.0 11.8
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table A5: Absolute Lymphocytes (xloVml blood) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 5.0 4.8 4.7 4.8 4.8
-7 5.1 4.7 4.4 4.6 4.7
0 5.4 5.0 4.5 4.7 4.8
7 5.7 6.7 6.2 6.8 6.4
14 7.2 8.3 8.9 9.8 8.6
21 7.2 10.8 12.2 9.2 10.0
28 7.2 9.5 11.2 8.0 8.7
35 5.0 10.1 11.1 9.4 9.7
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 4.2 9.9 6.5 4.6 5.5
-7 4.2 10.1 6.8 5.0 5.9
0 4.4 9.3 6.6 4.8 5.7
7 5.0 8.6 6.9 5.2 6.1
14 6.2 9.9 6.8 4.8 6.5
21 6.5 14.3 6.6 4.1 6.6
28 5.0 10.0 6.5 4.4 5.7
35 4.7 9.9 6.6 5.1 5.9
Days pre/post (c). TREATED GROUP
infection 2BF 3VVS 1499 2386 Median
-14 6.3 8.4 4.9 4.5 5.6
-7 7.1 7.6 4.8 5.0 6.0
0 6.6 8.5 4.9 4.7 5.7
7 6.4 8.3 4.9 5.7 6.1
14 7.7 11.0 6.7 8.6 8.2
21 12.0 13.5 6.7 8.1 10.1
28 12.2 111 6.2 8.1 9.6
35 13.9 10.4 6.8 6.6 8.6
-AH animals infected on day zero
- Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table A6: Absolute Monocytes (xl06/ml blood) following primary




1736 1863 2381 2383 Median
-14 0.2 0.1 0.1 0.2 0.2
-7 0.3 0.2 0.3 0.3 0.3
0 0.3 0.1 0.1 0.4 0.2
7 0.4 0.2 0.4 0.3 0.3
14 0.6 0.8 1.2 0.6 0.7
21 0.3 0.2 0.4 0.1 0.3
28 0.9 0.3 0.3 0.1 0.3
35 0.8 0.2 0.4 0.6 0.5
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 0.4 0.5 0.3 0.3 0.4
-7 0.2 0.4 0.2 0.2 0.2
0 0.3 0.4 0.3 0.3 0.3
7 0.3 0.3 0.3 0.3 0.3
14 0.2 0.2 0.7 0.3 0.3
21 0.3 0.3 0.4 0.2 0.3
28 0.1 0.7 0.7 0.4 0.5
35 0.1 0.3 0.4 0.4 0.3
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 0.6 0.5 0.4 0.2 0.4
-7 0.6 0.7 0.5 0.2 0.6
0 0.5 0.4 0.3 0.2 0.3
7 0.6 0.2 0.5 0.2 0.4
14 1.0 0.9 0.9 0.5 0.9
21 0.5 0.5 1.0 0.8 0.6
28 0.5 0.3 0.6 0.3 0.4
35 0.3 0.8 0.3 0.3 0.3
~ AII animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table A7: Absolute Neutrophils (xl06/ml blood) following primary




1736 1863 2381 2383 Median
-14 1.7 1.9 2.2 1.6 1.8
-7 1.7 2.1 2.2 1.7 1.9
0 1.5 2.1 2.2 1.6 1.9
7 1.7 2.9 3.2 2.3 2.6
14 1.6 1.9 2.6 1.5 1.8
21 2.0 0.5 1.0 0.6 0.8
28 2.5 1.5 1.7 1.1 1.6
35 7.9 6.7 2.6 0.5 4.6
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 1.5 2.2 1.5 1.6 1.6
-7 1.4 2.1 1.3 1.6 1.5
0 1.4 2.0 1.4 1.6 1.5
7 1.6 1.9 1.5 1.1 1.6
14 1.6 1.9 1.9 1.4 1.7
21 1.8 2.0 1.6 0.9 1.7
28 1.7 2.1 1.8 1.2 1.7
35 1.4 2.1 1.6 1.3 1.5
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 4.5 2.8 2.5 1.4 2.6
-7 4.3 3.2 2.8 1.5 3.0
0 4.6 2.7 2.8 1.4 2.8
7 4.0 3.0 2.6 1.6 2.8
14 J.J 2.9 2.5 1.0 2.7
21 4.6 2.3 3.2 1.6 2.7
28 2.8 2.4 1.1 0.3 1.7
35 2.6 -s -»J.J 1.2 1.0 1.9
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table A8: Absolute Eosinophils (xl06/ml blood) following primary




1736 1863 2381 2383 Median
-14 0.3 0.2 0.2 0.3 0.2
-7 0.3 0.2 0.1 0.2 0.2
0 0.2 0.1 0.2 0.3 0.2
7 0.2 0.3 0.2 0.3 0.3
14 0.2 0.2 0.3 0.4 0.2
21 0.1 0.1 0.1 0.2 0.1
28 0.4 0.1 0.1 0.3 0.2
35 0.1 0.2 0.1 0.2 0.2
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 0.1 0.4 0.3 0.3 0.3
-7 0.2 0.4 0.3 0.3 0.3
0 0.2 0.2 0.3 0.2 0.2
7 0.1 0.3 0.4 0.2 0.3
14 0.2 0.4 0.3 0.3 0.3
21 0.3 0.3 0.3 0.2 0.3
28 0.1 0.3 0.3 0.2 0.2
35 0.2 0.3 0.4 0.2 0.2
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 0.5 0.4 0.2 0.2 0.3
-7 0.4 0.2 0.3 0.1 0.3
0 0.5 0.2 0.2 0.2 0.2
7 0.5 0.4 0.2 0.1 0.3
14 0.1 0.3 0.3 0.2 0.3
21 0.0 0.3 0.1 0.1 0.1
28 0.2 0.1 0.2 0.1 0.1
35 0.5 0.6 0.3 0.2 0.4
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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APPENDIX III
RAW DATA FOR IN VITRO AND IN VIVO EFFICACY OF ISMM
TABLE B1: ISMM PLASMA PROFILE (ng/ml)
Days pre/post ISMM SHEEP NUMBER
administration 1618 1746 1826 1895 Median
1 3.21 6.86 23.32 40.52 15.09
2 1.21 3.16 12.85 20.94 8.01
j 1.33 3.14 4.95 14.80 4.05
4 1.19 1.99 2.58 10.13 2.29
7 1.08 1.33 1.58 6.89 1.46
14 1.05 1.12 1.35 4.52 1.24
21 1.04 1.10 1.16 3.00 1.13
TABLE B2: SENSITIVITY OF TRYPANOSOMES TO ISMM IN IITRO
ISMM conc. % GROWTH INHIBITION







TABLE B3: PREPATENT PERIOD (DAYS) FOR MICE WITH DIFFERENT
IMMUNE STATUSES INFECTED WITH T. CONGOLENSE
Mouse # Control Hvdrocort. ISMM Hvdroco.+ISMM
1 3 4 7 4
2 3 3 6 3
> 3 7 2
4 4 2 8
5 4 7 3
Median 3 3 7 3
TABLE B4: SURVIVAL TIME (DAYS) FOR MICE WITH DIFFERENT
IMMUNE STATUSES INFECTED WITH 7. CONGOLENSE
Mouse # Control Hvdrocort. ISMM Hvdroco.+ISMM
1 15 16 24 20
2 18 22 21 17
S) 19 19 26 15
4 23 14 27 28
5 17 18 29 16
Median 18 18 26 17
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APPENDIX IV
TABLES OF RESULTS FOR PBMC PHENOTYPES





1736 1863 2381 2383 Median
-14 39.4 50.3 61.2 40.1 45.2
-7 36.8 48.7 60.1 37.6 43.2
0 42.4 52.8 59.2 39.9 47.6
7 39.4 46.4 54.0 34.6 42.9
14 60.0 57.0 74.8 57.2 58.6
21 82.7 78.0 78.9 55.3 78.5
28 46.9 53.8 70.6 34.5 50.4
35 51.5 37.2 63.1 39.6 45.6
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 40.3 41.6 44.1 46.5 42.9
-7 39.9 44.1 45.4 49.5 44.8
0 39.2 40.5 41.7 45.3 411
7 41.6 44.7 47.1 49.1 45.9
14 53.5 51.8 52.8 53.5 53.2
21 45.2 41.1 55.2 58.6 50.2
28 47.1 43.9 47.4 46.9 47.0
35 41.3 44.2 44.5 47.4 44.4
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 37.4 49.8 41.6 40.2 40.9
-7 35.7 53.3 44.0 39.8 41.9
0 39.7 51.9 41.2 44.2 42.7
7 37.9 50.2 39.5 41.8 40.7
14 66.7 60.9 60.9 66.4 63.7
21 67.3 68.2 61.4 68.0 67.7
28 40.7 53.8 51.7 45.0 48.4
35 19.2 41.5 41.3 44.2 41.4
~ All animals infected on day zero
~Prophylaxis done four and halfmonths before infection
- Treatment done I / days post infection
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Table CI.2: Absolute B cells (xl06/ml blood) following primary infection
with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 1.98 2.39 2.90 1.91 2.19
-7 1.88 2.31 2.64 1.74 2.10
0 2.29 2.62 2.65 1.87 2.46
7 2.24 3.09 3.33 2.35 2.72
14 4.32 4.72 6.66 5.58 5.15
21 5.94 8.42 9.62 5.08 7.18
28 3.35 5.09 7.89 2.75 4.22
35 2.55 3.75 6.99 3.72 3.74
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 1.67 4.1 2.88 2.12 2.50
-7 1.67 4.44 3.09 2.46 2.78
0 1.73 3.77 2.76 2.16 2.46
7 2.1 3.85 3.26 2.57 2.92
14 3.33 5.14 3.58 2.55 3.46
21 2.94 5.87 3.64 2.41 3.29
28 2.34 4.39 3.08 2.06 2.71
35 1.96 4.38 2.93 2.42 2.68
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 2.26 4.18 2.03 1.83 2.15
-7 2.52 4.05 2.11 1.97 2.32
0 2.62 4.41 2.02 2.07 2.35
7 2.44 4.15 1.94 2.38 2.41
14 5.16 6.67 4.06 5.73 4.06
21 8.10 9.17 4.08 5.49 6.80
28 4.95 5.98 3.23 3.64 4.30
35 2.68 4.32 2.81 2.90 2.86
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
— Treatment done 14 days post infection
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1736 1863 2381 2383 Median
-14 51.4 41.2 42.1 54.6 46.8
-7 50.1 43.0 44.6 55.9 47.4
0 53.5 44.1 40.1 58.2 48.8
7 56.5 47.6 43.7 56.2 51.9
14 35.1 34.8 27.8 36.0 35.0
21 18.5 19 4 20.6 33.5 20.0
28 33.4 33.8 25.6 41.5 33.6
35 33.6 36.1 26.0 38.6 34.9
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 52.2 47.9 46.6 45.1 47.3
-7 54.1 49.9 48.6 44.5 49.3
0 53.8 52.5 52.3 48.7 52.4
7 51.4 46.5 45.9 43.9 46.2
14 39.5 41.2 41.2 39.5 40.4
21 47.8 55.9 37.7 36.4 42.8
28 45.9 50.1 46.6 49.1 47.9
35 52.7 49.8 49.5 44.6 49.7
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 42.5 49.6 53.7 45.3 47.5
-7 40.7 52.2 54.7 48.4 50.3
0 43.6 47.8 52.5 43.1 45.7
7 45.7 50.2 55.1 46.3 48.3
14 25.0 32.5 38.3 31.1 31.8
21 21.8 27.7 34.6 24.3 26.0
28 49.1 33.9 37.1 36.7 36.9
35 29.5 33.2 42.1 34.6 33.9
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
190
Table C2.2 Absolute CD5+ T cells (xl06/ml blood) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 2.59 1.96 2.00 2.29 2.15
-7 2.56 2.04 1.96 2.28 2.16
0 2.89 2.19 1.80 2.40 2.30
7 9.95 3.17 2.69 4.91 4.04
14 2.53 2.88 2.47 2.85 2.69
21 1.33 2.09 2.51 2.25 2.17
28 2.39 3.20 2.86 2.94 2.90
35 1.66 3.64 2.88 2.95 2.92
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 2.17 4.73 3.04 2.06 2.61
-7 2.27 5.02 3.30 2.21 2.79
0 2.37 4.88 3.46 2.34 2.92
7 2.59 4.01 3.18 2.30 2.89
14 2.36 4.09 2.80 1.88 2.58
21 3.11 7.98 2.49 1.50 2.80
28 2.28 5.02 3.03 2.16 2.66
35 2.50 4.94 3.26 2.28 2.88
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 2.68 4.17 2.62 2.06 2.65
-7 2.88 3.97 2.62 2.40 2.75
0 2.87 4.06 2.58 2.02 2.73
7 2.94 4.15 2.71 2.64 2.83
14 1.94 3.56 2.55 2.68 2.62
21 2.62 3.73 2.30 1.96 2.46
28 5.98 3.77 2.32 2.97 3.37
35 4.11 3.46 2.86 2.27 3.16
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before injection
~ Treatment done 14 days post injection
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1736 1863 2381 2383 Median
-14 13.3 15.8 8.1 16.8 14.6
-7 12.4 16.2 9.3 17.4 14.3
0 14.0 17.4 8.4 17.8 15.7
7 14.3 16.5 8.2 18.0 15 4
14 9.3 11.5 5.0 12.0 10.4
21 1.2 3.8 2.7 3.2 3.0
28 11.4 8.7 3.6 12.0 10.1
35 11.0 10.1 3.8 8.4 9.3
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 12.5 15.3 14.7 19.6 15.0
-7 13.5 14.8 13.0 18.7 14.2
0 12.1 15.6 16.6 21.9 16.1
7 9.7 10.0 9.8 18.9 9.9
14 0.4 4.9 5.0 14.0 5.0
21 13.9 17.2 11.6 14.1 14.0
28 12.9 16.0 16.5 23.9 16.3
35 15.5 14.0 19.2 17.4 16.5
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 13.9 16.9 9.1 10.8 12.4
-7 14.8 17.8 9.8 11.4 13.1
0 14.6 17.4 10.1 12.3 13.5
7 15.8 18.3 8.9 11.0 13.4
14 4.9 9.5 6.6 6.8 6.7
21 4.0 4.3 5.9 7.4 5.1
28 6.5 14.3 8.6 7.9 8.3
35 4.7 15.0 8.1 10.3 9.2
~All animals injected on day zero
~ Prophylaxis done Jour and halfmonths before infection
~ Treatment done 14 days post infection
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Table C3.2 Absolute y8+ T cells (xl06/ml blood) following primary




1736 1863 2381 2383 Median
-14 0.67 0.75 0.38 0.80 0.71
-7 0.63 0.77 0.41 0.80 0.70
0 0.76 0.86 0.38 0.83 0.80
7 1.03 1.10 0.51 1.22 1.07
14 0.67 0.95 0.44 1.17 0.81
21 0.09 0.41 0.33 0.29 0.31
28 0.82 0.82 0.40 0.96 0.82
35 0.54 1.02 0.42 0.79 0.67
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 0.52 1.51 0.96 0.89 0.93
-7 0.56 1.49 0.88 0.93 0.91
0 0.53 1.45 1.10 1.04 1.07
7 0.49 0.86 0.68 0.99 0.77
14 0.02 0.49 0.34 0.67 0.42
21 0.90 1.21 0.76 0.58 0.83
28 0.64 1.60 1.07 1.05 1.06
35 0.73 1.39 1.26 0.89 1.08
Days pre/post (c). TREATED GROUP
infection 2BF 3VVS 1499 2386 Median
-14 0.88 1.42 0.44 0.49 0.69
-7 1.05 1.35 0.47 0.56 0.81
0 0.96 1.48 0.49 0.58 0.77
7 1.02 1.51 0.44 0.63 0.83
14 0.38 1.04 0.44 0.59 0.52
21 0.48 0.58 0.39 0.60 0.53
28 0.79 1.59 0.54 0.64 0.72
35 0.65 1.56 0.55 0.68 0.67
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
Table C4.1 Percentage of CD8" T-cells following primary infection
with T.congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 13.4 5.8 5.5 16.4 9.6
-7 14.1 5.6 6.5 16.0 10.3
0 13.5 6.2 5.3 15.5 9.9
7 12.4 5.2 5.0 12.8 8.8
14 5.9 3.2 1.7 6.4 4.6
21 4.3 2.2 2.8 10.5 3.6
28 8.1 5.5 1.9 16.5 6.8
35 5.6 6.2 3.0 8.5 5.9
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 11.9 13.4 14.2 9.2 12.7
-7 12.6 12.6 13.6 8.7 12.6
0 13.3 14.2 13.9 10.0 13.6
7 12.3 14.5 13.4 7.9 12.9
14 13.2 15.0 15.3 9.1 14.1
21 6.8 10.2 5.3 5.7 6.3
28 7.2 13.8 7.7 9.2 8.5
35 10.6 13.0 8.0 9.9 10.3
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 5.7 7.8 12.1 11.6 9.7
-7 6.5 7.7 11.7 12.6 9.7
0 5.8 8.4 12.6 114 9.9
7 6.9 8.1 12.7 11.9 10.0
14 4.1 4.9 6.8 4.0 4.5
21 10.0 8.6 8.8 8.5 8.7
28 9.9 7.7 9.7 11.1 9.8
35 6.9 5.7 10.7 9.8 8.4
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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Table C4.2 Absolute CD8+ T cells (xl06/ml blood) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 0.68 0.28 0.26 0.78 0.48
-7 0.72 0.26 0.29 0.74 0.51
0 0.73 0.31 0.24 0.73 0.52
7 0.70 0.35 0.3 1 0.79 0.53
14 0.42 0.26 0.15 0.62 0.34
21 0.31 0.24 0.34 0.96 0.33
28 0.58 0.52 0.21 1.32 0.55
35 0.28 0.62 0.33 0.80 0.48
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 0.49 1.32 0.92 0.42 0.71
-7 0.53 1.27 0.92 0.43 0.73
0 0.59 1.32 0.92 0.48 0.76
7 0.62 1.25 0.93 0.41 0.78
14 0.82 1.49 1.03 0.43 0.93
21 0.44 1.46 0.35 0.23 0.40
28 0.36 1.38 0.50 0.40 0.45
35 0.50 1.29 0.53 0.21 0.52
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 0.36 0.66 0.59 0.53 0.56
-7 0.46 0.65 0.56 0.62 0.59
0 0.38 0.71 0.62 0.53 0.58
7 0.44 0.67 0.62 0.68 0.65
14 0.32 0.54 0.45 0.34 0.40
21 1.21 1.16 0.58 0.69 0.93
28 1.20 0.86 0.60 0.90 0.88
35 0.96 0.59 0.73 0.64 0.69
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
— Treatment done 14 days post infection
Table C5.1 Percentage of CD4+ T-cells following primary infection
with T.congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 23.8 14.3 16.1 24.2 20.0
-7 24.6 15.2 16.8 23.8 20.3
0 22.9 13.7 17.6 24.3 20.3
7 23.9 15.4 17.4 23.3 20.4
14 13.4 13.3 9.4 14.1 13.4
21 2.1 2.7 3.9 10.0 3.3
28 8.9 12.7 6.9 17.0 10.8
35 11.1 16.3 6.7 15.2 13.2
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 29.3 21.2 21.6 16.5 21.4
-7 28.0 20.2 22.0 17.1 21.1
0 28.4 22.7 21.8 16.8 22.3
7 29.4 22.0 22.7 17.1 22.4
14 25.9 21.3 20.9 16.4 21.1
21 27.1 23.0 20.8 16.6 21.9
28 25.8 20.3 22.4 16.0 21.4
35 26.6 22.8 22.3 17.3 22.6
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 13.2 11.4 23.3 17.1 15.2
-7 13.9 12.2 23.7 16.4 15.2
0 14.9 11.8 24.2 17.6 16.3
7 14.1 1 1.6 24.7 18.0 16.1
14 7.8 11.0 12.5 11.9 11.5
21 3.5 4.0 10.3 4.8 4.4
28 13.8 11.6 13.1 12.9 13.0
35 8.2 10.6 18.8 13.5 12.1
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
— Treatment done 14 days post infection
1%
Table C5.2 Absolute CD4T T cells (xloVml blood) following primary
infection with T. congolense
Days pre/post (a). CONTROL GROUP
infection 1736 1863 2381 2383 Median
-14 1.20 0.68 0.76 1.15 0.96
-7 1.24 0.72 0.74 1.10 0.92
0 1.22 0.68 0.79 1.14 0.97
7 1.34 1.03 1.07 1.58 1.21
14 0.96 1.10 0.84 1.38 1.03
21 0.15 0.29 0.48 0.92 0.39
28 0.64 1.20 0.77 1.36 0.99
35 0.55 1.64 0.74 1.43 1.09
Days pre/post (b). PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 1.22 2.09 1.41 0.75 1.32
-7 1.17 2.03 1.50 0.85 1.34
0 1.25 2.11 1.44 0.80 1.35
7 1.48 1.90 1.57 0.90 1.53
14 1.61 2.11 1.42 0.78 1.52
21 1.76 3.28 1.37 0.68 1.57
28 1.28 2.03 1.46 0.70 1.37
35 1.26 2.26 1.47 0.88 1.37
Days pre/post (c). TREATED GROUP
infection 2BF 3VVS 1499 2386 Median
-14 0.83 0.96 1.14 0.78 0.90
-7 0.98 0.93 1.14 0.81 0.96
0 0.98 1.00 118 0.82 0.99
7 0.91 0.96 1.22 1.03 1.00
14 0.60 1.20 0.83 1.03 0.93
21 0.42 0.54 0.68 0.39 0.48
28 1.68 1.29 0.82 1.04 1.17
35 1.14 1.10 1.28 0.88 1.12
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
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1736 1863 2381 2383 Median
-14 1.76 2.43 2.92 1.47 2.10
-7 1.72 2.77 2.55 1.49 2.14
0 1.67 2.19 3.29 1.56 1.93
7 1.91 2.94 3.45 2.00 2.47
14 2.28 4.23 5.60 2.22 3.26
21 0.48 1.21 1.41 0.96 1.09
28 1.10 2.31 3.67 1.03 1.71
35 1.96 2.64 2.24 1.79 2.10
Days pre/post (1)) PROPHYLACTIC GROUP
infection 1618 1746 1826 1895 Median
-14 2.49 1.58 1.53 1.78 1.68
-7 2.21 1.60 1.63 1.98 1.81
0 2.12 1.60 1.56 1.67 1.64
7 2.39 1.52 1.69 2.20 1.95
14 1.96 1.42 1.38 1.81 1.62
21 4.00 2.25 3.91 2.96 3.44
28 3.56 1.47 2.92 1.75 2.34
35 2.52 1.75 2.77 4.19 2.65
Days pre/post (c). TREATED GROUP
infection 2BF 3WS 1499 2386 Median
-14 2.30 1.45 1.93 1.47 1.70
-7 2.13 1.43 2.04 1.31 1.74
0 2.58 1.41 1.90 1.55 1.73
7 2.07 1.43 1.97 1.51 1.74
14 1.88 2.22 1.84 3.03 2.05
21 0.35 0.46 1.17 0.56 0.51
28 1.40 1.50 1.37 1.16 1.39
35 1.19 1.86 1.75 1.38 1.57
~ All animals infected on day zero
~ Prophylaxis done four and halfmonths before infection
~ Treatment done 14 days post infection
198
FIGURE CI: REPRESENTATIVE B CELL HISTOGRAMS FOR THE
CONTROL GROUP(Sheep 1736)
Day 0









































r i 11 M ir
103^04
201






















i i m ii i,■









=pnriWi i i i miir
































FIGURE C8: REPRESENTATIVE y5^ T CELL HISTOGRAMS FOR THF
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TABLES OF RESULTS FOR IFN-y, IL-12 AND PBMC IN VITRO
PROLIFERATION
Table Dl: Control group- Peripheral blood mononuclear cell proliferation
(Stimulation Index) in vitro
Days pre/| (a) Infected Control group - Tryps (b) Infected Control group - ConA
infection 1736 1863 2381 2383 1736 1863 2381 2383
-14 1.00 0.93 1.04 0.98 1.88 1.82 1.79 2.76
-7 0.95 1.01 0.98 1.03 1.95 1.78 1.68 2.92
0 0.93 0.95 0.92 0.94 1.83 2.03 1.95 2.89
7 1.03 1.20 0.83 1.24 1.94 1.88 1.56 2.90
14 0.99 1.00 0.90 1.02 1.19 0.86 1.07 1.51
21 0.13 0.02 0.00 1.34 0.13 0.02 0.00 1.34
28 0.88 0.92 1.06 0.80 1.44 0.75 0.67 1.27
35 1.67 1.64 1.38 1.68 1.30 1.18 0.69 1.30
Table D2: Prophylactic group- Peripheral blood mononuclear cell
proliferation (Stimulation Index) in vitro
Days pre/j (a) Infected Prophylactic group - Tryps (b) Infected Prophylactic group - ConA
infection 1618 1746 1826 1895 1618 1746 1826 1895
-14 1.37 1.30 1.39 1.37 3.04 1.97 2.91 2.77
1
- i 1.46 1.25 1.30 1.36 2.99 1.86 2.86 2.96
0 1.30 1.31 1.40 1.43 3.11 2.22 3.00 2.86
7 1.58 1.36 1.05 1.29 2.50 2.09 3.21 2.50
14 1.23 1.21 1.41 1.46 2.87 1.98 2.88 2.80
21 0.90 0.08 0.45 0.28 0.33 0.00 0.33 2.40
28 1.26 1.21 1.01 0.99 2.53 2.14 2.28 3.15
35 1.30 119 1.18 1.15 2.39 2.11 2.77 3.03
Table D3: Treated group- Peripheral blood mononuclear cell proliferation
(Stimulation Index) in vitro
Days pre/[
infection
(a) Infected Treated group - T ryps (b) Infected Treated group - ConA
2BF 3WS 1499 2386 2BF 3WS 1499 2386
-14 0.95 1.01 0.99 1.03 1.06 1.73 1.83 2.94
-7 1.04 0.94 0.98 0.94 1.01 1.68 1.74 2.84
0 0.98 0.98 0.94 0.91 0 90 1.68 1.82 3.05
7 0.84 1.14 1.16 1.06 0.98 1.20 1.77 2.83
14 0.97 0.92 1.10 0.96 0.97 1.01 1.12 1.82
21 0.49 2.04 1.19 0.80 0.49 2.04 1.19 0.80
28 1.03 1.26 1.36 1.05 0.72 2.59 2.14 1.57
35 1.31 1.92 1.85 2.30 0.36 1.42 1.49 1.92
Multiplication Index = Mean of test absorbance/ Mean of media only absorbance.
It indicates the rate at which cells multiply. An index of 1 represents normal multiplication
while that of zero indicate no cell multiplication. An index above 1 indicates a higher than
normal rate ofmultiplication.
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Table D4: Supernatant sheep IFN-y levels (Absorbance) for prophylactic
PBMCs in culture with trypanosomes
Days pre/| (a). Non-infected (Prophylactic): Tryps (b). Infected (Prophylactic): Tryps
infection 1618 1746 1826 1895 1618 1746 1826 1895
-14 0.132 0.125 0.126 0.126 0.150 0.140 0.317 0.144
-7 0.074 0.045 0.020 0.048 0.185 0.092 0.298 0.153
0 0.160 0.142 0.130 0.150 0.122 0.138 0.329 0.168
7 0.110 0.113 0.120 0.198 0.177 0.125 0.325 0.180
14 0.574 0.288 0.498 0.713 0.158 0.128 0.300 0.130
21 0.162 0.207 1.230 0.572 0.252 0.140 0.306 0.460
28 0.181 0.122 0.876 0.265 0.172 0.113 0.168 0.093
35 0.180 0.145 0.424 0.141 0.160 0.077 0.176 0.104
Table D5: Supernatant sheep IFN-y levels (Absorbance) for Control
PBMCs in culture with trypanosonies
Days with (a). Non-infected (Control): Tryps (b). Infected (Control): Tryps
to ISMM i 1736 1863 2381 2383 1736 1863 2381 2383
-14 0.143 0.149 0.159 0.150 0.147 0.136 0.134 0.151
-7 0.156 0.139 0.158 0.161 0.154 0.132 0.144 0.165
0 0.146 0.163 0.152 0.152 0.149 0.147 0.131 0.144
7 0.160 0.152 0.154 0.141 0.170 0.144 0.175 0.183
14 0.136 0.149 0.149 0.144 0.154 0.142 0.149 0.142
21 0.144 0.150 0.154 0.142 0.144 0.144 0.149 0.160
28 0.152 0.158 0.146 0.129 0.149 0.139 0.144 0.188
35 0.147 0.162 0.149 0.137 0.154 0.149 0.144 0.175
Table D6: Supernatant sheep IFN-y levels (Absorbance) for Prophylactic
PBMCs in culture with ConA
Days pre/p<
infection
(a). Non- nfected (Prophylaxis): ConA (b). Infected-Prophylactic group: ConA
1618 1746 1826 1895 1618 1746 1826 1895
-14 0.158 0.532 0.413 0.27 0.178 0.552 0.379 0.246
-7 0.132 0.517 0.404 0.228 0.136 0.564 0.419 0.222
0 0.17 0.54 0.432 0.23 0.160 0.528 0.400 0.239
7 0.139 0.546 0.408 0.23 0.132 0.536 0.410 0.262
14 0.186 0.543 0.395 0.256 0.170 0.554 0.408 0.225
21 0.176 0.542 0.394 0.241 0.146 0.562 0.432 0.284
28 0.178 0.51 0.418 0.221 0.166 0.550 0.390 0.256
35 0.141 0.52 0.394 0.216 0.142 0.594 0.395 0.220
Mean negative control = 0.139, SD = 0.012
Mean positive control 1.259. SD = 0.05
Cut-offpoint = mean ofnegative control plus 2SI) = 0.163
I alues are means ofduplicate sample tests performed twice
Prophylactic group: ISMM administered on day 0
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Table D7: Supernatant sheep IFN-y levels (Absorbance) for Control
PBMCs in culture with ConA
Days pre/p( (a). Non-infected (Control): ConA (b). Infected (Control): ConA
infection 1736 1863 2381 2383 1736 1863 2381 2383
-14 0.552 0.379 0.246 0.23 0.415 0.297 0.289 0.318
-7 0.564 0.419 0.222 0.198 0.386 0.304 0.304 0.324
0 0.528 0.4 0.239 0.21 0.441 0.387 0.355 0.269
7 0.536 0.41 0.262 0.224 0.345 0.252 0.278 0.283
14 0.554 0.408 0.225 0.215 0.412 0.242 0.309 0.306
21 0.562 0.432 0.284 0.193 0.432 0.337 0.276 0.234
28 0.55 0.39 0.256 0.233 0.342 0.257 0.219 0.340
35 0.594 0.395 0.22 0.246 0.345 0.325 0.281 0.312
Table D8: Non-infected splenic mouse IL-12 and IFN-y levels
(Absorbance)
IL-12 production (Absorbance) IFNy production (Absorbance)
Days post ISMM adminstration Days post ISMM adminstration
0 7 14 21 0 7 14 21
(a) Media only
Mouse 1 0.011 0.004 0.009 0.011 0.014 0.009 0.011 0.016
Mouse 1 0.009 0.008 0.011 0.010 0.015 0.011 0.015 0.013
Mouse 2 0.012 0.005 0.010 0.011 0.012 0.008 0.006 0.011
Mouse 2 0.011 0.006 0.012 0.013 0.013 0.010 0.017 0.009
Mouse 3 0.012 0.005 0.010 0.012 0.010 0.007 0.012 0.010
Mouse 3 0.010 0.004 0.009 0.011 0.011 0.009 0.013 0.012
Median 0.011 0.005 0.010 0.011 0.013 0.009 0.013 0.012
(b) LPS culture
Mouse 1 0.141 0.163 0.041 0.037 0.393 0.010 0.013 0.009
Mouse 1 0.140 0.172 0.038 0.043 0.401 0.007 0.011 0.010
Mouse 2 0.142 0.140 0.023 0.065 0.389 0.009 0.009 0.012
Mouse 2 0.143 0.155 0.034 0.058 0.421 0.015 0.015 0.015
Mouse 3 0.167 0.134 0.035 0.048 0.354 0.006 0.012 0.011
Mouse 3 0.150 0.146 0.033 0.050 0.335 0.017 0.013 0.009
Median 0.143 0.151 0.035 0.049 0.391 0.010 0.013 0.011
(c) Trypanosome culture
Mouse 1 0.159 0.232 0.243 0.018 0.023 0.005 0.018 0.015
Mouse 1 0.192 0.205 0.268 0.020 0.018 0.006 0.022 0.012
Mouse 2 0.183 0.227 0.231 0.024 0.022 0.005 0.017 0.013
Mouse 2 0.230 0.247 0.276 0.034 0.017 0.004 0.023 0.014
Mouse 3 0.213 0.231 0.251 0.019 0.016 0.010 0.016 0.011
Mouse 3 0.224 0.201 0.212 0.021 0.019 0.007 0.018 0.010
Median 0.203 0.229 0.247 0.021 0.019 0.006 0.018 0.013
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APPENDIX VI
DATA FOR BCG EXPERIMENTS




(a) CONTROL GROUP (b) ISMM GROUP
2212 2305 NT 2266 2327 2378
-14 16 21 24 12 21 20
-7 15 20 25 10 19 22
0 14 18 21 12 18 21
7 17 21 23 10 19 23
14 28 22 27 11 23 24
21 31 -> -»A J 33 24 27 24
28 31 38 44 19 16 19
35 34 24 22 18 31 15
Table E2 Percentage of B-cell following BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 28.0 48.8 46.0 39.2 44.8 39.2
-7 26.7 48.6 46.4 39.4 42.3 37.5
0 28.8 52.7 50.2 40.2 44.8 46.0
7 20.4 43.3 40.3 34.2 45.2 28.3
14 20.3 38.8 36.6 32.0 31.9 26.3
21 15.7 29.3 25.5 29.0 21.2 14.7
28 20.6 76.4 68.7 29.6 22.7 415
35 62.4 77.1 72.5 30.1 24.6 47.7
Table E3 Percentage of CD5 T-cells following BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 70.2 49.6 46.2 40.5 45.9 55.7
-7 68.4 46.3 44.1 41.8 46.0 52.4
0 66.0 45.7 39.8 43.4 50.3 50.1
7 69.8 51.0 42.7 46.4 44.8 58.1
14 70.4 50.4 44.4 48.5 53.1 62.6
21 70.7 41.9 37.6 36.2 46.3 55.0
28 28.3 14.4 23.8 46.2 68.6 48.5
35 26.2 37.4 24.1 44.6 63.7 32.9
Table E4 Percentage of y5T T-cells following BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 33.5 27.4 22.6 25.6 21.6 22.9
-7 30.5 26.0 19.8 23.4 19.6 22.7
0 31.4 25.5 214 26.1 17.3 21.3
7 31.2 25.6 17.7 30.1 19.9 20.4
14 36.3 26.0 17.2 29.2 20.7 18.5
21 14.1 10.4 3.4 12.2 8.3 5.0
28 11.6 3.2 7.8 31.3 33.9 19.4
35 12.4 3.6 9.3 35.2 42.8 21.3
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Table E5 Percentage of CD4+ T-cclls following BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 23.0 11.2 14.6 11.1 15.0 19.0
-7 22.4 10.6 14.9 12.3 16.3 16.8
0 20.5 10.8 15.7 14.0 17.3 16.6
7 24.3 13.9 15.6 11.4 17.0 21.2
14 23.1 12.2 14.5 13.5 16.0 23.2
21 26.7 11.4 12.9 10.6 16.4 21.3
28 5.2 3.1 6.0 7.1 20.0 11.1
35 6.3 4.2 4.1 9.6 19.6 12.6
Table E6 Percentage of CD8+ T-cells following BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 12.9 8.8 7.5 4.2 14.3 15.9
-7 12.1 8.9 8.6 4.0 14.8 14.4
0 13.2 9.4 9.4 4.3 15.4 13.7
7 12.5 5.2 6.5 3.0 11.9 15.4
14 7.5 6.3 8.0 2.5 9.8 14.8
21 6.9 4.8 4.9 2.0 6.9 12.9
28 4.8 2.2 5.8 0.9 9.3 13.6
35 6.2 4.2 5.1 1.2 8.7 7.4
Table E7 CD4 CDS
~
T-cell ratio follow ing BCG inoculation
Days pre/post (a) CONTROL GROUP (b) ISMM GROUP
inoculation 2212 2305 NT 2266 2327 2378
-14 1.78 1.27 1.95 2.64 1.05 1.19
-7 1.85 1.19 1.73 3.08 1.10 1.17
0 1.55 1.15 1.67 3.26 1.12 1.21
7 1.94 2.67 2.40 3.80 1.43 1.38
14 3.08 1.94 1.80 5.40 1.63 1.57
21 3.87 2.38 2.63 5.30 2.38 1.65
28 1.08 1.41 1.03 7.89 2.15 1.77
35 1.02 1.00 0.80 8.00 2.25 1.70
Table E8 Skin thickness (mm) after PPD injection 35 days post BCG inoculation
Hours post PPD (a) CONTROL GROUP (b) ISMM GROUP
injection 2212 2305 NT 2266 2327 2378
0 5.8 5.8 5.5 5.6 5.7 4.7
21 1 1.6 1 1. 1 8.9 13.8 1 1.6 5.0
48 15.4 21.3 9.8 18.4 18.5 5.0
72 13.3 22.4 10.0 19.2 19.6 7.0
- BCG inoculation was performed on Day 0
- ISMM administered 14 da\ s before BCG inoculation
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FIGURE El: SHEEP 2212- DOT PLOTS FOR DETERMINING LYMPHOCYTE
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FIGURE E3: SHEEP NT- DOT PLOTS FOR DETERMINING LYMPHOCYTE
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FIGURE E4: SHEEP 2327- DOT PLOTS FOR DETERMINING LYMPHOCYTE
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FIGURE E5: SHEEP 2266- DOT PLOTS FOR DETERMINING LYMPHOCYTE
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FIGURE E6: SHEEP 2378- DOT PLOTS FOR DETERMINING LYMPHOCYTE
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STATISTICAL ANALYSIS OF RESULTS
(Mann-Whiteny Non-parametric tests)
Ft. STATISTICAL ANALYSIS OF FEVER AND HAEMATOLOGICAL RESULTS
Table Fl.l MAGINITIJDE OF FEVER
COMPARISONS Median (mm2) P-value Comment




150 0.029 Significant difference




2775 0.029 Significant difference




2775 0.029 Significant difference
Table FL2 PCV
COMPARISONS Median (%) P-value Comment
(a) Control Group
-14 - 0 days
14 - 35 da\s 28 <0.0001 Significant decrease
(b) Prophylactic Group
-14 - 0 day s
14 ~ 35 davs
38
38 0.8900 Not significant
(c) Treated Group
-14 - 0 days
14-28 da\ s
35
31 <0.0001 Significant decrease
Table Ft.2 Absolute RBCs










12.0 0.341 Not significant
(c) Trcated
-14 - 0 days
14 - 35 davs
12.6
12.6 0.659 Not significant
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Table F1.3 Absolute WBCs
COMPARISONS Median (xl06/ml) P-value Comment
(a) Control Group
-14 - 0 days
14-35 davs
7.2
11.2 0.0001 Significant increase
(b) Prophylactic Group
-14 ~ 0 days
14 ~ 35 davs
7.8
8.8 0.472 Not significant
(c) Treated Group
-14 ~ 0 days
14-35 davs
10.0
11.5 0.057 Not significant
Table F1.4 Absolute Lymphocytes
COMPARISONS Median (xl06/ml) P-value Comment
(a) Control Group
-14 — 0 days
14-35 davs
4.8
9.3 <0.0001 Significant increase
(b) Prophylactic Group
-14 - 0 days
14-35 dav s
5.7
6.5 0.626 Not significant
(c) Treated Group
-14 - o days
14-28 davs
5.6
8.9 0.002 Significant increase
Table F1.5 Absolute Monocytes
COMPARISONS Median (xl06/ml) P-value Comment
(a) Control Group
-14 - 0 days
14-35 davs
0.23
0.42 0.022 Significant increase
(b) Prophylactic Group
-14 - 0 days
14-35 davs
0.31
0.34 0.853 Not significant
(c) Treated Group
-14 - 0 days
14-21 davs
0.44
0.83 0.004 Significant increase
Table F1.6 Absolute Neutrophils





1.7 0.594 Not significant
(b) Prophylactic Group
-14 - 0 day s
14-35 dav s
1.5





2.4 0.256 Not significant
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Table F1.7 Absolute Eosinophils
COMPARISONS Median (xl()6/ml) P-value Comment
(a) Control Group
-14 - 0 days
14-35 days
0.22
0.20 0.194 Not significant
(b) Prophylactic Group
-14 ~ 0 days
14-35 davs
0.26
0.26 0.710 Not significant
(c) Treated Group
-14 - 0 days
14-28 davs
0.24
0.16 0.082 Not significant
F2. STATISTICAL ANALYSIS FOR EFFICACY OF ISMM IN MICE
Table F2.1 Prepatent period
COMPARISONS Median (days) P-value Comment
(a) Control & ISMM Groups
Control
ISMM 1 0.008 Significant difference




•> 0.841 Not significant




3 0.008 Significant difference
Table F2.2 Survival time
COMPARISONS Median (days) P-value Comment




26 0.016 Significant difference




17 1.000 Not significant




17 0.095 Not significant
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F3. STATISTICAL ANALYSIS FOR CELL PHENOTYPES AND IgG ANTIBODIES
Table F3.1 Absolute B cells
COMPARISONS Median (xl06/ml) P-value Comment
(a) Control Group
-14-0 days
14 ~ 28 davs
2.3










5.3 0.0004 Significant increase
Table F3.2 Absolute CD5+ T cells





2.9 0.003 Significant increase
(b) Prophylactic Group
-14 - 0 days
14-35 davs
2.7





2.7 0.816 Not significant
Table F3.3 Absolute T cells















0.53 0.038 Significant decrease
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Table F3.4 Absolute CD8+ T eells
COMPARISONS Median (xl06/ml) P-value Comment
(a) Control Group
-14 - 0 days
7~ 35 davs
0.50
0.38 0.781 Not significant
(b) Prophylactic Group(Sheep 1618 &
-14-0 days
21 ~ 35 davs
1826)
0.76
0.47 0.026 Significant decrease
(c) Treated Group
-14 — 0 days
21- 35 davs
0.58
0.80 0.003 Significant increase
Table F3.5 Absolute CD4+ T cells
COMPARISONS Median (xl06/nil) P-value Comment
(a) Control Group
-14 - 0 days
21 davs
0.95
0.39 0.034 Significant decrease
(b) Prophylactic Group
-14-0 days
14 - 35 davs
1.33





0.48 0.005 Significant decrease
Table F3.6 CD4T: CD8" T cell Ratio





1.09 0.005 Significant decrease
(b) Prophylactic Group
-14-0 days
21 - 35 davs
1.65
2.85 0.005 Significant increase
(c) Treated Group
-14 — 0 days
21 davs
1.73
0.51 0.005 Significant decrease
Table F3.7 Serum I«G antibodies 35 days post infection
COMPARISONS Median titre P-value Comment




10 0.029 Significant difference




0 0.029 Significant difference




0 0.029 Significant difference
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F4. STATISTICAL ANALYSIS FOR PROLIFERATION AND CYTOKINE RESULTS
Table F4.1 PBMC proliferation in culture with trypanosomes
COMPARISONS Median Stimulation Index P-value Comment
(a) Control Group
-14 ~ 0 days
21 davs
0.95
0.02 0.016 Significant decrease
(b) Prophylactic Group
-14 - 0 days
21 davs
1.37





1.15 0.037 Significant increase
Table F4.2 PBMC proliferation in culture with ConA
COMPARISONS Median Stimulation Index P-value Comment
(a) Control Group
-14 - 0 days
14 - 35 davs
1.92
1.13 <0.0001 Significant decrease
(b) Prophylactic Group
-14 - 0 days
21 davs
2.89
0.33 0.0131 Significant decrease
(c) Treated Group
-14 - 0 davs
14-28 davs
1.74
1.07 0.0830 Not significant
Table F4.3 Sheep PBMC culture supernatant IFN-y levels for prophylactic group
COMPARISONS Median Absorbance P-value Comment
Prophylactic Group (Pre-infeetion)
-14 - 0 dav s before ISMM adminstration
14-28 davs after ISMM adminstration
0.126
0.276 0.001 Significant increase
Prophylactic Group (Post-infection)
-14-0 days before infection
14-28 dav s after infection
0.146
0.146 0.435 Not significant
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Table F4.4 Mice splenic ceil culture supernatant IFN-y levels
COMPARISONS Median Absorbance P-valuc Comment
Untreated & 21davs on ISMM
(Cultures with LPS)
Untreated 0.389
21 davs on ISMM 0.011 0.001 Significant decrease
Table F4.5 Mice splenic cell culture supernatant IL-12p40 levels
COMPARISONS Median Absorbance P-value Comment
Untreated & 14 davs on ISMM
(Cultures with LPS)
Untreated 0.142
14 davs on ISMM 0.049 0.002 Significant decrease
Untreated & 21 davs on ISMM
(Cultures with LPS)
Untreated 0.142
21 davs on ISMM 0.034 0.002 Significant decrease
Untreated & 21 davs on ISMM
(Cultures with Trypanosomes)
Untreated 0.202
21 davs on ISMM 0.020 0.002 Significant decrease
F5. STATISTICAL ANALYSIS OF BCG RESULTS
Table F5.1 In vivo PBMC proliferation
GROUP COMPARISONS Median (%) P-value Comment
(a) Control
-14-0 davs 20
7-35 davs 28 0.003 Significant increase
(b) ISMM
-14 - 0 davs 19
7-35 davs 19 0.257 Not significant
Table F5.2. Percentage of B-cell following BCG inoculation
GROUP COMPARISONS Median (%) P-value Comment
(a) Control
-14 — 0 davs 46
7-2 Idavs ->o^ 7 0.028 Cinnirioont rlor-rAoroOlhjllillN-CiHl UV.V.1CUOV.
-14 — 0 days i s•+0
28 -35 davs 71 0.039 Significant increase
(b) ISMM
-14-0 davs 40
7 - 35 davs 30 0.007 Significant decrease
Table F5.3. Percentage of CD5+ T-cells following BCG inoculation
GROUP COMPARISONS Median (%) P-value Comment
(a) Control
-14 ~ 0 days
11. IS rlo' CZ* i J J UU > 3
46
IS?





46 0.791 Not significant
Table F5.4. Percentage of T-cells follow ing BCG inoculation
GROUP COMPARISONS Median (%) P-value Comment
(a) Control
-14 - 0 days
21 - 35 davs
26





8 0.016 Significant decrease
Table F5.5. Percentage of CD4
"
T-cells following BCG inoculation
GROUP COMPARISONS Median (%) P-value Comment
(a) Control
-14-0 days
28 - 35 davs
15
0 002 Significant decrease
(b) ISMM
-14 - 0 days
28 - 35 davs
16
12 0.479 Not significant
Table F5.6: Percentage of CDS T-cells following BCG inoculation





6 0.001 Significant decrease
(b) ISMM
-14 - 0 days
7-35 davs
14
9 0.084 Not significant
Table F5.7: CD4": CDS" T-cell ratio following BCG inoculation
GROUP COMPARISONS Median P-value Comment
(a) Control
-14 - 0 days
7-21 davs
1.67
2.40 0.002 Significant increase
(b) ISMM
-14 - 0 days
7-35 days
1.19
2.15 0.028 Significant increase
Table F5.8: Skin thickness (mm) after PPD injection 35 days post BCG
GROUP COMPARISONS Median (mm) P-value Comment
(a) Control
0 ~ 24 hrs 7.40
48 ~ 72hrs 14.40 0.041 Significant increase
(b) ISMM
0 — 24 hrs 5.70
48 ~ 72hrs 18.50 0.093 Not significant
(c) Control & ISMM
48 ~ 72hrs 14.40
48 ~ 72hrs 18.50 0.818 Not significant
